Bionanotechnology

BioNanotechnology
Copyright © 2007 by Morgan & Claypool
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in
any form or by any means—electronic, mechanical, photocopy, recording, or any other except for brief quotations
in printed reviews, without the prior permission of the publisher.
BioNanotechnology
Elisabeth S. Papazoglou, Aravind Parthasarathy
www.morganclaypool.com
ISBN: 1598291386 paperback

ISBN: 9781598291384 paperback
ISBN: 1598291394 ebook

ISBN: 9781598291391 ebook
DOI: 10.2200/S00051ED1V01Y200610BME007
A Publication in the Morgan & Claypool Publishers’ series

SYNTHESIS LECTURES ON BIOMEDICAL ENGINEERING #7
Lecture #7
Series Editor: John D. Enderle, University of Connecticut
Library of Congress Cataloging-in-Publication Data
Series ISSN: 1930-0328 print

Series ISSN: 1930-0336 electronic
First Edition
10 9 8 7 6 5 4 3 2 1
BioNanotechnology
Elisabeth S. Papazoglou, Aravind Parthasarathy
School of Biomedical Engineering
Drexel University
SYNTHESIS LECTURES ON BIOMEDICAL ENGINEERING #7
M
&C Morgan &Claypool Publishers
iv
ABSTRACT
This book aims to provide vital information about the growing field of bionanotechnology for
undergraduate and graduate students, as well as working professionals in various fields. The
fundamentals of nanotechnology are covered along with several specific bionanotechnology
applications, including nanobioimaging and drug delivery which is a growing $100 billions
industry. The uniqueness of the field has been brought out with unparalleled lucidity; a balance
between important insight into the synthetic methods of preparing stable nano-structures
and medical applications driven focus educates and informs the reader on the impact of this
emerging field. Critical examination of potential threats followed by a current global outlook
completes the discussion. In short, the book takes you through a journey from fundamentals
to frontiers of bionanotechnology so that you can understand and make informed decisions on
the impact of bionano on your career and business.
KEYWORDS
Bionanotechnology, Bionano initiatives, Bionano threats, Gold nanoparticles, Nano-
bioimaging, Nano drug-delivery (or nano-vectors or targeted drug-delivery), Nano synthetics,
and Bionanotoxicology, MRI, Titania nanoparticles, and Zinc nanoparticles.
v
Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
0.1 Bionanotechnology: A Historical Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
0.2 Nanotechnology and Bionanotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
0.3 Notable Nanoimages in Bionanotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
0.3.1 AFM-Qd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
0.3.2 Nano-drug Delivery Chip . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
0.3.3 Atomic Force Microscopy Image (AFM) of SWNT . . . . . . . . . . . . . . . . . . 7
0.3.4 Scanning Electron Microscopy Image (SEM) of SWNT . . . . . . . . . . . . . . 7
0.4 Opportunities and Challenges of Bionanotechnology . . . . . . . . . . . . . . . . . . . . . . . . 8
0.5 Growth potential of Nanotechnology
and Related Expenditures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12
1. The Significance of Nano Domain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

1.1 Limitations of Micron Size . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.2 Need for Nano-Size—Surface Volume Ratio Significance . . . . . . . . . . . . . . . . . . . 15
1.3 Significance and Key Features of Nano-Size . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.4 Derivation of Bohr’s Atomic Radius
of a Hydrogen Atom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.5 Comparison of Particle Behavior at Nano-Size
to Macro Size: Gold and Titania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
1.6 Advantages of Scaling Down—Nano-Size . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27
2. Nano Drug Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

2.1 Conventional Drug Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.1.1 First Pass Effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.1.2 Routes of Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.2 Targeted Drug Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.3 Chemistry of Drug Delivery Vehicles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.3.1 Nanocapsules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.3.2 Unilamellar Liposomal Vesicles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
vi BIONANOTECHNOLOGY
2.3.3 Nanoparticles. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36
2.3.4 Microemulsions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.4 Delivery Profiles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.4.1 Rate-Preprogrammed Drug Delivery Systems . . . . . . . . . . . . . . . . . . . . . . 39
2.4.2 Activation-Modulated Drug Delivery Systems . . . . . . . . . . . . . . . . . . . . . . 39
2.4.3 Feedback-Regulated Drug Delivery Systems . . . . . . . . . . . . . . . . . . . . . . . . 40
2.4.4 Site-Targeting Drug Delivery Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.5 The Role of Nanotechnology in Drug Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.5.1 Transdermal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.5.2 Blood Brain Barrier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.6 Advantages of Targeted Drug Delivery Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43
3. BioNanoimaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.1 Quantum Dots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.2 Ultrasound Contrast Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.3 Magnetic Nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .63
4. Successful Applications of Bionanotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

4.1 Nanostructures and Nanosystems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.1.1 Nanopore Technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.1.2 Nano Self-Assembling Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.1.3 Cantilevers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.1.4 Nanoarrays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.2 Nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2.1 Quantum Dots (QDs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2.2 Paramagnetic Iron Oxide Crystals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.2.3 Dendrimers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.2.4 Carbon Nanotubes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.2.5 Nanosomes and Polymersomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.3 In Vitro Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.4 Medical Application of Nanosystems
and Nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.4.1 Drug Delivery Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4.4.2 Nanoparticles in Molecular Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.5 Summary and Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
CONTENTS vii
5. Synthesis of Gold, Titania, and Zinc Oxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1 Synthesis of Gold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1.2 Brust Method of Synthesis of Thiol Derivatized Gold NPs
by Biphasic Reduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1.3 Gold Colloids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
5.1.4 Gold Nanofilm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
5.1.5 Gold Nanorods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.2 Synthesis of Titania Nanostructures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.2.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.2.2 Solvo-Thermal Synthesis of Titania Nano Crystals . . . . . . . . . . . . . . . . . . 89
5.2.3 Sol-Gel Template Synthesis of Titania Nano Tubes and Rods . . . . . . . 89
5.2.4 Overview of Other Synthesis Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.3 Synthesis of Zinc Oxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.3.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.3.2 The Solid-Vapor Synthesis of ZnO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
by Biphasic Reduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
5.2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
5.2.1 Solvo-Thermal Synthesis of Titania Nano Crystals . . . . . . . . . . . . . . . . . 102
5.2.2 Sol-Gel Template Synthesis of Titania Nano Tubes and Rods . . . . . . 102
5.2.3 Overview of Other Synthesis Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5.3.1 The Solid-Vapor Synthesis of ZnO: Horizontal Tube Furnace . . . . . . 104
5.3.2 Wurtzite Structure of ZnO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
6. Is Bionanotechnology a Panacea?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .109

6.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
6.2 Primary Concerns . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
6.3 Assessing Potential Risks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
6.3.1 Inhalation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
6.3.2 Contact/Dermal Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
6.3.3 Other Routes of Contact . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
6.3.4 Environmental Impacts of NPs and the Food Chain . . . . . . . . . . . . . . . 113
6.3.5 Explosion Hazards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
viii BIONANOTECHNOLOGY
6.4 Lessons from the Past . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
6.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
7. Roadmap to Realization of Bionanotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121

7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
7.2 Nano Vision: the Futuristic Goals of Bionanotech . . . . . . . . . . . . . . . . . . . . . . . . . 121
7.3 Working toward Realization: Current Progress. . . . . . . . . . . . . . . . . . . . . . . . . . . .122
7.4 Screenshot of Reality: Bionano-Unbiased/Uncensored . . . . . . . . . . . . . . . . . . . . . 123
7.5 The Nano Mission: Roadmap to Realization
of Translation Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
7.5.1 Bionano in the US . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
7.5.2 Bio-Nano in Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
7.5.3 Bio-Nano in UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
7.5.4 UK–Japan Joint Initiative for Bionanotechnology . . . . . . . . . . . . . . . . . . 126
7.5.5 The EU Initiative in Bionanotech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
7.5.6 Bionano in Asia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Author Biography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139

1
Introduction
0.1 BIONANOTECHNOLOGY: A Historical Perspective
The first written concept of the possibility to manipulate matter at the nano-level was proposed
by Richard Feynman who during his lecture “Room at the Bottom” discussed the use of atomic
blocks to assemble at a molecular level [1, 2]. In this now famous quote, Feynman argues that,
“The principles of physics, as far as I can see, do not speak against the possibility of maneuvering
things atom by atom. It is not an attempt to violate any laws; it is something, in principle, that can
be done; but in practice, it has not been done because we are too big” [2, 3]. In today’s definitions,
“nanotechnology is the understanding and control of matter at dimensions of roughly 1 to 100
nanometers, where unique phenomena enable novel applications” [2–4].
The nanotechnology field was however really established by the work of Eric Drexler,
Richard Smalley and in the bionanotechnology arena by Chad Mirkin.
a) Richard Smalley
Dr. Richard E. Smalley, a chemistry professor at Rice University, pioneered the field of nan-
otechnology and shared a Nobel Prize in 1996 for the development of bucky-balls, shown in
Fig. 0.1. His contribution to nanotechnology is significant and the research team he established
between Rice and the M.D. Anderson Cancer center has been a strong innovation force in the
area of bionanotechnology.
Dr. Richard E. Smalley—Nobel Laureate

(June 6, 1943–October 28, 2005)
2 BIONANOTECHNOLOGY
FIGURE 0.1: Fullerene (Bucky ball)—discovery by Dr. Richard Smalley
Smalley along with Robert Curl at Rice and Sir Harold Kroto at the University of Sussex
discovered fullerenes, or bucky-balls, these unexpected spherical arrangements composed of 60
carbon atoms. Outside this fundamental, seminal contribution, Smalley’s team continued with
innovative contributions that impacted nanotechnology and its biomedical applications.
These include a practical way to produce large quantities of carbon nano tubes, a vital step
in the commercial development of nanotechnology, and the founding of Carbon Nanotech-
nologies in 2000, to produce large quantities of nanotubes for research and commercialization.
b) Eric Drexler
K. Eric Drexler received his doctorate degree in Molecular Nanotechnology from MIT in 1991,
the first degree of its kind. As a researcher, author, and policy advocate he has been one of the
pioneers to focus on emerging technologies and their impact for the future.
He founded the Foresight Institute and presently serves as the Chief Technical Advisor
of Nanorex, a company that develops software for the design and simulation of molecular ma-
chine systems. His thought provoking publications “Engines of Creation: The Coming Era of
Nanotechnology,” “Nanosystems: Molecular Machinery, Manufacturing, and Computation,”
and “Unbounding the Future: The Nanotechnology Revolution,” made great impact by in-
troducing the very topic of nanotechnology to many, and exposing an engineering approach
INTRODUCTION 3
Dr. Eric Drexler (April 25, 1955- )
to nanotechnology and nanosystems [5–6]. In Chapter 7, we will see a summary of ideas ex-
changed between Richard Smalley and Eric Drexler on the feasibility and scope of “molecular
assemblers” with regard to future [6].
c) Chad Mirkin
Chad A. Mirkin is presently a Professor in the Department of Chemistry and Institute for
Nanotechnology at Northwestern University, and has been a pioneer in chemical modifications
of nanosystems leading to breakthrough contributions to bionanotechnology.
Dr. Chad Mirkin (November 23, 1963- )

4 BIONANOTECHNOLOGY
His research work focusing on new ligand design, self-assembled monolayers, design of
molecule-based electronic devices, nanolithography, nanoparticles, and DNA-directed mate-
rials synthesis provided the foundation for bionanotechnology research in many diverse appli-
cation areas [7–18].
A most insightful quote of Chad Mirkin explains the need to open our minds and change
our attitude as we embark on learning this new field: “ At the nano level atoms do not belong to
any field of science.” In a very elegant way, this conveys the extreme diversity and uniqueness of
nanotechnology, while stressing the preparation required by those aspiring to contribute to it.
Our goal in this short book is to expose the reader in a methodical way to the necessary concepts
and key advances of the field so as to enable further study of the subject or an informed decision
involving use of bionanotechnology.
0.2 NANOTECHNOLOGY AND BIONANOTECHNOLOGY

In an effort to define the borders of this new and emerging discipline the National Nanotech-
nology Institute (NNI) proposed the limitation that truly “nanotechnology is the understanding
and control of matter at dimensions of roughly 1 to 100 nm, where unique phenomena enable
novel applications” [4]. As length scale is a continuum, a seeming fuzziness exists in the tran-
sition from the micrometer to the nanometer scale. For example, are structures of 800 nm (0.8
microns) true nanostructures or not?
According to the NNI definition, any structure less than 100 nm is a true nanostructure
and unique phenomena are expected at that scale [4]. By the same approach however, if novel
phenomena are exhibited by a structure at 200 nm this is a nanotechnology enabled material
and as such is the realm of study in nanotechnology.
Nanotechnology is defined as, engineering and manufacturing at nanometer scales, with
atomic precision. The term is interchangeable with “molecular nanotechnology” [1].
Bionanotechnology is a subset of nanotechnology where the biological world provides
the inspiration and/or the end goal. It is defined as atom-level engineering and manufacturing
using biological precedence for guidance (Nano-Biomimetics) or traditional nanotechnology
applied to biological and biomedical needs [1].
In order to gain a feeling of the relative size of a nanometer, let us compare some
everyday objects with some biological basic blocks using a nano-ruler. Table 0.1 summarizes
several such examples including Qd, Micelles, glucose, nanoparticles, and hemoglobin. For
instance, the thickness of human hair is 50,000 nm, while the size of a glucose molecule is
less than 1 nm [19]. It is remarkable that a molecule 50,000 times smaller in size than one
strand of human hair provides energy for our metabolic activities. Table 0.1 compares entities
of bionanotechnology with matters of daily life so as to give a lucid picture of what it takes
to be nano and to feel how small they are. Other examples of nano entities could be found
elsewhere [19].
INTRODUCTION 5
TABLE 0.1: Comparison of Nanoparticles with Matter of Macro World
1. Glucose Thickness of human Thickness of A man of 8.3 feet

molecule hair 0.050 mm human hair height
diameter: 1 nm 0.050 mm
1: 50,000 1: 50,000
2. Gold Apple of diameter: Apple of 65% of diameter of
nanoparticle of 8 cm diameter 8 cm earth 0.65 *12,576
diameter: 8 nm km = 8,170 km
1: 10,000,000 1: 10,000,000
3. Micelle Soap bubble 1.3 cm Soap bubble of Diameter of earth
diameter: 1.3 cm 12,576 km
13 nm
1: 10,000,000 1: 10,000,000
4. Quantum dot Diameter of a cent Diameter of a 55% of diameter of
diameter: 1.9 cm cent 1.9 cm moon 1,9050 km
20 nm
1: 10,000,000 1: 10,000,000
5. Hemoglobin Riffle bullet of Riffle bullet of A land of diameter
diameter: diameter: 6.5 mm diameter: 6.5 km (three times
6.5 nm 6.5 mm as big as Vatican
City)
1: 1,000,000 1: 1,000,000
0.3 NOTABLE NANOIMAGES IN BIONANOTECHNOLOGY

0.3.1 AFM-Qd
Fig. 0.2 is an image of quantum dots (QDs) obtained from the atomic force microscope (AFM)
which will be discussed in detail in Chapter 3. The AFM is a form of microscope having
the ability to image nano-sized objects. The imaging of nano-sized objects is facilitated via
mechanical interaction of a very sensitive tip (which is the probe of the microscope) with the
sample. The quantum dots or QDs are semiconductor particles of smaller diameters ranging
between 2- and 10 nm.
Their small size, sharp optical features, and excellent fluorescence make them an ideal
candidate for biological imaging applications [20]. Fig. 0.2 shows an AFM image of quantum
dots made of InAs imaged at 1 µm × 1 µm [21].
6 BIONANOTECHNOLOGY
FIGURE 0.2: AFM image of quantum dots
0.3.2 Nano-drug Delivery Chip

Fig. 0.3 is an image of the front and back views of a drug delivery microchip made of silicon and
coated with gold, with a U.S. dime (10 cents). The chip in the picture consists of 34 nano-sized
wells each of which is capable of housing 24 nl (nano liters) of drug. It is possible to make at
least 400 wells or even 1000 or more in these chips which are very inexpensive, costing less than
$20 [22, 23].
FIGURE 0.3: Drug delivery microchip

INTRODUCTION 7
FIGURE 0.4: SWNT ropes with SWNT probe
0.3.3 Atomic Force Microscopy Image (AFM) of SWNT

Fig. 0.4 shows the AFM image of single wall carbon nanotube (SWNT) bundles obtained with
a SWNT probe (tip), by using a phase contrast technique [24].
0.3.4 Scanning Electron Microscopy Image (SEM) of SWNT

Fig. 0.5 shows the scanning force micrograph of “crop circle” of SWNT. The circle has an
apparent height of 1.0–1.2 nm and a width of 4–8 nm. The actual tube height is close to
1.5 nm (typical of SWNT) [25].
The carbon nanotubes (CNT) will be discussed in detail, later in Chapter 5.
FIGURE 0.5: SEM images of CNT

8 BIONANOTECHNOLOGY
0.4 OPPORTUNITIES AND CHALLENGES

OF BIONANOTECHNOLOGY
The size of one to several nanometers is of central importance to life, justifying the term
“nature’s yard stick” for this dimension. The size of cellular organelles and other interesting
objects with regard to bionanotechnology is summarized in the following graph, Fig. 0.6.
It is then easy to understand that interacting, controlling, and altering cellular and
subcellular organelles, protein molecules, receptors, and cytokines can be achieved best with
structures at the same size level as the biomolecular components of interest. Already capabilities
made possible by fluorescent semiconductor nanoparticles, known as quantum dots, allowed
dynamic angiography in capillaries hundreds of micrometers below the skin of living mice.
This corresponds to about twice the depth of conventional angiographic materials and has been
obtained with one-fifth of the irradiation power [26]. The development of hyperthermia nano
agents for cancer therapy is underway and could impact patients in the next 2–5 years [27],
while transparent sun screens sensing the amount of damage to skin are the next generation
products in the sun protection industry [26, 28].
An example of advances in other nanotechnology fields that impact bionanotechnology is
the successful development of nanotube-based fibers requiring three times the energy-to-break
of the strongest silk fibers and 15 times that of Kevlar fiber; such fibers are further functionalized
to detect toxic agents and deliver protection and warning to the user [29]. Examples of successful
water decontamination where iron particles can remove up to 96% of trichloroethylene from
groundwater are another application of bionanotechnology where environmental remediation
can be accomplished [18].
FIGURE 0.6: Various nano-sized entities in bionanotechnology [Courtesy of Dr. Papazoglou, Drexel
University]
INTRODUCTION 9
Disease treatment is reaching a turning point, with the emerging fields of molecular
based medicine and personalized medicine. A cellular level control is not possible without
nanotechnology as the key enabling technology. We can look forward to clinicians diagnos-
ing diseases much faster with higher sensitivity and specificity. The possibilities of developing
multifunctional nano-devices are attracting more attention [28]. This creates a collaborative
effort for different fields to come together and collectively advance knowledge in solving a
problem. Molecular understanding of cellular function in health and disease is augmented
by nano-tools, while disease treatment is also impacted by the same methods. The distinc-
tions of basic and applied science merge as they synergize each other to improve human
health.
An example of a persistent difficult problem to understand in detail from nature in-
volves the dynamics of self-assembly [30, 31]. Bionanotechnology could allow us to synthe-
size biomimetic nanostructures [30] to control and model the self-assembly process. This
would be an area where nanotechnology helps augment our basic biological understanding
[31].
The greatest challenge of bionanotechnology today is understanding the long-term im-
pact on human health and the environment of structures we cannot see even with the most
sophisticated optical microscopes and structures that can interact with the basic components
of life. A scientific approach of utmost rigor is required to reveal interactions of nanostructures
that may be affecting human health [23, 26, 28, 32].
0.5 GROWTH POTENTIAL OF NANOTECHNOLOGY

AND RELATED EXPENDITURES
The opportunity for nanotechnology to revolutionize diverse technical areas has been well
understood. It is not easy to estimate the expenditures for bionanotechnology from the pooled
nanotechnology investment.
Conservative estimates place the bionanotechnology portion to at least 50% of nan-
otechnology dollars spent, while breakthroughs and advances in the general nanotech-
nology field benefit bionanotechnology directly or indirectly. Table 0.2 provides a yearly
summary of the US national level expenditure incurred in the field of nanotechnology
[33, 34].
The projection of expenditures shows a drastic increase with forecasts anticipating an
astounding $1 Trillion by the year 2015 [35]. The 21st Century Nanotechnology Research
and Development act [35] of the US senate enables and encourages such high level of ex-
penditures to ensure the competitiveness of the US workforce in the global environment
[35–38].
10 BIONANOTECHNOLOGY
TABLE 0.2: Yearly US Nanotechnology Expendi-

ture during 1997–2015
ANNUAL BUDGET USD

YEAR IN MILLIONS
1997 116
1998 190
1999 255
2000 270
2001 465
2002 697
2003 862
2004 961
2005 1,200
2006 1,302.5
2007 1,278.3∗
2015 1,000,000
NOTE: Year 2007* is subjective to changes.
It can confidently, be stated that:
1. Nanotechnology is still in its infancy and has an almost unpredictable growth, which
seems steady and increasing.
2. The field has excellent potential to consume more resources attracting further
investment.
The following graph in Fig. 0.7 (adapted from Roco, M.C. and NNI budget for 2007) shows
the yearly expenditures incurred in nanotechnology research [33, 34].
A global comparison of the annual expenditure in nanotech research reveals a similar
trend as observed in the United States. Fig. 0.7 charts a comparison of US annual expenditures
in nanotechnology versus Western Europe, Japan, and Others [39]. May it be global or in the
United States, the research initiatives and expenditure in nanotechnology are steadily increasing.
The growth and the present trend in nanotechnology as well as bionanotechnology
are quite promising and booming. A detailed insight into international Bionanotechnological
initiatives and funding will be dealt in detail in Chapter 7.
INTRODUCTION 11
FIGURE 0.7: Annual Research Expenditure in Nanotechnology in the US
FIGURE 0.8: Annual nanotechnology expenditure—a global outlook (Adapted from ref. [39])
REFERENCES
[1] D. S. Goodsell, Bionanotechnology: Lessons from Nature. Willey-Less, 2004, pp. 1–8
(311), New Jersey, USA.
[2] R. Feynman, There’s Plenty of Room at the Bottom. The Vega Science Trust, December
29th 1959, The American Physical Society at CalTech, California.
[3] R. Feynman, There’s Plenty of Room at the Bottom. 1959 [cited 2006 10/02/2006]; [Tran-
script]. Available from: http://www.zyvex.com/nanotech/feynman.html [A web-
site based from Georgia].
[4] (NNI), N.N.i. Nanotechnology: What is Nanotechnology? 2000 [cited 2006 10/2/2006];
Available from: http://www.nano.gov/html/facts/whatIsNano.html [It is a web-
page, place of publication unkonwn].
[5] E. K. Drexler, Nanotechnology Essays: Revolutionizing the Future of Technology
[EurekAlert! Incontext]. 2006 [cited 2006 10/02/2006]; Available from: http://
www.eurekalert.org/context.php?context=nano&show=essays [Washington DC, USA].
[6] R. Baum, “Nanotechnology: Drexler and Smallye make the case for and against molecular
assemblers,” Chem. Eng. News, vol. 81, pp. 37–42, 2003.
[7] M. Covington, et al., “Observation of surface-induced broken time-reversal symme-
try in YBa2Cu3O7 tunnel junctions,” Phys. Rev. Lett., vol. 79, pp. 277–280, 1997.
doi:10.1103/PhysRevLett.79.277
[8] R. Elghanian, et al., “Selective colorimetric detection of polynucleotides based on the
distance-dependent optical properties of gold nanoparticles” Science, vol. 277, pp. 1078–
1080, 1997. doi:10.1126/science.277.5329.1078
[9] B. J. Holliday, and M.C. A., “Strategies for the construction of supramolecular com-
pounds through coordination chemistry,” Angew. Chem., Int. Ed., vol. 40, pp. 2022–2043,
2001. doi:10.1002/1521-3773(20010601)40:11<2022::AID-ANIE2022>3.0.CO;2-D
[10] R. Jin, et al., “Photo-induced conversion of silver nanospheres to nanoprisms” Science,
vol. 294, pp. 1901–1903, 2001. doi:10.1126/science.1066541
[11] C. A. Mirkin, et al., A DNA-based method for rationally assembling nanoparticles into
macroscopic materials. Nature, vol. 382, pp. 607–609, 1996. doi:10.1038/382607a0
[12] S. J. Park, T. A. Taton, and C. A. Mirkin, Array-based electrical detec-
tion of DNA using nanoparticle probes. Science, 295, pp. 1503–1506, 2002.
doi.org/10.1126/science.283.5402.661
[13] R. D. Piner, et al., Dip pen nanolithography. Science, vol. 283): pp. 661–663, 1999.
doi:10.1126/science.283.5402.661
[14] J. J. Storhoff, et al., One-Pot Colorimetric Differentiation of Polynucleotides with Sin-
gle base imperfections using gold nanoparticle probes. J. Am. Chem. Soc., vol. 120(9),
pp. 1959–1964, 1998. doi:10.1021/ja972332i
INTRODUCTION 13
[15] J. J. Storhoff, and C. A. Mirkin, Programmed materials synthesis with DNA. Chem.
Rev., vol. 99, pp. 1849–1862, 1999. doi:10.1021/cr970071p
[16] J. J. Storhoff, R. C. Mucic, and C. A. Mirkin, Strategies for organizing nanoparticles
into aggregate structures and functional materials. J. Clust. Sci., vol. 8, pp. 179–216, 1997.
doi:10.1023/A:1022632007869
[17] T. A. Taton, C. A. Mirkin, and R. L. Letsinger, Scanometric DNA ar-
ray detection with nanoparticle probes. Science, vol. 289, pp. 1757–1760, 2000.
doi:10.1126/science.289.5485.1757
[18] W.-X. Zhang, Nanoscale iron particles for environmental remediation: an overview. J.
Nanopart. Res., vol. 5(3-4), pp. 323–332, 2003. doi:10.1023/A:1025520116015
[19] C. Bruce, Nanotechnology: molecular speculations on global abundance, B. C. Crandall,
Ed., MIT Press, 1996, pp. 1–5 (226) [Cambridge, MA, USA].
[20] A. Smith, et al., Engineering luminescent quantum dots for invivo molecular and cellular
imaging. Ann. Biomed. Eng., vol. 34(1): pp. 3–14, 2006. doi:10.1007/s10439-005-9000-9
[21] S. Barik, H. H. Tan, and C. Jagadish, Comparison of InAs quantum dots
grown on GaInAsP and InP. Nanotechnology, vol. 17, pp. 1867–1870, 2006.
doi:10.1088/0957-4484/17/8/010
[22] R. Langer, and N. A. Peppas, Advances in biomaterials, drug delivery, and bionanotech-
nology. Bioeng., Food, Natural Prod.—AIChE, vol. 49(12), pp. 2090–3006, 2003.
[23] E. A. Thomson, Microchip Stores, Releases Chemicals for Many Uses. 1999 [cited 2006
10/02/1006]; Available from: http://web.mit.edu/newsoffice/1999/chip-0203.html.
[24] F. Nano, SWNT Ropes with SWNT Probe. [Bitmap Image] 2005 [cited 2006 10/02/2006];
Available from: http://www.firstnano.com/applications.html# .
[25] J. Liu, et al., Fullerene crop circles. Nature, vol. 385, pp. 780–781, 1997.
doi:10.1038/385780b0
[26] T. W. Foundation, The Whitaker Foundation 2004 Annual Report: Biomedical Engi-
neering and the Medical Applications of Nanotechnology, The Whitaker Foundation,
pp. 1–48, 2004.
[27] D. Misirlis, “Development of a novel drug delivery system based on polymeric, ther-
moresponsive, hydrogel nanoparticles,” in Institute of Integrated Biosciences, École Poly-
technique Fédérale De Lausanne, pp. 1–149, 2005.
[28] W. C. W. Chan, Bionanotechnology progress and advances. Biol. Blood Marrow Trans-
plant., vol. 12, pp. 87–91, 2006. doi:10.1016/j.bbmt.2005.10.004
[29] C. Q. Sun, et al., Dimension, strength, and chemical and thermal stability of a sin-
gle C-C bond in carbon nanotubes. J. Phys. Chem. B, vol. 107, pp. 7544–7546, 2003.
doi:10.1021/jp035070h
[30] Z. Ökten, et al., Myosin VI walks hand-over-hand along actin. Nat. Struct. Mol. Biol.
vol. 11, pp. 884–887, 2004. doi:10.1038/nsmb815
[31] P. D. Vogel, Nature’s design of nanomotors. Eur. J. Pharm. Biopharm., vol. 60, pp. 267–
277, 2005. doi:10.1016/j.ejpb.2004.10.007
[32] I. L. Medintz, et al., Self-assembled nanoscale biosensors based on quantum dot FRET
donors. Nat. Mater., vol. 2, pp. 630–638, 2003. doi:10.1038/nmat961
[33] (NNI), N.N.I., NNI Annual Budget for 2007: Supplement to the President’s 2007 Budget,
N.S.a.T.C. (NSTC), NNI, pp. 1–76, 2006.
[34] M. C. Roco, The US National Nanotechnology Initiative after 3 years (2001–2003). J.
Nanopart. Res., vol. 6, pp. 1–10, 2004. doi:10.1023/B:NANO.0000023243.25838.73
[35] US, G., The 21st Century National Nanotechnology Research and Development Act. pp. 1–2,
2004.
[36] (NSTC), N.S.a.T.C., National Nanotechnology Initiative and a Global Perspective. “Small
Wonders”, Exploring the Vast Potential of Nanoscience, pp. 1–8, 2002.
[37] (WTEC), W.T.E.C., Nanostructure Science and Technology: R&D Status and Trends
in Nanoparticles, Nanostructured Materials, and Nanodevices. [Chapter 12], R.S.H.-P.
Williams and G.D.U. Stucky, Eds., pp. 181–201 1998.
[38] R. Lux, The Nanotech Report 2004. 2004 [cited; Available from: http://www.nanoxchange.
com/NewsFinancial.asp?ID=264.
[39] M. C. Roco, National Nanotechnology Initiative and a Global Perspective. “Small Won-
ders”, Exploring the Vast Potential of Nanoscience, 2002, National Science and Technology
Council (NSTC), Nanoscience, Engineering and Technology (NSET), pp. 1–8.
15
CHAPTER 1
The Significance of Nano Domain
1.1 LIMITATIONS OF MICRON SIZE

In biomedical applications such as drug delivery and imaging, size plays a significant role in
the efficacy and success of the treatment. Macro size has notable draw-backs when compared
to nano-size with regard to biological applications, due to the size of cellular and subcellular
compartments. For instance, conventional micron-size drug delivery techniques in cancer ther-
apy suffer from inefficacy of delivery, inadequate targeting, toxic effects on healthy tissues, and
impaired transport to tumor sites.
Earlier in drug delivery applications, different modes of administering the drug such
as oral, nasal, transdermal, intra venal, and others were adapted. Oral and nasal deliveries
exhibit high drug levels in blood and have poor release profiles; aerosol design is complex
and problematic with regard to loading issues, while transdermal delivery lacks targeting and
causes damage to healthy cells too [1]. These challenges led to the development of “targeted
drug delivery” as a way to overcome the delivery issues. However, micron sized (µm) delivery
vehicles cannot traverse in a passive fashion through cells and cell pores, and this also includes
tumor cells with pore sizes as big as 380–780 nm. As a result, the ideal system for biological
applications would be a targeted nano-delivery system [2–4].
1.2 NEED FOR NANO-SIZE—SURFACE VOLUME RATIO

SIGNIFICANCE
For smaller/finer particles the area occupied by a unit volume of the nano-particles is higher
than that occupied by the same volume of micron sized particle; therefore the number of
particles available per square unit of area in a nano system is very much higher than a bigger
(micron) sized system. The surface area when divided by the volume of the sample gives the
surface area to volume ratio; this is a very significant factor which determines the extent of activity
of a nanoparticulate system [5]. In a sample of NPs, the greater the surface to volume ratio the
greater is its activity (catalytic or drug delivery related) [6]. This has been demonstrated with
nano-particles of gold, titania, zinc oxide, palladium [7].
1.3 SIGNIFICANCE AND KEY FEATURES OF NANO-SIZE

The world of nano conflicts with the macro world in almost every functionality. The nano
world is immune to laws of gravity and inertia unlike the macro world. Nano-machines and
nano-particles may appear “weird” owing to utmost disobedience to Newtonian Physics of
inertia and gravity. For instance, the bacterial model discussed by Purcell is a classic example
of the nano (micro as well) world’s disobedience to the laws of inertia. The bacterial cell uses a
flagellum to swim in water and is able to come to an abrupt halt without any observed inertia
[8]. Our expectation to see an inertial effect before the stop, i.e., to see it move further and then
stop is not observed. This puzzle is solved when we consider that inertial effects are negligible
at that size and not observable by us. The contribution of inertial effects to the bacterium’s
motion before the halt is less than the diameter of an atom (in Angstroms) [8].
Another fascinating aspect is the negligible impact of gravity on nano-particles (NP). In
the nano-world, particle–particle attractions/repulsions are more prominent than gravitational
forces. For instance, water droplets hanging down from the ceiling are an excellent example
of particle–particle attraction being far greater than the pull of gravity in small sized systems.
Having said about the failure of classical physics in governing the nanosystems, it is much with
the phenomenon associated with the quantum world that better dictate the performance of
nanoparticulate systems.
A nanoparticulate system may be sensitive to its environmental conditions such as tem-
perature, visible light, ultraviolet (UV), infrared (IR), etc. depending on its own physical and
chemical properties. Hess and Mikhailov put forth that, any two molecules “within a µm sized
cell meet each other every second.” Thermal energy (heat) provides a driving force, by increasing
the diffusion and the system’s physiochemical interactions [8]. There are also some general fac-
tors that interact with most of the nanoparticulate systems; this includes pH, and surface charge
(forces of attraction/repulsion), and vibration forces, centrifugation, stirring etc. can easily and
effectively impact a nanoparticulate system. A notable and important aspect of the NPs system
is that of atomic granularity. The system is granular at the atomic dimensions; one cannot
expect smooth surfaces or interfaces between different particles. The atom–atom interaction
determines the NP’s shape, size, geometry, and orientation. All the above-mentioned features
greatly contribute to the “self-assembly” property of certain nanoparticulate systems, mostly
observed in proteins and nature’s biomachines [9, 10].
Measurements and characterization of NP systems are crucial processes during which
one has to pay attention to bring the system to a complete rest. This is done to settle down the
random Brownian motion which is observed in aqueous suspended NP systems. It is notable
that many of the NP systems of interest to bionanotechnological applications are suspended in
an aqueous phase in order to study its viability in aqueous medium; this is because, the cells in
the human body have vast aqueous medium that the NP system will have to interact with [8].
THE SIGNIFICANCE OF NANO DOMAIN 17
As mentioned earlier, the laws of quantum mechanics govern the interaction of NP with
their environment. Usually, in a system of NPs, the covalent bond holds intact one NP to the
other, defining the particles’ geometry and shape. Steric hindrance, electrostatic interaction,
and hydrogen bonds also influence particle–particle interactions to a certain extent. Thus a
system of NP under study should encompass all of the above-mentioned factors in order to
understand and model the system.
1.4 DERIVATION OF BOHR’S ATOMIC RADIUS

OF A HYDROGEN ATOM
The failure of classical physics to explain the properties of matter at the atomic scale led to the
evolution of quantum mechanics. Fundamental concepts of quantum mechanics were developed
by Neils Bohr who put forth in 1913 that in a free atom, electrons occupy discrete energy states
associated with shells or orbits in an atom [11].
Depending on the excitation energy electrons can jump from one energy level to the
other. They later return to their ground state which is their most stable state.
Neils Bohr modeled and predicted the energy levels in a hydrogen atom which is popularly
referred to as the Bohr’s atomic model. This model serves as a corner stone for quantum theory
which is able to answer various puzzles in physics with accuracy and precision that classical wave
theory had not been able to resolve. Bohr’s model is arguably the simplest and most realistic
model of quantum mechanics [11].
Combining the energy of the classical electron orbit with the quantization of angular
momentum, the Bohr approach yields expressions for the electron orbit radii and energies [11].
To arrive at the Bohr’s radii of a hydrogen atom consider an electron of mass m present
in an orbit of radius r with respect to the nuclei.
mv 2
Kinetic energy of electron =
2
Angular momentum of the electron with respect to the nuclei
L = mvr sin θ
But θ = 90◦ for a circular orbit, so Sin 90 = 1.

Therefore angular momentum of the electron
L = mvr (1.1)
Kinetic energy expressed as angular momentum
(mvr )2
(1.2)
2mr 2
2 2
(this is same as mv2 mv2 ).
According to DeBroglie’s equation of wavelength,
h
λ=
p
where
λ = wavelength in meters (m)

h = Planck’s constant = 6.626 × 10−34 JouleSec. = 4.136 × 10−15 eV.Sec;
kg.m
p = momentum = mass × velocity = mv.
Sec.
Therefore
h
λ= (1.3)
mv
According to the standing wave condition, the circumference of an orbit of a particle (electron)
is equal to the whole number times the associated wavelength.
nλ
Circumference = 2πr = nλn Or r = (1.4)
2π
where r is the radius of the orbit, n is the whole number of the associated orbit (nth orbit from
the nuclei), and λn refers to the wavelength of the nth orbit.
By putting (1.3) in (1.1) we get . . . . . .
hr
L = mvr = (1.5)
λ
Putting (1.4) in (1.5) gives
nh
L = mvr = (1.6)
2π
(This is referred to as quantized angular momentum).
By using quantization of angular momentum, kinetic energy
n2 h 2
(1.7)
8π 2 mr 2
(obtained by putting (1.6) in (1.2)).
Total energy of the classical orbit of hydrogen atom = potential energy + kinetic energy
of the electron
Potential energy
Ze 2
U =−
4π ε0r
Kinetic energy
Ze 2
T= (1.8)
8π ε0r
Total energy
Ze 2
T+U = − (1.9)
8π ε0r
Equating (1.2), (1.7), and (1.8) to the equation of kinetic energy
mv 2 (mvr )2 n2 h 2 Ze 2
Kinetic energy = = = =
2 2mr 2 8π 2 mr 2 8π ε0r
n2 h 2 ε0 n2 a 0
By substituting for r = Zπme 2
= Z
in the equation of total energy in (1.9) gives
Z2 me 4 13.6Z2
E=− = − eV
8n2 h 2 ε02 n2
n2 h 2 ε0 n2 a 0
ln r = = ;
Zπ me 2 Z
a 0 = 0.539Å = BohrRadius
The Bohr’s radius is defined as the least distance from the nuclei at which a single electron
revolves in an orbit which is at the lowest energy state.
(OR)
The Bohr radius a 0 can be derived by equating.

The centrifugal force of an electron following a circular trajectory (in its orbit) around a
proton and the electrostatic force experienced by the electron is given by
v2 q2
m =
r 4π εo r 2
where
m is the mass of the electron in kg,

v is the velocity of the electron in m/sec,
r is the radius of the orbit in m,
q is the charge (usually point charge when considered) in Coulomb, and
εo is the permittivity of free space = 8.8541878176 × 10−12 farads per meter (F/m).
According to DeBroglie’s equation of wavelength,

h
λ= ,
p
where lambda, λ is the wavelength in meters (m),
h = Planck’s constant = 6.626 × 10−34 JouleSec. = 4.136 × 10−15 eV.Sec

kg.m
p = momentum = mass × velocity = mv.
Sec.
According to the standing wave condition, the circumference of an orbit of a particle
(electron) is equal to the whole number times the associated wavelength.
2πr = nλ
For first orbit 2πr = λ.

From p = h/λ and λ = 2πr one finds that
h
p=
2πr
Therefore
2
2 h
2
mv p 2π q2
= = =
r rm mr 3 4π εo r 2
On simplifying for the Bohr’s radius r , we get
4π εo h 2
r = ,
mq 2
this radius is represented by a 0 . The numeric value is
a 0 = 0.539Å = BohrRadius
The Bohr’s radius is defined as the least distance from the nuclei at which a single electron
revolves in an orbit which is at the lowest energy state.
Bohr’s model assumes that the energy of the particles in an atom is restricted or confined
to certain discrete values, i.e., the energy levels are quantized. This translates into the existence
of only certain orbits with certain radii while intermediate orbits are not allowable and therefore
do not exist. Fig. 1.1 illustrates Bohr’s atomic model for the hydrogen atom [11].
In Bohr’s hydrogen model, the number n is defined as the quantum number which takes
the values of various positive integers; n = 1, 2, 3 . . . and each number corresponds to an “energy
state” or “energy level.” Fig. 1.2 illustrates the different energy levels [11].
The lowest energy level is referred to as ground state; the successive higher energy states
are called first excited state, second excited state, and so on. Further, in the energy state (level)
beyond the “ionization potential” the electron is no longer bound to the atom, forming a
continuum. The “ionization potential” of a hydrogen atom is 13.6 eV (electron-volt).
FIGURE 1.1: Bohr’s atomic model
Atoms are excited or de-excited by absorbing or emitting the energy required to move
between different orbits. Fig. 1.3 shows the excitation and de-excitation caused by photonic
emissions [11].
One can comprehend from Bohr’s model that an atom can absorb or emit only discrete
energy “packets.” This energy will follow the equation [12].
E = hν
FIGURE 1.2: Quantized energy levels in hydrogen

FIGURE 1.3: Excitation by absorption of light and de-excitation by emission of light
Also
hc c
E= since ν=
λ λ
where,
E is the energy required for excitation or de-excitation,

h is Planck’s constant,
ν (pronounced nu) is the frequency (sec−1 ),
c is the velocity of light (m sec−1 ), and
λ is the wavelength (m).
1.5 COMPARISON OF PARTICLE BEHAVIOR AT NANO-SIZE

TO MACRO SIZE: GOLD AND TITANIA
This section elucidates the importance and applications of NP of gold (AuNP) and titanium
di-oxide (TiO2 –titania) nanoparticles—TNP. We start with a comparison of the macro size
to the nano domain of each material to obtain an insight of the value of nanosize for various
applications.
a) Gold Nanoparticles (AuNP)
Mining of gold and using it for various decorative and medical purposes has been of great interest
since ancient times. With technological developments, the smelting of gold too took crucial
turns thereby opening newer techniques of synthesis. In the present day gold nanoparticles
(AuNP) seem to be of more interest than their macro counterparts, at least to the world of
research. AuNP have interesting properties that scientists are able to exploit. Key properties of
AuNP include their stability, non-toxicity, bio-compatibility, characteristic optical properties,
and surface plasmon resonance (SPR) behavior. These provide the potential for unique catalytic
and biological applications [13–15].
AuNP includes colloidal gold as well as thin film gold. The synthesis of colloidal gold is
a highly reproducible robust process with capability of producing colloidal AuNP as small as
1.5 nm [15]. A popular application of colloidal gold is the use of 1.4 nm AuNP as an electronic
switch to control the hybridization and re-hybridization of DNA by conjugating the AuNPs
to the DNA [16].
Colloidal gold particles of different sizes emit visible light of different wavelengths. The
smallest of gold NP will emit pink or purple while aggregated sample turns yellow [13]. Unlike
metallic gold of micron size, AuNP has a unique property called the SPR. This SPR is being
utilized as a popular tool in biological applications for enzyme kinetics (as in the Biacore
instrument) or in combination with Raman spectroscopy.
SPR is excited at a metal or dielectric interface by a monochromatic light source. SPR
is observed as a deep minimum in the p-polarized reflected light as the angle of incidence is
increased. The plasmon, a ray of light bound onto a surface, propagates among the surface and
presents itself as an electromagnetic field [17].
SPR can then be used to amplify refractive index changes due to the adsorptions of thin
layers of materials (proteins, antigens, etc.) adsorbed on a film of metal. For instance a protein
in a buffer, when adsorbed on the surface of a metallic gold film, produces a change in the
refractive index of the film compared to the system with just the buffer. The difference between
the refractive index of the buffer and that of the adsorbate is converted to mass of the adsorbate.
The initial refractive index is characteristic of the metal used. AuNP or thin films of gold ex-
hibit excellent SPR effects. This method is rapidly replacing tedious and time-consuming
enzyme kinetics experiments to determine binding affinities of antigens and antibodies
[17, 18].
The SP could be used as a probe in biological applications as it is very sensitive to
environmental changes close to the interface. Popular biological and immunological sensing
techniques have been developed with AuNP–SPR that is remote and non-destructive. Also SP
finds excellent applications in surface enhanced spectroscopy for example in surface plasmon
fluorescence spectroscopy and surface enhanced Raman spectroscopy (SERS) [18, 19].
b) Titanium Di-oxide Nanoparticles (TNP)—Titania (TiO2 )
TiO2 (titania), the naturally occurring oxide of titanium, not available in pure form is often
synthesized from the ilmenite or leuxocene ores. Of the various forms of titania, rutile, anatase,
brookite, and titanium dioxide (B) are the most common. TNP have superior catalytic properties
to micron size or larger titania particles. TNP being smaller have higher surface area to volume
ratio and hence improved catalytic activity [20].
A number of techniques are used for the synthesis of nanoparticles of TiO2 , namely the
sol-gel method, the microemulsion technique, and the flame oxidation method. The outstand-
ing catalytic properties of TNP make it one of the dominant catalysts used in the decomposition
of organic pollutants and also in water treatment plants [6, 21]. The photocatalytic applications
of TNP including water cleansing and pollution disinfection are often triggered by exposure
to visible or UV irradiation [6]. Doping of titania with metals and/or semiconductors further
its photocatalytic activity, the identification and optimization of such parameters represent an
active area of bionanotechnology’s academic and industrial research as manifested by several
recent publications [22–27].
1.6 ADVANTAGES OF SCALING DOWN—NANO-SIZE

The main advantages of scaling down to nano-size in biological application include the following
and become very important in drug delivery applications [1, 28].
Nanoparticles are able to:
1. Accumulate in the tissue of mononuclear phagocyte system (MPS) (formerly

RES).
2. Leave the vasculature through leaky angiogenic vessels and accumulate in tumor inter-
stitia. (drug delivery + imaging).
3. Achieve enhanced permeability and retention effect (EPR effect).
As mentioned earlier the concept of targeted drug delivery goes hand in hand with nano-
size only. Choosing a nano-model of application in targeted drug delivery involves various
notable advantages including, stability of drug in targeted delivery, prevention of phagocytosis,
easy/passive transport of drug vehicles across epithelia, high surface volume ratio and hence
better performance & appropriate drug release at target sites [29–37]. Current trends in research
focus on creating multifunctional NP for in vivo use, for non-invasive visualization of molecular
markers for early stage disease, for targeted delivery of therapeutics, reduction of deleterious
side effects, and interception and containment of lesions before they reach lethal stage, with
minimal or no loss of quality of life [36–41].
FIGURE 1.4: Multifunctional nanoparticle—nanovector
Fig. 1.4 is a schematic of a multifunctional nano-device (nanovector) comprising of two

drugs, namely A and B for delivery, a contrast-enhancing agent for better imaging, a permeation
enhancer for easier and sooner reachability to site, PEG coating to fool the immune system
and targeting moieties for better specificity in targeting. All this being in the nanodomain will
ensure quick passage of the vectors through the cells and pores and enable them to reach the
disease target with ease [39].
Fig. 1.5 is a representation of the multifunctional targeting strategy in a tumor site.
The nanovectors reach the tumor site by passing through the fenestrations of the angiogenic
vasculature. One or more antibodies present in these nanovectors enable them to specifically
and selectively bind to chosen sites. Having reached their specific sites, the nanovectors can
be triggered to release their cytotoxic agents to create an antitumor action. The trigger could
be accomplished by an external source (ultrasound, IR, MRI, etc.) or by using internal factors
such as pH or temperature [39].
FIGURE 1.5: Multifunctional targeting strategy in a tumor site
REFERENCES
[1] H. Frieboes and J. Sinek, Handbook of BioMEMS & Bio-Nanotechnology—Prospectus,
Biological and Biomedical Nanotechnology: Nanotechnology in cancer drug therapy: a Biocom-
putational approach. In Onco-Imaging, Medicine-Hematology/Oncology., A. Lee, L. Lee,
Eds. Berlin: Springer, vol. 1, pp. 435–460, 2006.
[2] P. Gerwins, E. Skoldenberg, L. Claesson-Welsh, “Function of fibroblast growth factors
and vascular endothelial growth factors and their receptors in angiogenesis,” Crit. Rev.
Oncol./Hematol., vol. 34 (3), p. 185, 2000. doi:10.1016/S1040-8428(00)00062-7
[3] S. Muro, R. Wiewrodt, A. Thomas, L. Koniaris, S. M. Albelda, V. R. Muzykantov,
M. Koval, A novel endocytic pathway induced by clustering endothelial ICAM-1 or
PECAM-1. J. Cell Sci. vol. 116(8), pp. 1599–1609, 2003. doi:10.1242/jcs.00367
[4] B. Peppas, L. Blanchette, O. James, Nanoparticle and targeted systems for cancer therapy.
Adv. Drug Deliv. Rev. vol. 56, pp. 1649–1659, 2004. doi:10.1016/j.addr.2004.02.014
[5] A. Majumdar, Nanotechnology Research in Support of Homeland Security: Chem-
ical, Biological, Radiological, and Explosive (CBRE) Detection and Protection.
http://www.nano.gov/html/news/SpecialPapers/Nanotechnology%20Research%20in%
20support%20of%20Homeland%20Security cbre.htm (10/09/2006),
[6] S. Ma, J. Zhou, Y. C. Kang, J. E. Reddic, D. A. Chen, Dimethyl methyl-phosphonate
decomposition on Cu surfaces: supported Cu nanoclusters and films on TiO2 (110).
Langmuir vol. 20, pp. 9686–9694, 2004. doi:10.1021/la048594x
[7] G. Nagaveni, M. S. Sivalingam, Hegde; Giridharmadras, Photocatalytic degradation of
organic compounds over combustion-synthesized nano-TiO2. Environ. Sci. Technol. vol.
38, pp. 1600–1604, 2004. doi:10.1021/es034696i
[8] D. S. Goodsell, Bionanotechnology: Lessons from Nature. Wiley-Liss, (311), pp. 9–14,
2004.
[9] D. S. Goodsell, Bionanotechnol. Lessons Nat. (311), 103–116, 2004.
[10] V. P. Zharov, J.-W. Kim, D. T. Curiel, M. Everts, Self-assembling nanoclusters in
living systems: application for integrated photothermal nanodiagnostics and nanotherapy.
Nanomedicine vol. 1(4), pp. 326–345, 2005.
[11] N. Bohr, Astronomy Lectures—The Bohr Model. http://csep10.phys.utk.edu/
astr162/lect/light/bohr.html (10/10/2006),
[12] C. R. Nave, Hyperphysics: Planks Theory. http://hyperphysics.phy-astr.gsu.edu/
hbase/whframe.html (10/10/2006),
[13] M.-C. Daniel, Didier, Gold nanoparticles: assembly, supra-molecular chemistry,
quantum-size-related properties, and applications toward biology, catalysis, and nan-
otechnology. Astruc Chem. Rev. vol. 104, pp. 293–346, 2004. doi:10.1021/cr030698+
[14] I. El-Sayed, X. Huang, and M. El-Sayed, Surface plasmon resonance scattering and ab-
sorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: ap-
plications in oral cancer. Nano Lett. vol. 5(5), pp. 829–834, 2005. doi:10.1021/nl050074e
[15] K. V. Sarathy, G. Raina, R. T. Yadav, G. U. Kulkarni, C. N. R. Rao, Thiol-derivatized
nanocrystalline arrays of gold, silver, and platinum. J. Phys. Chem. B vol. 101, pp. 9876–
9880, 1997. http://dx.doi.org/10.1021/jp971544z
[16] H. K. Schifferli, “DNA hybridization: electronic control,” Dekker Encyclopedia of
Nanoscience and Nanotechnology. Taylor & Francis Books, Oxford, UK, pp. 963–974,
2004.
[17] M. Zangeneh, R. Terrill, Surface plasmon spectra of silver and gold nanoparticle as-
semblies Dekker Encyclopedia of Nanoscience and Nanotechnology, Taylor & Francis Books,
Oxford, UK, 2004.
[18] J. W. D. P. B. Attridge, J. K. Deacon, G. P. Davidson, Sensitivity enhancement of
optical immunosensors by the use of a surface plasmon resonance fluoroimmunoassay.
Biosens. Bioelectron. vol. 6(3), pp. 201–214, 1991. doi:10.1016/0956-5663(91)80005-I
[19] Z. Salamon, Y. Wang, G. Tollin, H. A. MacLeod, Assembly and molecular organiza-
tion of self-assembled lipid bilayers on solid substrates monitored by surface plasmon
resonance spectroscopy. Biochim. Biophys. Acta vol. 1195, pp. 267–275, 1994.
[20] S.-H. Lee, “Photocatalytic nanocomposites based on TiO2 and carbon nanotubes,"
Doctoral Thesis, University of Florida, Gainesville, 2004.
[21] C. N. Rusu, J. T. Yates Jr., Photooxidation of dimethyl methyl-phosphonate on TiO2
powder. J. Phys. Chem. B vol. 104, pp. 12299–12305, 2000.
[22] A. Dawson, P. V. Kamat, Semiconductor-metal nanocomposites. photoinduced fusion
and photocatalysis of gold-capped TiO2 (TiO2 /Gold) nanoparticles. J. Phys. Chem. B
vol. 105(5), pp. 960–966, 2001. doi:10.1021/jp0033263
[23] T. Hirakawa, P. V. Kamat, Charge separation and catalytic activity of AgTiO2 core-shell
composite clusters under UV-irradiation. J. Am. Chem. Soc. vol. 127(11), pp. 3928–3934,
2005. doi:10.1021/ja042925a
[24] K. S. Mayya, D. I. Gittins, F. Caruso, Gold-titania core-shell nanoparticles by polyelec-
trolyte complexation with a titania precursor. Chem. Mater. vol. 13(11), pp. 3833–3836,
2001. doi:10.1021/cm011128y
[25] V. Subramanian, E. Wolf, P. V. Kamat, Semiconductor-metal composite nanostructures.
to what extent do metal nanoparticles improve the photocatalytic activity of TiO2 films?
J. Phys. Chem. B vol. 105(46), pp. 11439–11446, 2001. doi:10.1021/jp011118k
[26] V. Subramanian, E. E. Wolf, P. V. Kamat, Influence of metal/metal ion concentration
on the photocatalytic activity of TiO2 -Au composite nanoparticles Langmuir vol. 19(2),
pp. 469–474, 2003.
[27] V. Subramanian, E. E. Wolf, P. V. Kamat, Catalysis with TiO2 /gold nanocomposites.
effect of metal particle size on the Fermi level equilibration. J. Am. Chem. Soc. vol. 126
(15), pp. 4943–4950, 2004.
[28] M. Ferrari, “Cancer nanotechnology: opportunities and challenges,” Nat. Rev.-Cancer
vol. 5, pp. 161–171, March 2005.
[29] L. Brannon-Peppas, J. O. Blanchette, Nanoparticle and targeted systems for cancer
therapy. Adv. Drug Deliv. Rev. vol. 56(11), pp. 1649–1659, 2004.
[30] P. Couvreur, et al., Nanotechnologies for drug delivery: Application to cancer and au-
toimmune diseases. Prog. Solid State Chem., vol. 34(2–4), pp. 231–235, 2006.
[31] R. Duncan, Nanomedicine gets clinical. Mater. Today vol. 8 (8, Supplement 1), p. 16,
2005.
[32] R. A. Freitas Jr., What is nanomedicine? Nanomedicine vol. 1 (1), pp. 2–9, 2005.
[33] A. Hughes Gareth, Nanostructure-mediated drug delivery. Disease-a-month: DM vol.
51(6), pp. 342–61, 2005.
[34] E. S. Kawasaki, A. Player, Nanotechnology, nanomedicine, and the development of new,
effective therapies for cancer. Nanomedicine vol. 1(2), pp. 101–109, 2005.
[35] J. Kreuter, “Application of nanoparticles for the delivery of drugs to the brain," Int.
Congress Series vol. 1277, p. 85, 2005.
[36] Y. Nishioka, H. Yoshino, Lymphatic targeting with nanoparticulate system. Adv. Drug
Deliv. Rev. vol. 47(1), p. 55, 2001.
[37] J. E. Schnitzer, Vascular targeting as a strategy for cancer therapy. N. Engl. J. Med. vol.
339(7), pp. 472–474, 1998.
[38] S. Kim, Y. T. Lim, E. G. Soltesz, A. M. De Grand, J. Lee, A. Nakayama, J. A. Parker,
T. Mihaljevic, R. G. Laurence, D. M. Dor, L. H. Cohn, M. G. Bawendi, J. V. Frangioni,
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat.
Biotech. vol. 22(1), p. 93, 2004.
[39] M. Ferrari, “Cancer nanotechnology: opportunities and challenges," Nat. Rev.—Cancer
vol. 5, pp. 161–171, 2005.
[40] A. Wickline Samuel, M. Lanza Gregory, Nanotechnology for molecular imaging and
targeted therapy. Circulation vol. 107(8), pp. 1092–5, 2003.
[41] W. Zhao, Ehrlich’s magic nanobullets. Nanomedicine vol. 1(3), p. 238, 2005.
31
CHAPTER 2
Nano Drug Delivery
IMPORTANCE OF NANOSIZE IN DRUG DELIVERY

This chapter elucidates the fundamentals of drug delivery systems, starting with traditional
drug delivery vehicles and routes of delivery. The need for nano-vehicles and the advantages
they offer is explained with specific examples. The concept of targeted delivery and the role of
nano technology in combination with targeted delivery are also covered.
2.1 CONVENTIONAL DRUG DELIVERY

2.1.1 First Pass Effect
Despite the discovery of a large number of active compounds as potential drugs, very few of these
research products achieve clinical success mostly due to problems related to their bioavailability.
Bioavailability [1] depends on the route of administration of a particular drug and depends on
the rate of absorption and metabolism of the drug by the body [2].
The most popular route adapted for the intake of a drug is the peroral route better known
as the oral route. The drug stays in the stomach for a considerable time during the process of
digestion. Various body fluids such as gastric acids interact with the pill in the stomach. After
digestion, the pill, along with other food particles that are broken down in the stomach, goes
through the intestine where it is absorbed through the intestinal walls into the enterohepatic
circulation where the pill, now broken down to its constituent drugs, is taken to the liver for
detoxification. The process of the drug’s encounter with the liver is referred to as the first pass
effect [3]. After having undergone the first pass effect the drug completely mixes with the blood
stream. Fig. 2.1 [3] depicts, step by step, various barriers encountered by an orally delivered
drug [2]. The first pass effect is of great significance to the pharmaceutical and health care
industries because it greatly determines the fate of a drug. A schematic of classical drug delivery
is shown in Fig. 2.2 where the drug is seen to be depleted from the body through metabolism
and excretion [3].
Oral administration in strict terms refers to the process where the drug is directly absorbed
into the circulation through the mouth itself, by placing the pill under the tongue, or placing
it between the gingiva and the cheeks [4]. This mode is also known as the buccal route. The
FIGURE 2.1: Schematic representation of barriers encountered by a drug en route to the target site
mouth is then an active participant in drug absorption; the drug easily diffuses into the mucous
membrane and reaches the circulatory system via the jugular vein. Although, in the buccal route
of drug delivery, there is a chance of partial drug swallowing, this route has the considerable
advantage of bypassing the first pass effect and escaping the strong acidic environment in the
stomach. Overcoming the first pass effect or bypassing it has become a popular trend in many
drug delivery applications, widely practiced today.
FIGURE 2.2: Schematic representation of drug and its pharmacological effect

NANO DRUG DELIVERY 33
TABLE 2.1: Various routes of drug delivery and forms of drug administered
ROUTE OF DRUG STATE/FORM OF

DELIVERY DRUG DELIVERED
Oral Pill, capsule, liquid, suspension, cream
Nasal Liquid, aerosol, vapor
Ophthalmic Liquid, gel, cream, ointment, suspension
Parenteral {all non-Gastro- Liquid (by injection—including
intestinal routes qualify} intravenal)
Topical and transdermal Ointment, gel, foam, cream, powder, liquid
Pulmonary (through lungs) Deep nasal inhalations of liquid, aerosol
Vaginal Suppositories, cream, foam, solutions, gel, ointment
Rectal Suppositories (mostly torpedo shaped), cream,
foam, solution, gel, ointment
2.1.2 Routes of Delivery

The choice of appropriate route of delivery is often based on the type and location of the
injury or disease. Table 2.1 gives a brief idea of the various routes and forms of drug delivery.
It is notable that all the following routes of delivery, except oral, bypass the first pass effect
[3, 5–12].
The ultimate consideration for a drug’s efficacy is its availability at the target site, referred
to as “bioavailability” [2]. In the case of oral administration there are two distinct levels of
bioavailability, a systemic response and a site-specific cellular availability response. Both are
critical not only because they determine the functionality of a drug but also because they control
the side effects of a particular formulation.
Fig. 2.3 [2] illustrates various physiological factors that interfere with a drug; this in-
cludes protein binding, receptor affinity, membrane permeability, protein expression, gene reg-
ulation, and others, which depend on the physicochemical properties and the site of the drug
action [2].
Factors such as drug transport and drug metabolism are determined by their dosage and
the physiological conditions. In a collective manner, all the above-mentioned factors result in
determining the bioavailability of the drug which initiates a pharmacological response in the
target site. In case of over dosage, toxicological and inflammatory responses are provoked at the
target site.
FIGURE 2.3: Schematic representation of factors that influence the bioavailability of a drug
2.2 TARGETED DRUG DELIVERY

One approach to improve bioavailability is targeted drug delivery, avoiding over dosage-toxicity
[13] and consequential inflammatory response [14, 15]. Targeted delivery aims to achieve
perfection by delivering the right amount at only the site of disease or injury. One of the prime
aspects of a competent targeted-drug delivery system is the selection of an appropriate delivery
profile [2]. The delivery profile is usually a plot of the concentration of drug delivered from
the vehicle with respect to time. The drug delivery profile is characteristic of the type of drug,
the type of drug vehicle, and the physiological factors at the delivery site. For instance, pore
size, thickness, geometry, drug loading, temperature, surface roughness, bio-degradation, etc.
of the drug vehicle determine the amount of drug that is released, thus controlling the profile
of delivery. Drugs can be classified into organics, carbohydrates, surfactants, polymers, lipids,
fats, amino acids, peptides, and proteins [16]. This choice of a drug determines how it will
interact with its delivery vehicle and hence the delivery profile, for instance hydrophobicity or
hydrophilicity plays a crucial role in releasing of the drug.
Table 2.2 [16] lists a few notable drug delivery vehicles of interest to bionanotechnol-
ogy and their corresponding sizes. Others include metal nanoshells [17], dendrimers [18],
nanofibers, nanotubes etc.
TABLE 2.2: Microparticulate colloidal carrier systems
NANOSIZE DRUG DELIVERY VEHICLES

SIZE OF DELIVERY VEHICLE (NM)
Nanocapsules 50–200
Uni-lamellar liposomal vesicles 25–200
Nanoparticles 25–200
Microemulsions 20–50
2.3 CHEMISTRY OF DRUG DELIVERY VEHICLES

2.3.1 Nanocapsules
Nanocapsules are polymeric membranes with an oily or aqueous core. They can be defined
as a vesicular system in which “drug is confined to an aqueous or oily cavity surrounded by a
single polymeric membrane” [19]. They are colloidal carriers applied for drug delivery [20].
Usually the nanocapsules contain an outer surfactant adsorption layer as shown in Fig. 2.4.
Polyalkylcyanoacrylates and poly-lactides are some of the polymers used for the outer coating.
While the core of the vehicle comprises of “soya bean oil or other triglycerides having long
and medium chain fatty acids” [20]. Nanocapsule of polyisobutylcyanoacrylate (PIBCA) finds
extensive applications in drug delivery.
2.3.2 Unilamellar Liposomal Vesicles

Liposomes are one of the popular delivery vehicles that are used in the modern day. Extensive
application of liposomal delivery for tumor and cancer therapy has caused much development
FIGURE 2.4: Construction of a nanocapsule

and widespread know-how of factors that facilitate efficient delivery in liposomal vehicles [21].
They are “vesicular colloidal particles composed of self-assembled amphiphillic molecules” [21]. They
have both hydrophilic as well as hydrophobic groups in them, thus enabling a possible self-
assembly in an aqueous medium [21]. Liposomes consist of “neutral or anionic lipids” which
may be synthetic or natural, e.g., natural lipids include lecithins, sphingomyelins etc., which
are extracted from egg yolk, soya beans etc, while their synthetic counterparts include chains
of dimyristoyl, dipalmitoyl, distearoyl, and dioleoyl. Functionally liposomes can be classified as
conventional, cationic, stealth, and targeted liposomes [21].
Size is a prominent factor that determines the targeting efficiency and the associated
therapeutic effects in liposomes. It has been substantiated that the very size determines the
liposomal accumulation in tumor site, efficacy of therapy, level of toxicity, cross vessel perme-
ation, and overall transport in the body [14]. Further, it has been revealed that lesser the size
better the extent of targeting and efficacy of therapy which can be associated with the amount
of drug reaching the tumor site in particular. Liposomes of 100 nm size and less have exhibited
better targeting and accumulation in tumor site [14].
2.3.3 Nanoparticles
Nanoparticles (NP) are collection of several atoms of a particular element in a given fashion.
Usually the NP is in the submicron range, mostly less than 200 nm which are of high interest
to bionanotech [19]. NP of gold, silver, zinc oxide, titania etc. finds excellent applications in
bionanotech. When functionalized with antibodies, these nanoparticles can perform targeted
delivery [22]. Usually NP is employed as drug delivery vehicles and biomarkers of tumors and
cancer cells. Having high “enhanced permeability and retention” (EPR), they are much preferred
for tumor and cancer therapy [19]. Alginate NPs are one other type of the class of nanoparticles
being extensively used for drug delivery [23]. They are made of tiny calcium/sodium alginate
gel. Notable of the bio-imaging nanoparticles include polystyrene fluorescent NP. Muller book
[23].
2.3.4 Microemulsions
The microemulsions are “clear, stable, isotropic mixtures of oil, water and surfactant, frequently
in combination with a cosurfactant” [24]. Microemulsion when loaded with drug serves as
efficient drug delivery vehicles. Spherical micelle, rod-shaped micelle, hexagonal phase, lamellar
phase, reverse hexagonal phase, and reverse micelle are the most commonly observed “self-
association” structures of micelle. Fig. 2.5 shows the commonly seen microstructures in the
microemulsions [24].
FIGURE 2.5: Various microstructures in a microemulsion
2.4 DELIVERY PROFILES

The delivery profile of a drug delivery system determines the bioavailability of a drug at a given
time [2]. A classical drug delivery profile is shown in Fig. 2.6, where two important types of
delivery, one shot delivery (single dose) and multiple dose delivery, are depicted [2]. A single
dosage drug, when delivered, attains a concentration peak in its release profile and then decays.
FIGURE 2.6: Plot of drug concentration versus time for single and multiple doses
FIGURE 2.7: Various controlled release profiles. (A) Initial time lag release profile, (B) sustained release
profile, and (C) linear time release profile
A multiple dose delivery has several peaks in its concentration/release profile and then falls
down as time goes on. In both single and multiple doses, it is important to distinguish the
different levels of bioavailability shown in Fig. 2.6; insufficient level, therapeutic level, and toxic
level. An ideal delivery profile should achieve constant delivery in the therapeutic region, with
a safe margin below the toxic level and above the ineffective level [2].
The delivery profiles shown in Fig. 2.6 are not the preferred. Different types of controlled
delivery profiles are depicted in Fig. 2.7 [3].
The most appropriate selection for a drug delivery would be that of the sustained release
because it lies mainly in the therapeutic region. Fig. 2.7(A) is a type of controlled release
where the initial drug release is nearly zero and then there is a sharp rise in release whereas in
Fig. 2.7(B) a sustained release is observed while Fig. 2.7(C) shows a linear time release profile.
Fig. 2.8 shows release profiles of a prolonged release and controlled releases which have a major
drug release within in the Therapeutic Level [2]. Often in controlled drug release, the main
factor of interest is drug release in the therapeutic region.
The controlled release drug delivery systems can be subdivided into the following four
categories:
FIGURE 2.8: Plot of drug concentration versus time for different release systems
2.4.1 Rate-Preprogrammed Drug Delivery Systems
2.4.2 Activation-Modulated Drug Delivery Systems

2.4.3 Feedback-Regulated Drug Delivery Systems
2.4.4 Site-Targeting Drug Delivery Systems
2.5 THE ROLE OF NANOTECHNOLOGY IN DRUG DELIVERY

An ideal drug delivery vehicle would be capable to navigate on its own, hunt, and find every
single diseased cell and destroy it. In chronic diseases, an implanted miniature drug reservoir
would administer life-saving drugs in the right amount at the right time. We would like to see
that the drug was able to kill the diseased cells without harmful radiation and we would like
to help control the navigation of delivery vehicles with precision [25] at will without invasive
procedures.
The above wish list is neither imaginary nor utopian; it is very close to reality in a few
years with the advances and research focus in bionanotechnology. The breakthroughs of bio-
nanotechnology in the area of drug delivery [25, 26] have been some of the most remarkable
applications of nanotechnology in medicine and include immuno-isolated nano porous im-
plants with embedded pancreatic cells delivering insulin for diabetic patients, polarity-based
gated nanosieves for selected ion transport, externally controlled nanoshell delivery vehicles
for precision targeting, single virus detectors, gene engineered biological robots, artificial RBC
[27].
2.5.1 Transdermal
Experimental researches over years have been exploring the possibility and extent of realization
of transdermal drug delivery. The first successful model of transdermal delivery was a scopo-
lamine patch created in 1979. There have been earlier studies on the barriers to a transdermal
delivery dating back to as early as 1924. In the United States, annual expenditure in drug
delivery in more than $3 billions, such a high profile industry namely health care is not driven
for mere disease and injury therapies but also for novel applications such an nicotine delivery
[28]. The consequences of delivery nicotine by patches through skin have led to creation of
more than one million smokers who were otherwise [28].
The major challenges faced in the transdermal application are the possibility of an
efficient and easy delivery of drug through skin’s major barrier such as stratum corneum (SC),
the epidermis etc. Of the two mentioned, SC is the major challenge. The stratum corneum is
10–15 µm thick, while epidermis is 50–100 µm thick and the dermis layer is about 2–3 mm
thick. Usually, a drug/vehicle for a transdermal delivery cannot easily pass through the SC.
[29].
Nanotechnology plays a promising role in transdermal applications. The smaller size
enables easy permeation. Further, surface modifications enable targeted delivery. The present
day research explores the use of certain external agencies in combination with nano vehicles for
delivery. Notable among them are chemical enhancement, electricity assisted electroporation,
low frequency ultrasound, PW mediated, and micro needles [28].
In order to deliver drugs at therapeutic useful rates, micro needles which are in the size
of a micron dimensions were designed [30]. capable of delivering drugs when poked into the
skin. Drugs made of nanoparticles can efficiently be delivered directly into the epidermis via
this method. Needles of different sizes, shapes, and materials namely stainless steel, titanium,
and silicon wafers are available. These needles usually have a small radius tip with thick walls.
[30] which have lesser probability of fracture when using. To further improve this, micro needle
arrays were designed which would have about 480 needles of each 430 µm long within a 2 sq.
cm. area. Although this method could not be considered in case of skin burns and injuries, it is
promising otherwise [30].
The application of PW facilitates temporary poration in the SC and allows the
drugs/vehicles to easily pass through. Moreover it is painless, efficient, and has immediate
recovery with regard to SC functionality by resuming to its normal character of being a high
barrier [29]. The duration of exposure to PW is a crucial factor as it is directly proportional
to the permeation through SC. The successful establishment of delivering 100 nm latex beads
shows promising future for the delivery of DNA plasmids and proteins into the epidermis.
Pressure waves (PW) generated from intense laser radiation applied on skin for transdermal
drug delivery are gaining interest. It has been substantiated to show better permeation of drug
vehicles across the stratum corneum (SC) and cell membrane, and ease of the very process of
delivery [29]. A typical PW for the transdermal delivery would be of several hundred bars, a
PW of 300–1000 bar for a period of 100 ns to 1 µm; here insulin was delivered to control
blood glucose level [29]. The damages that might be caused due to PW are minimal and can
be reduced by appropriate design of PWs [29].
Instead of having a traditional approach, even targeting the sweat glands and hair follicle
being explored which show a sooner and better delivery when compared to overall skin flux
[31], they work as shunt routes.
Other transdermal applications include dendrimers which are extensively used to deliver
drugs, vaccines, and chemotherapeutic agents for cancer therapy [18]. Some of the dendrimer-
based bionano applications include gene delivery, targeted cancer therapy, in vivo diagnoses
(MRI), antiinfective agent delivery, vaccine and peptide delivery and drug delivery through oral
and transdermal routes and ocular applications [18].
2.5.2 Blood Brain Barrier

BBB is one of the chief barriers usually not easy for to break in for drugs such as anticancer
agents, antibiotics, peptides, oligo-molecules, and macromolecules [32]. The inaccessibility of
drug to the brain tissues is attributed to the presence of “tight junctions between the endothelial
cell linings in the brain blood vessels” [32]. Further, any drug across the endothelial lining
is transported back into the blood stream by means of ABC transporters which are referred
to as the “very active drug transport system.” Thus, cranial drug delivery seems to be a major
challenge in the medical world.
The transcytotic vesicular mechanism enables the transport of large molecules, while
“specific transport systems for solute uptake are present on apical and basal membranes” but
the efflux transporters of broader specificity are also present [33]. Efflux transporters do so
with lipid-soluble drugs making them unreachable from the CNS. The dynamic of brain
interstitial fluid (ISF) and the disease-caused BBB dysfunction contribute to the complication
[33] of choosing a therapy. After all considerations, the drug vehicle interacts with the above-
mentioned barriers at various point of time.
Nanoparticles provide to be an attractive solution to the BBB issue. Nanoparticles of
smaller size when functionalized or suitably surface modified, mimicking LDL, bind to their
specific receptors and diffuse into the endothelial cells ultimately reaching the interior of
brain [34]. Hence the size and surface modification/functionalization enable the transport of
nanodelivery vehicles across the BBB. However, the possibility of unintended intrusion via
BBB into the brain is widely speculated; thus there must be high selectivity with regard to any
uptake via BBB to avoid the unwelcome particles.
One of the successful establishments of drug delivery to brain includes the delivery of
nanoparticles coated by polysorbate 80. Nanoparticles of drug vehicles coated with polysorbate
80 showed better uptake across BBB [32]. A notable instance was, during delivery of doxorubicin
where the drug level in brain was in the ratio of 60:1 for the polysorbate-coated delivery versus
the non-coated respectively [32].
With regard to nano drug delivery the possibility of delivery vehicles crossing the BBB
can be reasoned to [33], an increased retention of the nanoparticles in the brain capillaries along
with adsorption to the capillary walls could cause high concentration gradient facilitating the
transport across the endothelial cells and ultimate delivery to the brain, “a general surfactant
effect characterized by a solubilization of the endothelial cell membrane lipids that would lead
to membrane fluidization and an enhanced drug permeability through the blood–brain barrier”
[33], nanoparticles reaching the openings in tight junctions between endothelial cells could
permeate either in free form or in bound form together with the nanoparticles, endocytosed
NP releasing drug within the cells and delivered into brain, nano vehicles could be transcytosed
through endothelial cells into brain, polysorbate 80 coating on nano vehicles could inhibit the
efflux system. As mentioned earlier the NP delivery vehicle confronts the above-mentioned
mechanism individually or collectively, hence the reason for a nano vehicle entering the brain
could be attributed to one of these mechanisms or a combination of them.
2.6 ADVANTAGES OF TARGETED DRUG DELIVERY SYSTEMS

Targeted drug delivery systems are the future in drug delivery due to their specificity and efficacy.
The benefit that one reaps through opting for a targeted drug delivery system includes protected
payload and improved therapeutic index which is a comparison of the amount of drug that causes
the therapeutic effect to the amount that causes toxic effects. Quantitatively, it is the ratio of
the dose required to produce the toxic effect and the therapeutic dose. Also, targeted delivery
enables increased specific localization, decreased toxic side effects, reduced dose, modulated
pharmacokinetics, controlled bio-distribution, and importantly improved patient compliance.
REFERENCES
[1] A. Kidane, P. P. Bhatt, “Recent advances in small molecule drug delivery,” Curr. Opin.
Chem. Biol., vol. 9(4), pp. 347–351, 2005.
[2] T. S. BingheWang, Richard Soltero., Drug Delivery: Principles and Applications (Textbook)
Wiley-Interscience, NJ. 2005, pp. 57–83 (462).
[3] L. S. A. B. C. Yu, Dekker Pharmaceutical Technology: Biopharmaceutics. Dekker
Encyclopedias, Taylor and Francis Books, NY–USA. 2002.
[4] J. C. McElnay, C. M. Hughes, Encyclopedia of Pharmaceutical Technology: Drug Delivery—
Buccal Route. Dekker Encyclopedias, Taylor and Francis Books, NY–USA. (April 28).
[5] M. J. Akers, Encyclopedia of Pharmaceutical Technology: Drug Delivery—Parenteral Route.
Dekker Encyclopedias—Taylor and Francis Books, NY–USA. (May 8).
[6] M. C. A. L. W. H. Bhagat, Encyclopedia of Pharmaceutical Technology: Drug Delivery—
Ophthalmic Route. Dekker Encyclopedias—Taylor and Francis Books, NY–USA. (May
8).
[7] R. Bommer, Encyclopedia of Pharmaceutical Technology: Drug Delivery Nasal Route. Dekker
Encyclopedias—Taylor and Francis Books, NY–USA. (May 8).
[8] J. H. R. J. A. Fix, Encyclopedia of Pharmaceutical Technology: Drug Delivery—Rectal Route.
Dekker Encyclopedias—Taylor and Francis Books, NY–USA. (May 8).
[9] B. N. S. K. H. Kim, Encyclopedia of Pharmaceutical Technology: Drug Delivery—Oral
Route. Dekker Encyclopedias—Taylor and Francis Books, NY–USA. (May 8).
[10] Y. W. C. C. H. Lee, Encyclopedia of Pharmaceutical Technology: Drug Delivery—Vaginal
[11] M. T. Newhouse, Encyclopedia of Pharmaceutical Technology: Drug Delivery—Pulmonary
[12] K. A. Walters, Encyclopedia of Pharmaceutical Technology: Drug Delivery—Topical and
Transdermal Route. Dekker Encyclopedias—Taylor and Francis Books, NY–USA
(May 8).
[13] F. Chellat, Y. Merhi, A. Moreau, L. H. Yahia, Therapeutic potential of nanopar-
ticulate systems for macrophage targeting, Biomaterials, vol. 26(35), pp. 7260–7275,
2005.
[14] A. Nagayasu, K. Uchiyama, H. Kiwada, The size of liposomes: a factor which affects
their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs,
Adv. Drug Deliv. Rev., vol. 40, (1–2), p. 75, 1999.
[15] A. Wickline Samuel, M. Lanza Gregory, Nanotechnology for molecular imaging and
targeted therapy, Circulation, vol. 107(8), pp. 1092–5, 2003.
[16] D. R. Karsa, R. A. Stephenson, Chemical Aspects of Drug Delivery System. Bradford: The
Royal Society of Chemistry, pp. 1–10, 1996.
[17] O. Bomati-Miguel, M. P. Morales, P. Tartaj, J. Ruiz-Cabello, P. Bonville, M. Santos,
X. Zhao, S. Veintemillas-Verdaguer, Fe-based nanoparticulate metallic alloys as con-
trast agents for magnetic resonance imaging, Biomaterials vol. 26(28), pp. 5695–5703,
2005. doi:10.1016/j.biomaterials.2005.02.020
[18] R. Duncan, L. Izzo, Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev.,
vol. 57(15), p. 2215, 2005. doi:10.1016/j.addr.2005.09.019
[19] I. Brigger, C. Dubernet, P. Couvreur, Nanoparticles in cancer therapy and diagnosis, Adv.
Drug Deliv. Rev., vol. 54(5), pp. 631–651, 2002. doi:10.1016/S0169-409X(02)00044-3
[20] Y. Nishioka, H. Yoshino, Lymphatic targeting with nanoparticulate system, Adv. Drug
Deliv. Rev., vol. 47(1), p. 55, 2001. doi:10.1016/S0169-409X(00)00121-6
[21] D. D. Lasic, Liposomes in Gene Delivery. Boca Raton, FL: CRC Press, 1997, pp. 67–113.
[22] P. Couvreur, et al., Nanotechnologies for drug delivery: Application to cancer and
autoimmune diseases, Prog. Solid State Chem. vol. 34(2–4), pp. 231–235, 2006.
doi:10.1016/j.progsolidstchem.2005.11.009
[23] J. E. Diederichs, R. H. Muller, Future Strategies for Drug Delivery with Particulate Systems.
Stuttgart-Germany: Medpharm GmbH Scientific Publishers, pp. 29–45, 1998.
[24] M. J. Lawrence, G. D. Rees, Microemulsion-based media as novel drug delivery systems,
Adv. Drug Deliv. Rev., vol. 45(1), p. 89, 2000. doi:10.1016/S0169-409X(00)00103-4
[25] E. S. Kawasaki, A. Player, Nanotechnology, nanomedicine, and the development of new,
effective therapies for cancer, Nanomedicine, vol. 1(2), pp. 101–109, 2005.
[26] R. Duncan, Nanomedicine gets clinical, Mater. Today, vol. 8(8, Supplement 1), p. 16,
2005. doi:10.1016/S1369-7021(05)71032-4
[27] R. A. Freitas, Jr., What is nanomedicine? Nanomedicine, vol. 1, (1) pp. 2–9, 2005.
[28] R. Langer, Transdermal drug delivery: past progress, current status, and future prospects,
Adv. Drug Deliv. Rev., vol. 56(5), p. 557, 2004. doi:10.1016/j.addr.2003.10.021
[29] A. G. Doukas, N. Kollias, Transdermal drug delivery with a pressure wave, Adv. Drug
Deliv. Rev., vol. 56(5), p. 559, 2004. doi:10.1016/j.addr.2003.10.031
[30] M. R. Prausnitz, Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev.,
vol. 56(5), p. 581, 2004. doi:10.1016/j.addr.2003.10.023
[31] B. W. Barry, Drug delivery routes in skin: a novel approach, Adv. Drug Deliv. Rev.,
vol. 54 (Supplement 1), p. S31, 2002. doi:10.1016/S0169-409X(02)00113-8
[32] J. Kreuter, Application of nanoparticles for the delivery of drugs to the brain, Int. Congress
Series, vol. 1277, p. 85, 2005.
[33] N. J. Abbott, Physiology of the blood-brain barrier and its consequences for drug transport
to the brain, Int. Congress Series, vol. 1277, p. 3, 2005. doi:10.1016/j.ics.2005.02.008
[34] P. H. M. Hoet, I. Brueske-Hohlfeld, O. V. Salata, Nanoparticles-known and unknown
health risks, J. Nanobiotechnol., vol. 2(1), pp. 12–17, 2004. doi:10.1186/1477-3155-2-12
47
CHAPTER 3
BioNanoimaging
QUANTUM DOTS, ULTRASOUND CONTRAST AGENTS,

AND MAGNETIC NANOPARTICLES
Background: The use of nanoparticles as biomarkers covers a broad range of materials and ap-
plications. Of the today’s most popular contemporary bionano imaging applications, quantum
dots (QDs), the ultrasound contrast agents (UCA), and the magnetic nanoparticles are the
chief. Quantum dots are based on fluorescence optical properties, ultrasound contrast agents
on differential absorption of ultrasound energy, and magnetic nanoparticles on unique super-
paramagnetic properties associated with their small size. Applications can be in diagnostic
imaging or targeted delivery or in novel multifunctional approaches. This chapter covers the
basic function and properties of these materials and highlights their key applications.
3.1 QUANTUM DOTS

Quantum dots are nearly spherical, luminescent nanosized crystals made of semiconductor ma-
terials [1], of the order of 2–10 nm comprising 200–10 000 atoms [2]. Their optical properties
are size-dependent [1]. A decrease in the crystal size causes an increase in energy shift between
the absorbing and the emitting state [1]. Optical excitation across the band gap in a semicon-
ductor depends on the size of the crystal even for larger crystals, as large as those comprising
10 000 atoms. A similar trend can be expected with the quantum dots which are often far too
small with a minimum of 200 atoms extending to a maximum of 10 000 atoms [1, 2]. The band
gaps of such nanocrystals are often tunable to the interest of the user, for instance a CdS crystal
can be tuned between 2.5 and 4 eV [1].
Optical tunability [3, 4], better photostability, [3] and multicolor [5] light emission
position QDs as the preferred fluorescent probes for dynamic live cell imaging tool and in vivo
animal models [6–8]. They have unparalleled sensitivity and spatial resolution [2], compared
to the organic fluorophores currently available. QDs with organic capping perform even better;
these QDs usually have a core crystal with an inorganic capping with outer organic group which
help during QD conjugation for functionalization [1]. For instance, a ZnS capped [7, 9] CdS
FIGURE 3.1: (A) Fluorescent images of CdS QDs using a 365 nm source. Sizes are 2.2 nm (blue), 2.9
nm (green), 4.1 nm (orange), and 7.3 nm (red) respectively. (B) Fluorescent spectra of the QDs indicating
narrow emission spectra with minimal overlap; excitation of 400 nm. (C) The broad absorption spectra
of these same four CdS QD’s suggests the possibility of using a wide spectrum source for excitation (both
absorption and emission spectra are plotted in AU—arbitrary units)
QD is 20 times brighter than rhodamine (a popular organic dye) and at the same time 100
times more stable to photobleaching [10].
Fig. 3.1 depicts CdS quantum dots of different sizes and how each size corresponds to a
different color [2]. The same figure demonstrates the emission and absorption spectra of CdS
BIONANOIMAGING 49
QDs in the presence of a UV source [2]. Further Fig. 3.1 indicates that the QDs have narrow
wavelength and could be used with an exciting source having a wide spectrum.
QDs synthesis was first pioneered by Efros and Ekimov in the early 1980s [11–13].
Usually QD synthesis is followed by subsequent processes that functionalize the nanoparti-
cles to become bio-active. The first step is the synthesis of the semiconductor core where a
semiconductor precursor is chosen to synthesize a core. The chosen semiconductor determines
the wavelength of the QD as being characteristic of the material chosen. Around the core, a
shell is grown or capped such that the shell material processes a wider band gap than the core,
thus providing higher electronic insulation, enhanced photoluminescence efficiency, and higher
immunity to oxidation and degradation. This phase is referred to as shell growth phase [2].
The third phase of the QD synthesis is the aqueous stabilization. Attaining aqueous
solubility is a prerequisite to enable use of the QDs for biological applications. Two different
approaches are undertaken: either the QDs are synthesized in an aqueous solution or they are
synthesized in an organic phase later followed by a phase transfer [2]. The latter method is
often preferred due to its superior monodispersity, crystallinity, and high fluorescent efficiency.
Finally, the QDs are conjugated with biological agents such as proteins, peptides, small organic
molecules, and nucleic acids, thereby rendering them bioactive; this step is referred to as bio-
conjugation [2].
Bioconjugation dictates the role and targeting of QDs in cellular and tissue applications
by determining its affinity to a particular subcellular location or other biological entity. Usually,
after aqueous stabilization, most QDs are covered with carboxylic groups. The carboxylic group
plays a crucial role during bioconjugation reactions by forming a covalent bond with the amine
groups of biomolecules participating in the bioconjugation. Most QDs are negatively charged
and are dispersed in basic or neutral buffers. Hence, a positive biomolecule could be coated
on the QDs based on the electrostatic interaction. Fig. 3.2 schematically describes various
methods of bioconjugation [2]. The four methods depicted in Fig. 3.2 are coupling to QD
surface, covalent coupling electrostatic attraction, and receptor-ligand binding where every
method aims at coupling of biomolecules to the QD surface. The QDs shown in Fig. 3.2 are
made water soluble by adding mercaptoacetic acid.
QDs can be used for the study of live cell single-molecule [14] dynamics, monitoring of
intracellular protein–protein interactions, disease detection in deeper tissues, detection of can-
cer/tumor cells based on selective binding of bioconjugated QDs to known cancer biomarkers,
and much more [2].
Fig. 3.3 shows green QDs conjugated to streptavidin, emitting green fluorescence. The
image shows F-actins of fixed fibroblasts. Fig. 3.4 shows the image of cellular uptake of
QD-cationic peptide conjugates [2]. The red-fluorescent (CdSe)ZnS QDs were incubated
with a monolayer of living human cancer cells. The QDs were previously conjugated with
FIGURE 3.2: Schematic representation of common methods to conjugate QDs to biological molecules
such as proteins, peptides, nucleic acids, or small organic-molecules
TAT peptides. The image further suggests, from the aggregation of QDs in internal cellular
structures, that they are present in endocytotic vesicles [2].
QDs have been used for live imaging of animal organs [6] which are often delivered
through the intravenous route to the animals. These studies have successfully demonstrated
the ability of QDs to achieve highly specific targeting in animal models. Also such studies
reveal that the use of PEGylated QDs could adequately escape the RES providing a unique
opportunity for extensive application of QDs in animal models [15]. Fig. 3.5 is the result of
a study conducted to evaluate the efficiency of PEG-coated QDs in vivo in escaping from
the RES and in finding their efficiency for targeted applications. GFE is a peptide having
selective binding affinity to the lungs. Injecting mice with red GFE-conjugated QDs showed
BIONANOIMAGING 51
FIGURE 3.3: Immunocytochemical stain of F-actin in fixed fibroblast cells using green quantum dots
preferential aggregation in the lungs, while brain and kidney did not show any QD aggregation,
thus proving the high selectivity of targeted QDs [15].
Testing different kinds of QDs in animal models revealed the usability and efficiency of
QDs over other luminescent materials. It was notable that PEGylated QDs are readily accepted
by the body without resistance from the immune system [15] and also increase the lifetime (of
circulation) in the body [6].
F3 is a peptide that selectively binds to the blood vessels and cells of tumor sites. LyP-1
is a peptide that specifically binds to tumor and endothelial cells of tumor lymphatics in certain
tumors. QDs conjugated with F3 and LyP-1 peptides were administered via intravenous route
in mice having tumor. Fig. 3.6 shows the binding of red F3-QDs binding to the tumor cells
and vasculature. While, Fig. 3.7 shows the use how PEGylation can improve the usability of
QDs in vivo. The LyP-1 QDs initially get trapped in RES and accumulate in liver and spleen,
but PEG-coated LyP-1 do not get entrapped in the RES and hence are unseen in spleen and
liver [15].
Fig. 3.8 depicts the versatility of the use of QDs in biomedical and biotechnology [7].
The applications of QDs have raised a few concerns, that is being extensively researched
currently [16]. Other applications such as live cell single-molecule dynamics study, monitoring
of intracellular protein–protein interaction, and disease detection in deeper tissues are possible
FIGURE 3.4: Cellular uptake of QD-cationic peptide conjugates. Monolayers of living human cancer
cells were incubated with red fluorescent (CdSe)ZnS QDs conjugated to TAT peptides. The aggregation
of QDs in internal cellular structures is indicative of their presence in endocytotic vesicles
with a higher efficiency in QDs [2, 17]. Also, QDs are even explored in potential applications
for cancer therapy. QDs become cytotoxic in the presence of UV; this cytotoxity is explored for
the possibility of killing cancer cells [18].
3.2 ULTRASOUND CONTRAST AGENTS

Introduction: Ultrasound is currently a well-established technology enabling real-time imaging
of the human body [19–22]. Traditional ultrasound, however, has its own limitation including
increase in attenuation with increasing insonating frequency, yielding low resolution of thicker
structures, and thus prohibiting deeper scans [23–25]. A possible solution to overcoming the
issues of deep scans and achieving improved resolution is the use of contrast agents (CA) for
ultrasound imaging [25, 26]. The ultrasound imaging contrast agents (UICA) can be classified
into liposomes (µm), polymeric nanosomes, and these are further classified according to the
type of ultrasound agent encapsulated in them [27]. Ultrasound imaging (UI) is a noninvasive
imaging technique that uses high frequency sound waves to produce images of internal body
BIONANOIMAGING 53
FIGURE 3.5: Red GFE-conjugated QDs injected via intravenous route through a mice tail, (a) red
QDs localized in lung tissue, (b) inhibited QDs accumulation owing to coinjected cilastatin, (c) absence
of QDs in brain, and (d) absence of QDs in kidney
parts, environment, other biological entities, and organs such as heart, liver, kidneys, fetus,
blood vessels, tissues etc. Usually an ultrasound probe which is in contact with the human body
(skin) propagates high frequency sound signal into the body which are reflected (echo) back
from the internal organs; these signals are reconstructed into images and displayed in a screen.
The technique is referred to as UI or ultrasonography (US) and the image obtained is called a
sonogram.
FIGURE 3.6: (a) Red F3 QDs colocalize with blood vessels in the tumors and (b) LyP-1 QDs inter-
nalized by tumor cells
Drawbacks of Traditional Ultrasound Imaging: The drawbacks in traditional UI and

Doppler include blocking of the US beam by anatomical structures, for instance bones; US
beam attenuation or reflection by air and other substances, such as free air, intestinal loops,
cirrhotic liver; dense fat pads in the region of organ or site interrogated such as the abdominal fat
pad, obese patients, liver enlargement, or hypertrophic muscle bundles; artifacts created by or-
gan movements such as vessels or intestinal loops; and deteriorated patients lacking cooperation
or poor patient compliance [24, 25].
Background: Imaging tumors is a prominent part of ultrasound imaging and CA are being
developed to improve resolution and diagnostic capability. Typical UICA consist of stabilized
gas bubbles. They work on the principle of impedance mismatch with the surrounding tissue,
thereby producing better sensitivity and resolution in the image [25, 28]. Traditional contrast
agents are mostly micron sized and they are still small enough to move through a capillary.
The maximum size that is not barred from entering a capillary is ∼8 µm [28]. The biggest
challenge, however, is offered by the vasculature of tumors. Tumor tissues have a characteristic
angiogenesis that can be easily identified with rich, irregular branching of vasculature that
supplies the fast sprouting tissue. The blood vessels observed in and around the tumor site are
dense and irregular in size [28].
In ultrasound imaging (UI) the pore size of the tumor vasculature is what determines
the maximum diameter of a contrast agent that can successfully penetrate the tumor site. Sub-
stantial research results estimate the tumor vasculature pore size between 380 and 780 nm
[28]. However, the pore size is characteristic of the type of tumor. The average pore size
cutoff for tumor vasculature could be placed at 400 nm. This highlights the very role of
BIONANOIMAGING 55
FIGURE 3.7: LyP-1 QDs administered to nude BALB mice with tumor: (a) QDs in liver, (b) QDs in
spleen. LyP-1/PEG QDs are not present in (c) liver and (d) spleen
bionanotechnology in creating appropriate nanosize contrast agents to enable imaging of tu-

mors. At present, there exist popular FDA-approved UICA such as OptisonR , DefinityR , and
ImagentR [28].
History of Contrast Agents: The history of CAs dates back to the late1960s when cardi-
ologist Dr. Charles Joiner pioneered the possibility of using microbubbles as echo-enhancing
agents [25]. Currently there are more than 29 echocontrast agents in clinical trials throughout
the world. They differ noticeably in their chemical composition, action mechanisms, and clini-
cal trial applications [24]. The role of the echocontrast agents (CA) is not limited to improving
the acoustic window; they also distend specific organs and fill them with a liquid by causing
homogenous attenuation of the ultrasound beam; they displace air-containing intestinal loops;
FIGURE 3.8: Versatile applications of QDs in biomedical and biotechnology
they can depict walls, shapes, and contours of cavities both normal and abnormal; they can
detect abnormal communications, fistulas, and drainages, as well as evaluate fluid volume in
the pleural, pericardial, and peritoneal cavities [24]. Contrast agents find applications in both
vascular and extravascular domain.
Most popular vascular CAs include Levovist (Germany), BR1 (Italy), and EchoGenR
TM
TM TM
(Abbott, USA). Extravascular CAs include SonoRx (Bracco, Italy) and Echovist (Scher-
ing, Germany) [24]. Vascular CAs are extensively used and are more popular compared to
extravascular CAs. Applications for vascular contrast agents in the United States include tran-
scranial color Doppler ultrasound using echocontrast enhancers, contrast echocardiography,
neck vessels, liver imaging, vessels in the upper and lower limbs, and focal and diffuse hepatic
lesions [24]. Substantial research indicates the higher confidence in diagnostic data with the
use of CAs.
Fig. 3.8 shows the image of a US scan of hepatocellular carcinomas (HCC) which is a
malignant tumor [24]. In certain cases owing to patient’s age, complexity of the developed
BIONANOIMAGING 57
FIGURE 3.8(A): Chemo-embolized hepatocellular carcinoma. Baseline scan, without any CA: no
apparent vasculature is seen
tumor lesion resection cannot be performed. For such patients, often nonsurgical/ inter-
vetional procedures are followed, and chemo-embolization is one among the interventional
procedures.
No apparent vascularization can be seen in Fig. 3.8 (A). When injected with Levovist, a
CA, more color spots and vasculature are noticed as shown in Fig. 3.8 (B) [24]. The prominent
FIGURE 3.8(B): Chemo-embolized hepatocellular carcinoma. Lesion after injection of CA—Levovist:

multiple color spots and vessels are seen
FIGURE 3.9(A): Benign popliteal schwannoma. (a) Before contrast agent injection
role of CAs can further be elucidated with another example. Fig. 3.9 (A) shows an image
of a benign popliteal schwannoma condition without any contrast agent. Here no prominent
features of the tumor are observed, While the same when injected with Levovist shows a
better image of the tumor as in Fig. 3.9 (B) which is a 3D construction of postinjection
stage [24].
FIGURE 3.9(B): Benign popliteal schwannoma. (b) 3D reconstruction after 2.5 g LevovistTM perfusion
at 200 mg:ml
BIONANOIMAGING 59
TABLE 3.1: Various Echogenic Liposomes and their Corresponding Size and Gray Scale Values
AVG. GRAY AVERAGE

SCALE VALUE SIZE
(BRIGHTNESS
FORMULATION LEVEL) (NM)
Inherently echogenic classical Liposomes 115 800
Inherently echogenic sterically stabilized liposomes 109 286
Inherently echogenic (vasoactive intestinal peptides)
VIP-sterically stabilized liposomes 119 264
Table 3.1 shows a list of different kinds of echogenic (echo efficient) liposomes that
are employed as contrast agents (CA) in ultrasound imaging [29]. It is interesting to note
that the liposomes are much preferred for this purpose as CAs because of the high loading
potential they possess in carrying an agent of interest. Usually these liposomes contain gas
which is either water soluble such as nitrogen and carbondioxide or water insoluble gases such as
perfluorates [29]. Gray scale is a measure of brightness in ultrasound imaging. Table 3.1 shows
the gray scale brightness and corresponding nm size of different echogenic liposomal CAs.
Gray scale brightness is maintained as the particle size of the liposomes is reduced from 800 to
260 nm.
Among the water-soluble and water-insoluble gas filled liposomes, those with water-
insoluble gas are often preferred, probably due to the improved stability and stronger, more
long lasting echogenicity because of being water insoluble [27]. Popular water-insoluble
CAs include EchoGen or QW3600, Imagent, FSO69, BR 1, NC 100100, and SHU
536 [27].
The most interesting advancement in bionanotechnology would be the design of a CA in
the nano domain. A nanosome CA is discussed in detail in this section. The UICA causes sig-
nificant increase in image resolution through enhanced backscattering signal which is observed
from the blood flow. A surfactant-stabilized nano bubble with attractive acoustic properties,
better yield, higher stability, longevity of life-time, higher resolution is being developed for
application as UICA called ST68-N. This CA is a gas-filled nanosome ranging from 450 to
700 nm in size. This research revolves around the creation of ST68-N as a CA made up of Span
60 and Tween 80. It is filled with perfluorocarbon—PFC (octafluoropropane) gas. In vitro test
reveals that ST68-N CAs cause in vitro enhancement in the UI signals in the range of 27–23
db [28].
The ST68-N contrast bubbles are stable up to 15 min in the body when delivered via
the intravenous route. The functioning of the CAs can be well understood with the governing
equation–Born’s equation that describes the backscattering cross-section σ as being directly
proportional to the sixth power of the bubble’s radius [28]:

4π 4 6 ks − k 1 3(ρs − ρ) 2
σ = k r +
9 k 3 2ρs + ρ
So the smaller the radius, the lower is the enhancement. However, the diameter is limited
to the pore size of the tumor vasculature [28].
Therefore, an optimal function that is able to penetrate tumor vasculature and maximize
contrast power needs to be developed. UICA have undoubtedly taken up as the state of art
in imaging [26, 30]; the future work in the development of UICAs in the bionano realm will
probably focus on the creation of nano CA which are conjugated to biomolecules, thereby
rendering them bioactive and site specific in imaging. The creation of CAs with site-specific
recognition capability and ability of extravasation from the blood vessels to the tumor site by
means of pressure waves and microstreaming [28] caused by ultrasound waves would be a giant
leap in the history of UICA. This would enable high resolution imaging of the tumor site
itself instead of the vasculature. Bioconjugating these bubbles to biomarkers would yield higher
selectivity in imaging the biological interaction in vivo.
3.3 MAGNETIC NANOPARTICLES

Introduction: Molecular imaging attempts to visualize quantitative biomolecules or biological
processes of interest in living organisms. Such imaging may be noninvasive and possess high tar-
geting and specificity. The contribution of magnetic particles in enhancing molecular imaging
increases with the wide clinical application of magnetic resonance imaging. Nanosize magnetic
particles enable early disease detection, accurate prognosis, and personalized treatment, mon-
itoring efficacy of a prescribed therapy, or study of cellular interaction in a certain biological
environment [31, 32].
The magnetizable particles can independently act as a magnetic probe [32] that can
perform an assigned task (bind to an agent). Magnetic contrast agents are dominated by various
forms of iron oxides especially magnetite/maghemite [33]. Magnetite and maghemite exhibit
similar magnetic properties, while maghemite has smaller magnetization saturation. Magnetic
saturation is a state at which there is no significant change in magnetic flux density when the
magnetization force is increased.
Often the super paramagnetic iron oxide (SPIO) core comes with outer coatings of
polysaccharide (mostly dextran) or synthetic polymer coatings which can generally be classified
as hydrophilic coatings [34]. Other counterparts of SPIO in the magnetic resonance contrast
BIONANOIMAGING 61
enhancement domain include gadolinium and cobalt-ferrite particles. The following is a list of
widely used coating materials on SPIO [31]:
1. Citric, gluconic, oleic

2. Dextran
3. Polycarboxymethyl dextran
4. Polyvinyl alcohol
5. Starches
6. PMMA
7. PLGA
8. PAM
9. PEG
10. PEG-lipid
11. Silane
12. Silica
Based on the overall diameter of a SPIO particle which comprises of the core diameter with
the hydrophilic coating, SPIO can be classified into oral SPIO which ranges between 300 nm
and 3.5 µm while those ranging between 60 and 150 nm are referred to as standard SPIO or
SSPIO. The ultrasmall SPIO (USPIO) refers to particles in the 10–40 nm range. The smallest
member of the SPIO group is the monocrystalline iron oxide nanoparticle—MION ranging
from 10 to 30 nm. Table 3.2 [31] gives a list of SPIO particles with corresponding size and the
level of development.
TABLE 3.2: Commercial SPIO Agents, Corresponding Size, and Developmental Stage
AGENT SIZE DEVELOPMENTAL STAGE

(CLINICAL TRIAL)
CODE 7228 18–20 nm Phase II
AMI-227 20–40 nm Phase III
SHU555A 62 nm Phase III
AMI-25 80–150 nm Approved
AMI-121 >300 nm Approved
OMP 3.5 µm Approved
Principle of operation: Paramagnetic materials are categorized according to their ability to align
their magnetic domains with external magnetic field. This property becomes important in
guiding small particles of paramagnetic material to a site of interest in the human body to
enhance magnetic resonance by deploying external magnetic field. The magnetic domains
of superparamagnetic materials exhibit a random orientation in the absence of an external
field but become aligned in response to an external magnetic field. Usually the paramagnetic
materials have positive magnetic susceptibility and this enables them to be controlled by external
magnetism. The SPIO materials possess very high susceptibility when compared to ordinary
paramagnetic material [31]. Magnetic susceptibility is defined as the degree of magnetization
of a material owing to an applied magnetic field; higher the susceptibility greater the particles
can be magnetized and hence the particular application becomes more efficient.
Coprecipitation and microenmulsion techniques are two most common methods to
produce SPIO, although methods using ultrasound irradiation, spray, and laser process are
described in the literature [31]. Current researches explore the thermal decomposition of
precursors (such as iron cupferron—FeCup3, by Alivisatos et al.) and a layer-by-layer self-
assembly techniques to produce high quality SPIO [31].
The MR contrast enhancement achievable in SPIO could be utilized for [31]:
r Passive Targeting
r Active Targeting
r Cell Tracking
r Magnetic Relaxation Switching
Passive targeting refers to the non-specific cellular uptake of the NPs leading to the
particulate accumulation (enhanced retention) in lymph nodes, liver, spleen and macrophage
encapsulation [32], and tumor site penetration, enabling better contrast during imaging. Im-
portant applications include liver, spleen, or lymph node imaging, as well as general oncological
imaging [34, 35]. On the other hand, active targeting relates to the molecule/site specific
targeting of SPIO by biomolecular conjugation. The SPIO NPs are functionalized with site-
specific biomolecules that render them highly specific and enable to target sites or proteins
of interest in the body. Active targeting includes cancer, apoptosis [36], and cardiovascular
imaging [31]. Fig. 3.10 [31] shows an application of active targeting of SPIO NPs. Fig. 3.10 is
an MRI image of mice with atherosclerosis. The image has been enhanced by the use of active
targeted SPIO in the cardiovascular region. The active targeting clearly shows the block in
the arterial pathway which is much evident from lack of signal intensity from the site (marked
between the red arrows). Another popular in vivo application of the SPIO NPs is tracking of
BIONANOIMAGING 63
FIGURE 3.10: MRI of mice with atherosclerosis—in the presence of targeted SPIO (yields better
contrast and allows detailed imaging)
cellular biodistribution which help us understand how cells migrate and distribute themselves
in vivo [37].
Another significant application of magnetic NP contrast agents is that of magnetic
relaxation switching (MRS)[36] which is being widely used for oligonucleotide, protein and
enzyme or enantiomer detection. MRS is a unique property of the SPIO which enables the iron
oxide core to diphase the spins of surrounding water molecule protons. This results in the
enhancement of T2 (a clarity factor of interest to MR images) or in the enhancement of the
spin–spin relaxation time [31, 38]. In either case, MRS improves image clarity multifold mostly
due to better contrast with the background. MRS is being used in monitoring and imaging
particle–particle interactions such as DNA-DNA, protein–protein, protein–small molecule
interactions, or enzyme reactions [38].
REFERENCES
[1] A. P. Alivisatos, “Perspectives on the physical chemistry of semiconductor nanocrystals,”
J. Phys. Chem., vol. 100(31), pp. 13226–13239, 1996.
[2] A. Smith, et al., “Engineering luminescent quantum dots for in vivo molecular and
cellular imaging,” Ann. Biomed. Eng., vol. 34(1), p. 3, 2006.
[3] M. Bruchez, et al., “Semiconductor nanocrystals as fluorescent biological labels,” Science,
vol. 281(5385), p. 2013, 1998. doi:10.1126/science.281.5385.2013
[4] R . E. Bailey and S. Nie, Alloyed Semiconductor Quantum Dots: Tuning the Optical
Properties without changing the particle size. J. Am. Chem. Soc., vol. 125(23), pp. 7100–
7106, 2003. doi:10.1021/ja035000o
[5] J. K. Jaiswal, et al., Long-term multiple color imaging of live cells using quantum dot
bioconjugates. Nat. Biotechnol., vol. 21(1), p. 47, 2003. doi:10.1038/nbt767
[6] B. Ballou, et al., Noninvasive imaging of quantum dots in mice. Bioconjug. Chem.,
vol. 15(1), p. 79. doi:10.1021/bc034153y
[7] X. Michalet, et al., Quantum dots for live cells, in vivo imaging, and diagnostics. Science,
vol. 307(5709), pp. 538–544, 2005. doi:10.1126/science.1104274
[8] J. K. Jaiswal, et al., Use of quantum dots for live cell imaging. Nat Meth., vol. 1(1), p. 73,
2004. doi:10.1038/nmeth1004-73
[9] B. O. Dabbousi, et al., (CdSe)ZnS core-shell quantum dots: synthesis and charac-
terization of a size series of highly luminescent nanocrystallites. J. Phys. Chem. B,
vol. 101(46), p. 9463, 1997. doi:10.1021/jp971091y
[10] W. C. Chan, et al., Quantum dot bioconjugates for ultrasensitive nonisotopic detection.
Science, vol. 281(5385), pp. 2016–2018, 1998. doi:10.1126/science.281.5385.2016
[11] A. L. Efros, and A. L. Efros, Interband absorption of light in a semiconductor sphere.
Sov. Phys. Semicond., vol. 16, pp. 772–774, 1982.
[12] A. I. Ekimov, A. L. Efros, and A. A. Onushchenko, Quantum size effect in
semiconductor microcrystals. Solid State Commun., vol. 56(11), pp. 921–924, 1985.
doi:10.1016/S0038-1098(85)80025-9
[13] A. I. Ekimov, and A. A. Onushchenko, Quantum size effect in the optical spectra
of semiconductor microcrystals. Sov. Phys., Semicond. (English translation of Fizika i
Tekhnika Poluprovodnikov), vol. 16(7), p. 775, 1982.
[14] M. Goulian, and S. M. Simon, Tracking single proteins within cells. Biophys. J., vol. 79(4),
p. 2188, 2000.
[15] M. E. Akerman, et al., Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci.,
vol. 99(20), pp. 12617–12621, 2002.
[16] J. K. Jaiswal, and S. M. Simon, Potentials and pitfalls of fluorescent quantum dots for bio-
logical imaging. Trends Cell Biol., vol. 14(9), p. 497, 2004. doi:10.1016/j.tcb.2004.07.012
[17] Y. T. Lim, et al., Selection of quantum dot wavelengths for biomedical assays and
imaging. Mol. Imaging, vol. 2(1), p. 50. doi:10.1162/153535003765276282
BIONANOIMAGING 65
[18] R. Bakalova, et al., Quantum dots as photosensitizers? Nat. Biotech., vol. 22(11), p. 1360,
2004. doi:10.1038/nbt1104-1360
[19] R. Campani, et al., The latest in ultrasound: three-dimensional imaging. Part II. Eur. J.
Radiol., vol. 27 (Supplement 2), p. S183, 1998.
[20] F. Candiani, The latest in ultrasound: three-dimensional imaging. Part 1. Eur. J. Radiol.,
[21] C. Martinoli, et al., Power Doppler sonography: clinical applications. Eur. J. Radiol.,
[22] M. Bazzocchi, et al., Transcranial Doppler: state of the art. Eur. J. Radiol., vol. 27
(Supplement 2), p. S141, 1998. doi:10.1016/S0720-048X(98)00055-2
[23] J. Langholz, et al., Contrast enhancement in leg vessels. Clin. Radiol., vol. 51 (Supplement
1), pp. 31–34, 1996. doi:10.1016/S0009-9260(96)80215-7
[24] R. Campani, et al., Contrast enhancing agents in ultrasonography: clinical applications.
Eur. J. Radiol., vol. 27 (Supplement 2), p. S161, 1998.
[25] F. Calliada, et al., Ultrasound contrast agents: basic principles. Eur. J. Radiol., vol. 27
(Supplement 2), p. S157, 1998. doi:10.1016/S0720-048X(98)00057-6
[26] D. Cosgrove, Ultrasound contrast agents: an overview. Eur. J. Radiol., vol. 60(3), pp.
334–330, 2006. doi:10.1016/j.ejrad.2006.06.022
[27] G. Maresca, et al., New prospects for ultrasound contrast agents. Eur. J. Radiol., vol. 27
(Supplement 2), p. S171, 1998. doi:10.1016/S0720-048X(98)00059-X
[28] B. E. Oeffinger, and M. A. Wheatley, Development and characterization of a nano-scale
contrast agent. Ultrasonics, vol. 42(1–9), p. 343, 2004. doi:10.1016/j.ultras.2003.11.011
[29] S. Dagar, et al., “Liposomes in Ultrasound and Gamma Scintigraphic Imaging,” Methods
in Enzymology. 373, pp. 198–214, 2000 doi:10.1016/S0076-6879(03)73013-4.
[30] M. B. Nielsen, and N. Bang, Contrast enhanced ultrasound in liver imaging. Eur. J.
Radiol. vol. 51 (Supplement 1), p. S3, 2004.
[31] D. Thorek, et al., Superparamagnetic iron oxide nanoparticle probes for molecular imag-
ing. Ann. Biomed. Eng. vol. 34(1), p. 23, 2006. doi:10.1007/s10439-005-9002-7
[32] W. J. Rogers, and P. Basu, Factors regulating macrophage endocytosis of nanopar-
ticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis,
vol. 178(1), p. 67, 2005. doi:10.1016/j.atherosclerosis.2004.08.017
[33] Z. G. Forbes, Magnetizable implants for targeted drug delivery, in School of Biomedical
Engineering, Science and Health Systems. Philadelphia: Drexel University, p. 139, 2005.
[34] A. Tanimoto, and S. Kuribayashi, “Application of superparamagnetic iron oxide
to imaging of hepatocellular carcinoma,” Eur. J. Radiol., vol. 58(2), p. 200, 2006.
doi:10.1016/j.ejrad.2005.11.040
[35] J.-K. Hsiao, et al., Labelling of cultured macrophages with novel magnetic nanoparticles.
J. Magn. Magn. Mater., vol. 304(1), p. e4, 2006. doi:10.1016/j.jmmm.2006.01.134
[36] M. Brauer, In vivo monitoring of apoptosis. Prog. Neuro-Psychopharmacol. Biol. Psy-
chiatr., vol. 27(2), p. 323, 2003.
[37] A. M. Morawski, G. A. Lanza, and S. A. Wickline, Targeted contrast agents for mag-
netic resonance imaging and ultrasound. Curr. Opin. Biotechnol., vol. 16(1), p. 89, 2005.
doi:10.1016/j.copbio.2004.11.001
[38] J. M. Perez, et al., Magnetic relaxation switches capable of sensing molecular interactions.
Nat. Biotech., vol. 20(8), p. 816, 2002.
67
CHAPTER 4
Successful Applications of
Bionanotechnology
INTRODUCTION
The need to diagnose diseases and medical conditions at an early stage has increased. This is
well in accordance with the saying: prevention is better than cure. Hence, the earlier we diagnose
a condition, the better we stand a chance to prevent a serious condition. New technologies are
needed to speed the diagnostic processes and help the scientists and clinicians in the initiation
of targeted treatments and in the follow up of treatment responses. An important milestone in
this process has been the advances made by researchers in biochemistry, immunology, and drug
discovery fields in the identification of molecular signatures of malignancy and cancer, using
complicated and cumbersome wet laboratory techniques. The objective now is to exploit those
initial accomplishments and combining them with available new technologies to identify the
earliest signatures of deadly conditions such as malignancies and cancer. Such developments
shall allow us to provide immediate and specific intervention and monitor the progress before it
cascades into chronic inflammation and malignancy. The fulfillment of this objective requires
the development of technologies of 1–100 nm size which display unique mechanical, electrical,
chemical, and optical properties and can assist in visualizing or sensing interactions with
receptors, cytoskeleton, specific organelles, and nuclear components within the cells. It would
be very rewarding to us when many of these technologies can migrate into monitoring the
disease condition through non-invasive methods in vivo in a physically undisturbed state, thus
minimizing the influence of artifacts induced by physical methods while securing biological
samples.
The integration of nanotechnology with biology and medicine has given birth to a new
field of science called “Nanomedicine.” The ultimate goal of nanomedicine is to develop well-
engineered nanotools for the prevention, diagnosis, and treatment of many diseases. In the
past decade, extraordinary growth in nanotechnology has brought us closer to be able to vividly
visualize molecular and cellular structures. These technologies are beginning to assist us in our
ability to differentiate between normal and abnormal cells and to detect and quantify minute
amounts of signature molecules produced by these cells. Most of these represent real-time
measurements and their dynamic relationship to other structures in the damaged area and also
to repair damaged tissues. Novel pharmaceutical preparations have been developed to fabricate
nanovehicles to deliver drugs, proteins and genes, contrast enhancement agents for imaging, and
hyperthermia agents to kill cancer cells. Several of these inventions have already transitioned
into basic medical research and clinical applications. Because of this, several social, ethical,
legal, and environmental issues have emerged. Thus, regulatory and educational strategy needs
to be developed for the society to gain benefit from these discoveries. The focus of this chapter
is to provide an overview of the state-of-the-art in nanotechnology focusing on to its successful
application in medicine and allied fields.
4.1 NANOSTRUCTURES AND NANOSYSTEMS

Nanotechnology finding applications in the world of medicine encompasses a wide range of
tools and techniques that could efficiently be used as drug delivery platforms, better con-
trast agents in imaging, chip-based biolabs (MEMS/NEMS), and nanoscale probes able to
track cell movements and manipulate molecules [1]. These tools and techniques comprise of
combinations of multifunctional nanostructures through cross-disciplinary interactions which
would further enhance our diagnostic and therapeutic capabilities, enabling us to monitor
intra/extracellular events in diagnostics and therapy.
Evolving avenues of bionanotechnology may impact diagnosis to such an extent that
it could facilitate early detection of inflammation, prevention and early detection of cancer
including several other diverse technological innovations. The newer avenues would include,
but are not limited to bio-mimicking self-assembling peptide systems which serve as building
blocks to produce nucleotides, peptides, and phospholipids that support cell proliferation and
differentiation and give insights into protein–protein interactions [2].
The microchip drug-release systems, micromachining hollow needles, and two-
dimensional needle arrays from single crystal silicon for painless drug infusion, intracellular
injections, microsurgeries, and needle-stick blood diagnosis form another group of tools which
classify under therapeutic applications [3, 4]. All these developments could one day transform
into elements of personalized treatments [5].
Let us recall that the creation, control, and use of structures, devices, and systems with
a length scale of 1–100 nm is the domain of nanotechnology and bionanotechnology deals
with the diagnostic, therapeutic, and clinical applications of nanotechnology in bioscience,
biomedical, and any subunit of Health Care for that matter. Macromolecular structures such
as dendrimers and liposomes at the nanoscale are also considered valid nanotools [6, 7]. The
application of various nanotools in many areas of medicine is depicted in Fig. 4.1. The list of this
figure is by no means exhaustive as nanotechnology continues to grow with newer technologies
SUCCESSFUL APPLICATIONS OF BIONANOTECHNOLOGY 69
FIGURE 4.1: Bionano tools in Medical applications. [Courtesy of Vishal Kamat and Dr. Papazoglou—
Drexel University, Poster Presentation, Biosensors REU Conference, June 2006, Philadelphia, PA.]
emerging each day as we speak. In the following section of this chapter we discuss various
capable nanosystems and nanostructures having potential contribution to Health Care.
4.1.1 Nanopore Technology

The biomolecular-nanopore detection technology was first developed to rapidly discriminate
between nearly identical strands of DNA thereby replacing the tedious process of running
billions of copies of DNA through sequencing machines and thus minimize errors and save
time [8]. In this technology single molecules of DNA are drawn through 1–2 nm in size pores
that serve as a sensitive detector. The detection system through its electronic signature process
can sequence more than one base pair per millisecond. This technology has the potential to
detect DNA polyploidy, and DNA mutations.
4.1.2 Nano Self-Assembling Systems

This field involves the feat of biomimetics, dealing with mimicking nature and creating
biomolecular nanomachines to address various biological problems. Many biological systems
use self-assembly as a means to assemble a variety of complex molecules and structures [9].
Numerous manmade self-assembling systems that imitate natural self-assembly of molecules
are created to snap together fundamental building blocks of complex polymer molecules that
are structured easily and inexpensively on beads, tubes, wires, flat supports, in suspensions,
and liposomes. These assemblies can have genetically introduced bio-functionality so that non-
specific molecules are repelled from fusing with the cell membrane fusion layers. DNA, lipid
bilayers, ATP synthase, peptides, and protein foldings are all target candidates for self-assembly.
Liposomes are a classical example of a manmade supramolecular self-assembling structure.
4.1.3 Cantilevers
Nanoscale cantilevers are about 50 µm-wide flexible diving board-like beams which can be
coated with antibodies and DNA complementary to a specific protein or a gene. When
molecules come in contact with these substrates coated on the surface of cantilevers, they
bind to the substrate and make the cantilevers resonate or bend as a result of this binding
event [10]. This bending deflection is proportional to the strength of binding thus making
it a quantitative technique. Multiple cantilevers could be used simultaneously to differentiate
between bound and unbound molecules. Likewise, multiple antibodies could be used in the
same reaction set-up to quantify several markers at a time. An important advantage of this
technique is that there is no need to add fluorescent tags to detect and quantify the molecule.
Any biological sample containing biomolecules of interest can be tested. Nanoscale cantilevers,
constructed as a part of a larger diagnostic device, can perform rapid and sensitive detection of
inflammation, procancer molecules, etc. and evaluate how various drugs bind to their targets at
a concentration 20 times lower than clinical threshold. A classical example of one of the most
successful technologies that evolved out of cantilevers is the atomic force microscopy (AFM)
and other scanning probe microscopic (SPM) techniques.
4.1.4 Nanoarrays
Bioassays which are integral part of biotechnology industries as well as associated researches
are often cumbersome and error prone. The need for easy and accurate means of conducting
the bioassays is an essential requirement. Recent explosive development in the field of mi-
crofluidics, biotechnology, and functional genomics has resulted in the miniaturization of these
bio-analytical assays to micron scales for routine and throughput screening [11]. These assays
could widely be used in genomics, proteomics, and other bioscience analysis. Their application
to proteomics still requires refinement since replication of proteins as opposed to DNA is yet
to be fully realized. Efforts are underway to further miniature microarrays, which are still used
for analyzing proteins. These include fabrication of AFM-based (atomic force microscope) Dip
pen nanolithography (DPN) that could probe complex mixtures of proteins, sense reactions
involving the protein features and antigens in complex solutions, and study the details of cellular
adhesion at the submicron scale. Protein nanoarrays Generated by Dip-Pen Nanolithography
are emerging [12] and sooner would evolve into a much power tool in biotechnology. The de-
velopment of miniaturization techniques like DPN would enable the design of nanoarrays that
can detect biological entities on a single-particle level in a timely and cost-efficient manner; also
it would profile new diagnostic biomarkers at a detection level much beyond our imagination.
4.2 NANOPARTICLES
Particles in the nano domain could generally be called as nanoparticles. Mostly these are
spherical particles with specific properties that allow their detection, analysis, and quantification
in a more efficient way. Exhibiting various physical and optical properties, the nanoparticles
combine with biomolecules, drugs, and other reagents becoming nanoprobes. For instance, iron
oxide nanoparticles exhibit super paramagnetic properties [13] while gold nanoparticles possess
specific optical absorption properties depending on their size [14]. It is important to note that
particles made from the same materials but of micron dimensions do not exhibit such unique
optical or magnetic properties [15]. One can thus combine the immense surface to volume ratio
of these nanostructures to deliver higher loads of compounds encapsulated or linked to their
surface, while their presence can be measured due to their characteristic magnetic or optical
properties. In the following section let us examine various successful applications unique to the
nano realm.
4.2.1 Quantum Dots (QDs)

Quantum dots abbreviated as QDs are tiny light-emitting particles on the nanometer scale.
They are emerging as a new class of biological probes (in the imaging field) which could replace
traditional organic dyes and fluorescent proteins. The fundamental benefit of using quantum
dots is their high quantum yield and strong emission intensity. The emission spectrum of QDs
is a function of the particle size and hence by varying particle size quantum dots can emit from
visible to infrared wavelengths [16]. Let us recall the definition and significance of the Bohr’s
radius and its relevance to quantum energy from Chapter 1.
The QDs can be excited by UV light and emit light, according to their size from the
visible to infrared wavelengths. Their broad excitation spectrum and narrow emission spectrum
with little or no spectral overlap makes them attractive for high resolution imaging of multiple
species at the same time without the need for complex optics and data acquisition systems.
QDs offer higher signal-to-noise ratios compared to traditional fluorochromes (fluopores).
The high sensitivity of the QDs allows accurate detection even in the presence of strong auto-
fluorescent signals encountered during in vivo imaging [17, 18]. Their excellent resistance
to photobleaching enable for long-term monitoring of biological phenomena, critical in live
cell imaging and thick tissue specimens. Already QDs are finding increasing use in live cell
imaging, by themselves or as FRET donors combined with traditional fluorochromes, in vitro
assays, and live animal imaging for cancer and tumor diagnostics. Further, they are used in
multimodal applications as contrast agents in bioimaging, microarrays, FACS analysis, and
monitor pharmacokinetics of therapeutic agents and in multicolor optical coding for high
throughput screening [19].
Limitations of quantum dots can arise from the stability of the core shell structure. Most
commercially available materials comprise a core of CdSe and a shell of ZnS. In order to render
this inorganic structure hydrophilic, amphiphilic polymers are used to cap the shell layer and
provide reactive sites for further linking to proteins. It is therefore the stability of this layer that
controls aggregation of quantum dots, as well as possible release of core materials (Cd ions) to
the surrounding which may result in toxicity [20]. This has limited the immediate clinical use of
quantum dots, but has focused applications to animal testing and in vitro assay developments.
Simon and colleagues [21] did not notice any cellular toxicity even under selection pressure
when they used QDs to track metastatic tumor cell extravasations in an animal model. Quantum
dots can have immediate applications in oncologic surgery if the safety profile can be established
for humans [22]. However, toxicity to humans is still being debated. Further research is needed
before we move forward toward widespread use of quantum dots in biological systems [23].
Another reported problem is the blinking property of the QDs. Quantum dots tend to blink at
the single dot level and hence present some limitation in absolute fluorescence quantification.
However, when used for imaging of biomarkers this property doesn’t affect much as there
are hundreds or thousands of quantum dots in a sample to allow proper averaging. More
fundamentals, synthesis, conjugation techniques, and applications of the QDs were dealt in
Chapter 3.
4.2.2 Paramagnetic Iron Oxide Crystals

Paramagnetic iron oxide nanoparticles are a new class of magnetic contrast agents that are
finding increasing applications in the field of diagnostic and molecular imaging based on
magnetic resonance (MR) [13]. Traditional MR imaging agents rely on the interaction of
the proton density, i.e., water molecules and the magnetic properties of the tissue. These
paramagnetic agents accelerate the rate of relaxation of protons in the longitudinal direction
resulting in bright images and hence are highly dependent on water molecules. However,
the super paramagnetic iron oxide nanoparticles by the virtue of their nanoscale properties
disturb the magnetic field independent of their environment and hence are not dependent
on the presence of water molecules. They are also called negative enhancers [24] as they act
as negative contrast agents and appear dark where they are sequestered. The traditional MR
agents such as gadolinium–diethylenetriamine penta-acetic acid (DTPA) enhance the signal
from the vascular compartments and are nonspecific, whereas the nanoparticle-based contrast
agents impact the MR signal from tissues and cells. The gadolinium-based neutron capture
therapy has several advantages including more efficient tumor killing effects and the potential for
simultaneous MR imaging to assess response. Fokumori and colleagues [25] utilized gadolinium
incorporated cationic polymer chitosan nanoparticles that resulted in efficient cellular uptake
and demonstrated significant in vitro tumoricidal effect at relatively low concentrations.
The superoxide paramagnetic crystals when used in combination with QDs provide
additional information of the specific molecular targets for imaging [26].
The advantage of these contrast agents lies in their ability to get sequestered anywhere
within a support matrix and still generate a contrast whereas the traditional MR agents need
water in their vicinity to generate contrast. These nanoparticles can be used for both passive and
active targeting. Because of the small size of these particles, tissue macrophages readily uptake
these agents and hence it is possible to image liver, spleen, lymph nodes, and lungs; also they
have been able to distinguish between the normal and tumor-bearing lymphatic nodes [27, 28].
These nanoparticles may also distinguish very small metastases (less than 2 mm in diameter)
within normal lymph nodes, a size well below the detection limit of the most sensitive imaging
techniques such as positron-emission tomography (PET) available today. Metal nanoshells can
serve as strong near infrared (NIR) absorbers. This property has been exploited to provide
targeted thermal therapy selective to tumor cells without damaging normal tissue using gold
nanoshells [29].
In addition, it is also possible to functionalize these nanoparticles using a wide variety of
ligands, antibodies, peptides, aptamers, drugs etc. to achieve site-specific or biomarker-specific
targeting. This is an added advantage since traditional paramagnetic formulations are difficult
to conjugate to antibodies and even when conjugated owing to the small number of cellular
receptors, the signal intensity is not sufficient for accurate imaging. The iron oxide nanoparticles
find applications as contrast agents for the imaging of cancer, brain inflammation, arthritis,
and atherosclerotic plaques. Cells loaded with iron oxide nanoparticles have shown that these
particles are nontoxic and are cleared from the cell after 5–8 divisions. Lewin et al. [30] labeled
stem cells with iron oxide particles using HIV TAT peptide and injected them systemically.
The labeled stem cells homed on to the bone marrow and the labeled stem cells didn’t cause
any impairment. However, due to the small size of these particles a long time is required
(up to 24 h) to clear them from the organs and blood to reduce background signals. Thus,
MR imaging with the use of super paramagnetic iron oxide particles may result in improved
sensitivity and selectivity and may assist to diagnose tumors at the earliest stages of malignancy
or metastasis. To have a grasp of insight of iron nano-particles, a thorough substance was
presented in Chapter 3.
4.2.3 Dendrimers
Dendrimers are a new class of hyper-branched polymer macromolcules that radiate from a
central core with structural symmetry. They could vary in shape, size, surface, flexibility, and
topography and thus enable fabrication of functional nanoscale materials having unique prop-
erties [31, 32]. Dendrimers could be used in the development of antiviral drugs, tissue repair
scaffolds, and targeted carriers of chemotherapeutics. Commercially certain dendrimers are now
being used as immuno-diagnostic agents and gene transfection vectors. Dendrimers complexed
with gadolinium III ions (gadomer-17) are being tested (phase I clinical trial) for magnetic
resonance imaging angiography [33], further extending its frontiers.
4.2.4 Carbon Nanotubes

Carbon nanotubes also referred to as “buckytube” or “buckyballs” are a member of the fullerene
(C60 ) structural family that show increasingly potential use in many biological applications. They
could be cylindrical (nanotubes), spherical (buckyballs), or branched (fullerenes). Nanotubes
could broadly be divided into single-walled nanotubes (SWNT) and multiwalled nanotubes
(MWNT). Having adequate characteristics of a “drug-vehicle”, the carbon nanotubes are used
in drug delivery and cancer therapy significantly backed up by their transporting capabilities
achieved via suitable functionalization chemistry and their intrinsic optical properties. Proper
surface functionalization is necessary to make carbon nanotubes biocompatible. In one of
the recent applications, SWNTs have been used to transport DNA inside living cells [34].
Intracellular protein transport has also been accomplished [35] though they are suspected to
provoke severe immune responses. Most SWNTs have diameters as close to 1 nm, with a
tube length that could be several thousands times larger. SWNTs with length up to orders of
centimeters have been produced [36]. Single-walled nanotubes are a very important class of
carbon nanotubes because they exhibit unique electric properties unlike the multi-walled carbon
nanotube (MWNT) variants. On the other hand, multi-walled carbon nanotubes fabricated
as multiple concentric nanotubes precisely nested within one another can be used for perfect
linear or rotational bearing. Technology has now advanced into merging these MWNTs with
magnetic nanomaterials like magnetite, which can be functionalized and open newer venues of
CNT-associated magnetic applications.
Gado-fullerenes (gadolinium + fullerenes) offer the ability to concentrate more gadolin-
ium at the site of disease (interest), than traditional Gd-DTPA. This is the result of the shielding
that the carbon structure provides and its ability to link more gadolinium per conjugate. Gado-
fullerenes also take advantage of the gadolinium–water interactions as the gadolinium is along
the periphery of the structure and can maintain its interaction with water, which is the basis of
traditional proton density MRI. These properties produce a stronger signal which can increase
detection sensitivity of even smaller lesions.
Recently there has been further improvement in the aforementioned technology by
developing smart bionanotubes which could be manipulated to produce open or closed end
nanotubes to encapsulate drugs or genes to deliver them in a particular location in the body
[37]. Thus, possibilities exist for using nanotubes to improve gene sensing, gene separation,
drug delivery, and detection of biomarkers for better quality of health care, advanced protection
from bioterrorism, and critical progress in other areas of molecular sensing.
4.2.5 Nanosomes and Polymersomes

Phospholipid bilayers exhibiting multifunctional characteristics could be grouped as polymer-
somes. The polymersomes facilitate the encapsulation of various classes of drugs and diagnostic
agents aimed at controlled delivery into cellular and therapeutic targets. Some notable drug
delivery strategies utilizing these agents include polymerosomes, hydrogel matrices, nanovesi-
cles/nanofiber mats, and biodegradable nanosomes [38]. They provide as a versatile platform
to perform bioscience or biological applications, for instance the biodegradable polymersomes
based on polyethylene oxide could be employed as a surface to anchor antibodies or other tar-
geting molecules. Quite recently fluorescent materials have been embedded into these cell-like
vesicles [39] to produce near-infrared emissive polymersomes which could be used to locate ar-
eas of inflammation and deliver a load of drug to inflammation sites. Interestingly inflammation
sites deeper than 1 cm could be imaged with this technique.
To increase the safety and efficacy of gene therapy and genetically derived vaccines,
efforts are underway to target DNA complexes into hepatocytes and macrophages. Undoubtedly
polymersomes would play a significant role in such applications. Small-sized micelles in the
nano domain also classify under nanosomes and are used to develop agents for γ -scintigraphy,
magnetic resonance imaging (MRI), and computed tomography (CT)[40]. Liposomes are
another integral member of the nanosome family; they are increasingly used in drug delivery
applications. A fairly detailed layout on liposomes, their synthesis, and applications is discussed
in Chapter 3 and Chapter 5.
A class of polymersomes called polymer nanotubes have been synthesized by directly
pulling on the membrane of polymersomes using either optical tweezers or a micropipette [41].
These tubes are unusually long (about 1 cm) and stable enough to maintain their shape in-
definitely. The pulled nanotubes are stabilized by subsequent chemical cross-linking. These
polymersomes are composed of amphiphilic diblock copolymers consisting of an aqueous core
connected to the aqueous interior of the polymersome, less than 100 nm in diameter. The
aqueous core of the polymer nanotubes together with their robust character offers opportuni-
ties for nanofluidics and other applications in biotechnology especially in the development of
nano-hyperdermic syringes [42].
4.3 IN VITRO DIAGNOSTICS

Diagnosis is a key stage in health care; the earlier we diagnose a disease/condition the more ef-
fective is the therapy, both from outcomes as well as from a total cost perspective. Bionanotech
plays a vital role in the improvement of diagnostic technologies. The development and use
of analytical tools in the diagnostic area present immediate benefits to the user. The diag-
nostic detection techniques involve measuring antibody or antigen-based complexes, enzyme-
based reaction rates, or polymerase chain reactions using micro-electro-mechanical systems
(MEMS)[43]. Other schemes of scaleable diagnostics include whole cell bacterial sensors and
biosensors utilizing aptamers, which are biomimetic synthetic bioreceptors able to complex
with proteins, nucleic acids, and drugs. In certain diagnostic methods, the nanoparticles are
interfaced with biological molecules such as antigens, antibodies, or chemicals and perform
as nanoprobes. Popular nanoparticles employed in diagnostics include quantum dots, metallic
nanobeads, silica particles, magnetic beads, carbon nanotubes, optical fibers, nanopores, etc
[43].
Similar to the above technologies, nanowires composed of 1–2 nm wide boron-doped
silicon wires laid down on a silicon grid can be coated with antigens and provide real-time
detection of antibodies (ABs). The AB binding to an immobilized antigen gives a measurable
conductance change at AB concentrations less than 10 nM. Detection of single copies of
multiple viruses has been accomplished via AB conjugated nanowire field effect transistors
(FET)[44].
The dream of optical biopsy is closer to reality with AB functionalized semiconductor
nanoparticles (QD’s) detected by fluorescence microscopy. Multiplexed assays can be developed
since the fluorescence emission of QDs is tunable by changing their size. Outstanding detection
sensitivity of antibodies in whole blood (picogram per ml) has been obtained by using gold
nanoparticle conjugates [45]. The realization of optical biopsy would revolutionarize the medical
world.
For detection and characterization purposes classical tools can be used as well as
nanobased-methods such as AFM and near-field scanning optical microscopy (NSOM), meth-
ods where quantum tunneling plays a key role in amplifying detection capability. This phe-
nomenon is possible due to the nanometer distance between the instrument probe and the
surface/specimen under examination. Atomic force microscopy is used to elucidate structures
of biomolecules under physiologic conditions [46], determine AB/antigen binding properties
[41], image topology of viruses, [47] and image pathologies at the molecular scale [48]. These
nano imaging techniques have extraordinary magnification and resolution and can image details
of less than 1 nm dimensions.
4.4 MEDICAL APPLICATION OF NANOSYSTEMS

AND NANOPARTICLES
It is a longstanding need of the pharmaceutical industry, physicians, and patients to im-
prove pharmaceutical formulations by establishing simpler, less expensive preparations and
treatments, while reducing toxicity. This need can be met with the know-how of nanotechnol-
ogy that has already made breakthrough developments in improved delivery of injectibles, oral
formulations, drug device implants, as well as topical and transdermal delivery formulations.
Especially in the case of drug delivery to the brain, an untouchable region by traditional drug
delivery systems, nanotechnology can make the difference. The reason behind the failure of
conventional delivery systems in reaching the brain is the blood brain barrier (BBB) composed
of tight tissues (Chapter 3) making it impervious to outside agents. Nanotechnology has the po-
tential to address and resolve this challenge and make brain a reachable target for drug delivery
systems, by combining unique elements of size, surface activity and charge of nanostructures.
Nanosystems and nanoparticles have opened up unforeseen avenues in diagnostics and
therapeutics in medicine. The previous treatment strategies in the fields of autoimmune dis-
eases and cancer involved non-targeted treatment options with extensive “collateral damage.”
Nanodelivery of drugs is envisioned to reduce this collateral damage, extend the drug’s avail-
ability and effectiveness at the site, and reduce toxicity and cost with a high pay-off load. In
this section we present the role of nanotechnology in drug delivery, imaging, and other appli-
cations in the biosciences and health care fields. Further details on the background and need of
nanotechnology and its potentials were discussed in Chapter 3.
4.4.1 Drug Delivery Applications

The focus of this section is to highlight several nanomedical applications, involving biologic
nanostructures increasingly used in drug delivery systems. The list of nanostructures include
lipid-, silica-, polymer-, fullerene (buckyballs, buckytubes)-based structures such as liposomes,
micelles, and other nanoparticle systems.
Liposomal Formulations for Drug Delivery
The definition, fundamentals, and properties of Liposomes were presented in fair detail in
Chapter 3; the synthetic techniques of liposomes will be discussed in the forthcoming chapter
on synthesis techniques of nanoparticles (Chapter 5). Liposomes, the vesicles with phospholipid
membranes containing hydrophilic substances in their core, often have their properties dictated
by the size, lipid composition, surface charge, and method of preparation [49]. Conventional
liposomes are short-lived in vivo and are rapidly cleared by the reticulo-endothelial system
(RES). A novel liposomal formulation with a polyethylene glycol (PEG) coating avoids RES-
mediated clearing and is called a STEALTH liposome, having properties of long circulation
half-life and targeted accumulation in tumor tissues [50].
Liposomes find extensive use in cancer therapy. Some of the major classes of anti-
cancer drugs in liposomal formulations are commercially available while others are in late
stages of development, and include anthracyclines, camptothecins, platinum derivatives,
anti-metabolites and cell-cycle specific drugs such as vincristine and doxorubicin. Liposo-
mal formulations have a demonstrated record of decreased cardiotoxicity as compared to
conventional formulations [51]. Current liposomal formulations include pegylated liposo-
mal doxorubicin (DoxilOrthobiotech,
R CaelyxSchering-Plough)
R non-pegylated doxoru-
bicin (MyocetElan
R Pharma), and liposomal daunorubicin (DaunoXome, R Gilead Sciences).
Liposomal derivatives such as the platinum-derived cisplatin and carboplatin are used
in the treatment of head and neck cancers, testicular cancer, lung cancer, and many other
malignancies. They have shown significantly reduced toxicity and better pharmacokinetic pro-
files compared to conventional formulations [52]. Liposomes can conveniently be deployed in
passive or active targeting in various cancer applications. In passive targeting, the liposomes
can navigate with ease to reach the tumor site due to the high angiogenesis, leaky vascu-
lature, and high permeability of malignant tumors. Passive targeting therefore presents an
exceptional opportunity to increase drug concentration at the targeted site by extravasations,
thereby reducing toxicity and collateral damage. Active targeting on the other hand depends
on c molecular strategies involving monoclonal antibody-liposomal conjugates (referred to as
immuno-liposomes) which enable specific tumor cell targeting by antigen identification and
drug delivery by internalization of the liposome by tumor cells [53]. The enhanced antitu-
mor activity of anti-HER2 immunoliposomes containing doxorubicin [54] and anti-epidermal
growth factor receptor (anti-EGFR) immunoliposomes was demonstrated by increased cyto-
toxic effect in vitro, in tumor cells overexpressing EGFR, and by enhanced efficacy in vivo in
xenograft models [55].
Liposomal drug delivery also finds good application in treating inflammations; a single
dose of PEG-liposome containing glucocorticoids injected in mice (collagen arthritis model)
resulted in long lasting joint inflammation reduction as compared to multiple injections required
of regular steroids [56]. The role of liposomes in respiratory conditions is also significant, as
demonstrated in their performance in asthma therapy [57] and in treating adult respiratory
distress syndrome (ARDS), sepsis, radiation lung injury, and emphysema [58] among others.
Enhanced drug delivery systems for analgesics [59–61] employ liposomes and are founding
increasing clinical acceptance.
4.4.2 Nanoparticles in Molecular Imaging

The basics of nanoparticles and their role in applications and advances of molecular imaging were
presented in Chapter 3 with special emphasis on QDs, MRI, and ultrasound contrast agents.
In this chapter, in Sections 4.2.1 and 4.2.2, we discussed QDs and iron oxide nanoparticles
which are classical examples of nano-based imaging methods. A variety of nanostructures
containing novel contrast agents such as quantum dots, gold nanoparticles, or nanoshells,
supramagnetic nanoparticles complexed with biological agents are used to detect malignancy
and cancer effectively [62, 63]. There have been efforts to combine drug delivery and imaging;
Bankiewicz et al. [64] described an integrated strategy to deliver drugs to the brain, where they
combined the conventional liposomal drug delivery with an MRI contrast agent (gadoteridol)
encapsulated in them. They then used MRI to obtain detailed magnetic resonance images of
drug moving through a living primate brain and monitor clinical efficacy. Molecular imaging
has now expanded into medical imaging through the use of smart imaging agents for in vivo
molecular imaging and imaging of animal models [65–67]. A representative example is the
use of magnetic nanoparticles conjugated with anti-VCAM-1 antibodies to detect VCAM-1
expression through fluorescence and magnetic resonance on endothelial cells, both in vivo and
in vitro [68].
4.5 SUMMARY AND CONCLUSIONS

Understanding the biological systems, their phenomena at the nanoscale where they oper-
ate and their interactions with extraneous nanostructures are the focus of bionanotechnology.
Nanomedicine, a much expected outcome of nanotechnology, is a desirable solution to moni-
tor and treat biologic systems in health and disease. This could be accomplished by real-time
monitoring of molecular signaling at the cellular and tissue level. The explosion in bionanotech-
nology research and the associated revolutionary advancements in biomedical applications lay
a strong foundation for a customized, personalized, and quantitative medicine in the future.
The present day nanotechnology initiatives include a range of successful and evolving
technologies encompassing targeted drug delivery aimed at minimizing side effects, creation of
implantable materials as scaffolds for tissue engineering, development of implantable devices,
surface modification and designing optimal topology for biomaterial implants, surgical aids,
nanorobotics, as well as high throughput drug screening and medical diagnostic imaging. Real-
izing that the advances possible by nanotechnology will revolutionize medicine, the nanoinitia-
tives are increasingly funded by government and private sources not only in the United States
but also in Europe and the world throughout to develop or to further refine the present technol-
ogy to provide the beyond imaginable, most sophisticated tools to the physicians and scientists.
There will be many technical, regulatory, and legal challenges along the road to implement and
realize these technologies. However, there is strong desire and commitment to overcome these
challenges and improve the quality of life in a global environment.
REFERENCES
[1] S. M. Moghimi, C. A. H., J. C. Murray, “Nanomedicine: current status and future
prospects,” FASEB J., 19(3), pp. 311–330, 2005. doi:10.1096/fj.04-2747rev
[2] S. Zhang, Emerging biological materials through molecular self-assembly. Biotechnol.
Adv. 20, pp. 321–339, 2002. doi:10.1016/S0734-9750(02)00026-5
[3] D. V. McAllister, M. G. Allen and P. M. R., Microfabricated microneedles
for gene and drug delivery. Ann. Rev. Biomed. Eng., 2, pp. 289–313, 2000.
doi:10.1146/annurev.bioeng.2.1.289
[4] D. Sparks and T. Hubbard , Micromachined needles and lancets with de-
sign adjustable bevel angles. J. Micromech. Microeng., 14, pp. 1230–1233, 2004.
doi:10.1088/0960-1317/14/8/016
[5] K. K. Jain, Role of nanobiotechnology in developing personalized medicine for cancer.
Technol. Cancer Res. Treat, 4(6), pp. 645–650, 2005.
[6] M. J. Cloninger, Biological applications of dendrimers. Curr. Opin. Chem. Biol., 6(6),
pp. 742–748, 2002. doi:10.1016/S1367-5931(02)00400-3
[7] M. E. Hayes, et al., Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable
for targeted gene delivery. Gene Ther., 13(7), p. 646, 2005. doi:10.1038/sj.gt.3302699
[8] V. W. Wenonah, et al., Rapid discrimination among individual DNA hairpin molecules
at single-nucleotide resolution using an ion channel. Nat. Biotechnol., 19, pp. 248–252,
2001. doi:10.1038/85696
[9] S. Zhang, Molecular self-assembly In Encyclopedia of Materials: Science & Technology. Else-
vier Science, pp. 5822–5829, 2001, Oxford, UK.
[10] A. Majumdar, Bioassays based on molecular nanomechanics. Dis. Markers, 18, pp. 167–
174, 2002.
[11] M. Lynch, et al., Functional protein nanoarrays for biomarker profiling. Proteomics, 4,
pp. 1695–1702, 2004. doi:10.1002/pmic.200300701
[12] K. B. Lee, et al., Protein nanoarrays generated by dip-pen nanolithography. Science, 295,
pp. 1703–1705, 2002.
[13] M. E. Kooi, et al., Accumulation of ultra-small super paramagnetic particles of iron oxide
in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging.
Circulation, 107, pp. 2453–2458, 2003. doi:10.1161/01.CIR.0000068315.98705.CC
[14] J. L. West and N. L. Halas, Applications of nanotechnology to biotechnology. Curr.
Opin. Biotech., 11, pp. 215–217, 2000. doi:10.1016/S0958-1669(00)00082-3
[15] A. Hernando, C. P., and G. M. A., Metallic magnetic nanoparticles. Sci. World J., 5,
pp. 972–1001, 2005.
[16] M. Han, et al., Quantum-dot-tagged microbeads for multiplexed optical coding of
biomolecules. Nat. Biotechnol., 19, pp. 631–635, 2001. doi:10.1038/90228
[17] I. L. Medintz, et al., Quantum dot bioconjugates for imaging, labeling and sensing. Nat.
Mater., 4, pp. 435–446, 2005. doi:10.1038/nmat1390
[18] P. Mitchell, Turning the spotlight on cellular imaging. Nat. Biotechnol., 19(11), pp. 1013–
1017, 2001. doi:10.1038/nbt1101-1013
[19] X. Michalet, et al., Quantum dots for live cells, in vivo imaging, and diagnostics. Science,
307(5709), pp. 538–544, 2005. doi:10.1126/science.1104274
[20] J. Lovric, et al., Differences in subcellular distribution and toxicity of green
and red emitting CdTe quantum dots. J. Mol. Med., 83(5), pp. 377–85, 2005.
doi:10.1007/s00109-004-0629-x
[21] E. B. Voura, et al., Tracking metastatic tumor cell extravasation with quantum dot
nanocrystals and fluorescence emission-scanning microscopy. Nat. Med., 10(9), pp. 993–
998, 2004. doi:10.1038/nm1096
[22] E. G. Soltesz, et al., Sentinel lymph node mapping of the gastrointestinal tract by using
invisible light. Ann. Surg. Oncol., 13, pp. 386–96, 2006. doi:10.1245/ASO.2006.04.025
[23] J. K. Jaiswal and S. M. Simon, Potentials and pitfalls of fluorescent quan-
tum dots for biological imaging. Trends Cell Biol., 14(9), pp. 497–504, 2004.
doi:10.1016/j.tcb.2004.07.012
[24] J. M. Perez, L. Josephson, and R. Weissleder, Use of magnetic nanoparticles as
nanosensors to probe for molecular interactions. Chembiochem., 5(3), pp. 261–264, 2004.
doi:10.1002/cbic.200300730
[25] F. Shikata, et al., In vitro cellular accumulation of gadolinium incorporated into chitosan
nanoparticles designed for neutron-capture therapy of cancer. Eur. J. Pharm. Biopharm.,
53(1), pp. 57–63, 2002. doi:10.1016/S0939-6411(01)00198-9
[26] A. J. Bogdanov, et al., Oligomerization of paramagnetic substrates result in signal ampli-
fication and can be used for MR imaging of molecular targets. Mol. Imaging 1(1), pp. 16–
23, 2002. doi:10.1162/153535002753395671
[27] Y. Anzai, Superparamagnetic iron oxide nanoparticles: nodal metas-
tases and beyond. Top. Magn. Reson. Imaging, 15(2), pp. 103–111, 2004.
doi:10.1097/01.rmr.0000130602.65243.87
[28] M. G. Harisinghani, et al., Noninvasive detection of clinically occult lymph-node
metastases in prostate cancer. N. Engl. J. Med., 348(25), pp. 2491–2499, 2003.
doi:10.1056/NEJMoa022749
[29] J. L. West, Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic
resonance guidance. Proc. Natl. Acad. Sci., 100, pp. 13549–13554, 2003.
[30] M. Lewin, et al., Tat peptide-derivatized magnetic nanoparticles allow in vivo
tracking and recovery of progenitor cells. Nat. Biotechnol., 18, pp. 410–414, 2000.
doi:10.1038/74464
[31] C. C. Lee, et al., Designing dendrimers for biological applications. Nat. Biotechnol., 12,
pp. 1517–26, 2005.
[32] H. Yang, and W. J. Kao, Dendrimers for pharmaceutical and biomedical applications. J.
Biomater. Sci. Polym. Ed., 17, pp. 3–19, 2006. doi:10.1163/156856206774879171
[33] G. P. Yan, et al., Synthesis and evaluation of gadolinium complexes based on PA-
MAM as MRI contrast agents. J. Pharm. Pharmacol., 57(3), pp. 351–357, 2005.
doi:10.1211/0022357055506
[34] N. W. Kam, Z. Liu, and H. Dai, Carbon nanotubes as intracellular transporters for
proteins and DNA: an investigation of the uptake mechanism and pathway. Angew.
Chem. Int. Ed. Engl., 45(4), pp. 577–581, 2006. doi:10.1002/anie.200503389
[35] N. W. Kam, and H. Dai, Carbon nanotubes as intracellular protein transporters: gen-
erality and biological functionality. J. Am. Chem. Soc., 127(16), pp. 6021–6026, 2005.
doi:10.1021/ja050062v
[36] H. W. Zhu, et al., Direct synthesis of long single-walled carbon nanotubes strands.
Science, 296, p. 884, 2002. doi:10.1126/science.1066996
[37] U. Raviv, et al., Cationic liposome–microtubule complexes: pathways to the formation
of two-state lipid–protein nanotubes with open or closed ends. Proc. Natl. Acad. Sci., 102,
pp. 11167–11172, 2005.
[38] F. Meng, G. H. Engbers, and J. Feijen, Biodegradable polymersomes as a basis for
artificial cells: encapsulation, release and targeting. J. Control Rel., 101, pp. 187–198,
2005. doi:10.1016/j.jconrel.2004.09.026
[39] P. P. Ghoroghchian, et al., Near-infrared-emissive polymersomes: self-assembled soft
matter for in vivo optical imaging. Proc. Natl. Acad. Sci. USA, 102(8), pp. 2922–2927,
2005. doi:10.1073/pnas.0409394102
[40] V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat. Rev.
Drug Discov, 4(2), pp. 145–160, 2005. doi:10.1038/nrd1632
[41] E. L. Florin, V. T. Moy, and H. E. Gaub, Adhesion forces between individual ligand-
receptor pairs. Science, 264(5157), pp. 415–417, 1994. doi:10.1126/science.8153628
[42] J. E. Reiner, et al., Stable and robust polymer nanotubes stretched from polymersomes.
Proc. Natl. Acad. Sci. USA, 103(5), pp. 1173–1177, 2006. doi:10.1073/pnas.0510803103
[43] T. Kubik, K. Bogunia-Kubik, and M. Sugisaka, Nanotechnology on duty in medical
applications. Curr. Pharm. Biotechnol., 6, pp. 17–33, 2005.
[44] F. Patolsky, et al., Electrical detection of single viruses. Proc. Natl. Acad. Sci.,
101, pp. 14017–14022, 2004.
[45] L. R. Hirsch, N. J. Halas, and J. L. West, Whole-blood immunoassay facilitated by gold
nanoshell-conjugate antibodies. Methods Mol. Biol., 303, pp. 101–111, 2005.
[46] Z. Shao, and Y. Zhang, Biological cryo atomic force microscopy: a brief review. Ultra-
microscopy, 66(3–4), pp. 141–152, 1996. doi:10.1016/S0304-3991(96)00087-3
[47] Y. G. Kuznetsov, et al., Atomic force microscopy imaging of retroviruses: human im-
munodeficiency virus and murine leukemia virus. Scanning, 26(5), pp. 209–216, 2004.
[48] X. Sheng, et al., Adhesion at calcium oxalate crystal surfaces and the effect
of urinary constituents. Proc. Natl. Acad. Sci. USA, 102(2), pp. 267–272, 2005.
doi:10.1073/pnas.0406835101
[49] J. Barauskas, M. Johnson, and E. Tiberg, Self-assembled lipid superstructures: beyond
vesicles and liposomes. Nano Lett., 5(8), pp. 1615–1619, 2005. doi:10.1021/nl050678i
[50] L. Cattel, M. Ceruti, and F. Dosio, From conventional to stealth liposomes: a new
frontier in cancer chemotherapy. J. Chemother., 16 Suppl (4), pp. 94–97, 2004.
[51] Y. Matsumura, et al., Reduced cardiotoxicity and comparable efficacy in a phase III trial
of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxoru-
bicin for first-line treatment of metastatic breast cancer. Ann Oncol., 15(3), pp. 440–449,
2004. doi:10.1093/annonc/mdh092
[52] P. K. Working, et al., Comparative intravenous toxicity of cisplatin solution and cisplatin
encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol
Sci., 46(1), pp. 155–165, 1998.
[53] E. Mastrobattista, G. A. Koning, and G. Storm, Immunoliposomes for the targeted
delivery of antitumor drugs. Adv. Drug Deliv. Rev. 10, 40(1-2), pp. 103–127, 1999.
doi:10.1016/S0169-409X(99)00043-5
[54] J. W. Park, et al., Anti-HER2 immunoliposomes: enhanced efficacy attributable to
targeted delivery. Clin. Cancer Res., 8(4), pp. 1172–1181, 2002.
[55] C. Mamot, et al., Epidermal growth factor receptor (EGFR)-targeted immunoliposomes
mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing
tumor cells. Cancer Res. 15, 63(12), pp. 3154–3161, 2003.
[56] J. M. Metselaar, et al., Liposomal targeting of glucocorticoids to synovial lining cells
strongly increases therapeutic benefit in collagen type II arthritis. Ann. Rheum. Dis.,
63(4), pp. 348–353, 2004. doi:10.1136/ard.2003.009944
[57] K. S. Konduri, et al., Efficacy of liposomal budesonide in experimental asthma. J. Allergy
Clin. Immunol., 111(2), pp. 321–327, 2003. doi:10.1067/mai.2003.104
[58] M. Christofidou-Solomidou, and V. R. Muzykantov, Antioxidant strate-
gies in respiratory medicine. Treat Respir. Med., 5(1), pp. 47–78, 2006.
doi:10.2165/00151829-200605010-00004
[59] W. Huang, et al., Preparation oral liposome-encapsulated recombinant Helicobacter
pylori heat shock protein 60 vaccine for prevention of Hp infection. Di Yi Jun Yi Da Xue
Xue Bao., 25(5), pp. 531–534, 2005.
[60] S. Jain, et al., Transdermal delivery of an analgesic agent using elastic liposomes: prepara-
tion, characterization and performance evaluation. Curr. Drug Deliv., 2(3), pp. 223–233,
2005. doi:10.2174/1567201054368020
[61] A. K. Seth, A. Misra and D. Umrigar, Topical liposomal gel of idoxuridine for the treat-
ment of herpes simplex: pharmaceutical and clinical implications. Pharm. Dev. Technol.,
9(3), pp. 277–89, 2004. doi:10.1081/PDT-200031432
[62] M. E. Ackerman, et al., Nanocrystal imaging in vivo. Proc. Natl. Acad. Sci., 99, pp. 12167–
12621, 2002.
[63] X. Gao, et al., In vivo cancer targeting and imaging with semiconductor quantum dots.
Biotechnology, 22(8), pp. 969–976, 2004. doi:10.1038/nbt994
[64] R. Saito, et al., Gadolinium-loaded liposomes allow for real-time magnetic resonance
imaging of convection-enhanced delivery in the primate brain. Exp. Neurol., 196,
pp. 381–389, 2005.
[65] A. F. Chatziioannou, PET scanners dedicated to molecular imaging of small animal
models. Mol. Imaging Biol., 4, pp. 47–63, 2002.
[66] S. R. Cherry, In vivo molecular and genomic imaging: new challenges for imaging
physics. Phys. Med. Biol., 49, pp. R13–R48, 2004.
[67] G. Choy, P. Choyke, and S. K. Libutti, Current advances in molecular imaging: non-
invasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol
Imaging, 2, pp. 303–312, 2003.
[68] A. Tsourkas, et al., In vivo imaging of activated endothelium using an anti-VCAM-1
magnetooptical probe. Bioconjugate Chem., 16, pp. 576–581, 2005.
85
CHAPTER 5
Synthesis of Gold, Titania,

and Zinc Oxide
INTRODUCTION
The small size of nanoparticles (NP) makes them desirable for many biological and biomedical
applications. Their size allows them to escape the reticuloendothelial system (RES) and if
their surface has been modified for conjugation with biomolecules they become a versatile
choice for site-specific drug delivery, imaging, and other diagnostic and therapeutic modalities.
NP synthesis addresses the methods and conditions necessary for achieving desirable size and
chemistry. In this chapter we discuss several routes and techniques for the synthesis of NPs of
gold, titania and zinc oxide, owing to their prevalent use in the health care industry.
5.1 SYNTHESIS OF GOLD

5.1.1 Background
Gold nanoparticles have found extensive biological and biomedical applications and their syn-
thesis is of great interest to the bionanotechnologists. Nanoparticles of gold when functionalized
with suitable biomolecules become equipped for targeted applications.
Among the many available synthetic routes [1–9], the most widely used for the synthesis of
gold NPs is the Brust method [2], which yields colloidal gold particles of very small dimensions
ranging from 1 to 3 nm. The reproducibility of this method makes it the ideal recipe for
gold NP synthesis. Thiol functionalization of the gold particle surface enables attachment of
biomolecules.

by Biphasic Reduction
This synthesis method involves the growing of nanogold clusters along with simultaneous
coating of thiol monolayer around the metallic growths. The governing equation of the Brust
method is given in (5.1) and (5.2) respectively. The phase transfer of AuCl4− from aqueous to
organic phase is a key step and is facilitated by the phase transfer agent TOAB. The addition of
FIGURE 5.1: Courtesy of Drexel bionanotechnology labs: (A) initial orange color of the aqueous and
organic mixture containing AuCl− 4 before adding the reducing agent and (B) dark brown color of the
solution after the addition of the reducing agent NaBH4
the reducing agent NaBH4 is marked by a significant color change from orange (before adding)
to dark brown (few seconds after the addition) as shown in Fig. 5.1 (A), (B). The reduction
has been carried out in the presence of DDT. This technique yields gold nanoparticles of 1–3
nm size. Fig. 5.2 shows the TEM images of the gold NPs obtained.
AuCl− + + −
4 (aq) + N(C8 H17 )4 (C6 H5 Me) → N(C8 H17 )4 AuCl4 (C6 H5 Me) (5.1)
mAuCl− −
4 (C6 H5 Me) → 4mCl (aq) + nC12 H25 SH(C6 H5 Me)
+ 3me − + (Aum )(C12 H25 SH)n (C6 H5 Me) (5.2)
FIGURE 5.2: TEM images of thiol derivatized gold NPs (A) low magnification and (B) high magni-
fication
SYNTHESIS OF GOLD, TITANIA, AND ZINC OXIDE 87
Alterations were made to the Brust method and to optimize synthesis of specific particle sizes
[1, 8]. Equations (5.3) and (5.4) suggest the possible particle sizes with respect to the chosen
molar concentration of the reactants.
0.11 M DDT (1 ml) + 0.11 M MPA (1 mL) followed by addition of NaBH4. = 5 nm

(5.3)
0.22 M DDT (1 ml) + 0.22 M MPA (1 mL) followed by addition of NaBH4. = 3 nm
(5.4)
This approach involves the use of mercaptopropionic acid (MPA) in combination with
DDT during reduction [8]. One of the key features of the Brust method is that the final product
(Thiol-functionalized gold NPs) is stable for several weeks unlike the usual products which
agglomerate over a period of time and eventually collapse from their colloidal assembly.
In the following sections of the chapter, we present a collection of various nano structures
of different materials of interest to the biotechnology Industries. These nano structures could
be classified on the basis of their size, shape, state, and so on. A general list would include nano
tubes, nano colloids, nano rods, nano “branched” rods, nano wires, nanofilms, nano shells, nano
spheres, etc.
5.1.3 Gold Colloids

The following TEM image in Fig. 5.3 shows colloidal gold nano-particles of sizes 3–8 nm [8].
5.1.4 Gold Nanofilm

Fig. 5.4 shows the 3D AFM image of ultra-thin (1–15 nm) gold films on glass substrates [3].
FIGURE 5.3: TEM images of colloidal gold (a) 3 nm, (b) 5 nm, and (c) 8 nm
FIGURE 5.4: 3D AFM images (150 × 150 nm2 ) of gold thin films (monolayer) (Arrows in the image
indicate coalescence)
5.1.5 Gold Nanorods

The TEM images in Fig. 5.5 correspond to gold nano rods of varying aspect ratios, namely 13
and 18 respectively [5].
5.2 SYNTHESIS OF TITANIA NANOSTRUCTURES

5.2.1 Background
Titanium-di-oxide (TiO2 -titania), the naturally occurring oxide of titanium, not available in
pure form is often synthesized from its ilmenite or leuxocene ores. Among the various forms
of TiO2 the rutile, anatase, brookite, and titanium dioxide (B) are the prevalent materials.
FIGURE 5.5: TEM images of gold nano rods of aspect ratio (A) 18 and (B) 13
Synthesis of titania had always been a subject of interest to the chemical and biochemical
industries because titania possesses versatile properties, extensively harnessed by a wide range of
industries. Substantial literature asserts the ability of titania to be used as an exemplary catalyst
[10–17], finding applications in the decomposition of organic pollutants, in water purification
installations, in the paint and polymer industry, the pharmaceutical, and cosmetics industry
(UV absorber).
Combining the activity of titania to a particle size in the nanorange expands its capabili-
ties and applications. Its catalytic activity is dependent mainly on the particle size [10, 15]. The
smaller the size, the greater is the activity. Earlier researchers mostly focused on the photo-
catalytic applications of TiO2 including water purification and pollutant decomposition. More
recent studies revealed that metal or semiconductor doped titania has superior photocatalytic
activity compared to pure titania [8, 18, 19]. Such results have created renewed interest in de-
veloping more efficient methods of TiO2 synthesis. Synthesis of titania NP can be achieved by
various routes, sol-gel, microemulsion, flame oxidation, and others. These can produce titania
particles from 4.4 nm to 2300 nm (2.3 µm). For our purpose, we will focus on methods yielding
particle sizes from 4 nm to 200 nm.
5.2.2 Solvo-Thermal Synthesis of Titania Nano Crystals

This process involves the synthesis of titania nanoparticles in toluene with an average particle
size of 20 nm using titanium isopropoxide (TIP) as the precursor [20].
The wt% ratio of the precursor (TIP) to the solvent (toluene) determines the ultimate
particle size. The reaction must be carried out in an inert atmosphere (argon).The nano crystals
produced by this method [20] when examined by TEM and XRD revealed an average crystal
size of 20 nm. Fig. 5.6 shows the TEM images of titania nanocrystals formed from TIP/toluene
solution of various ratios (SPECIFICS). Increase in the amount of the precursor (TIP) used
[20] results in corresponding increase in the nano-crystal size. The synthesis details of this
method could be referred in Appendix 5.2.2.
5.2.3 Sol-Gel Template Synthesis of Titania Nano Tubes and Rods

A template synthesis method usually comprises of a template into which the desired nanopar-
ticles are formed and grown. Titania nanoparticles produced by the sol-gel method are formed
into an alumina template. Several synthesis techniques existed already for the template synthesis
of titania [21–24]. This method emerged as the preferred method to produce titania nanopar-
ticles of uniform and controlled particle size yielding nano tubes of various desired thickness
and diameters [25].
FIGURE 5.6: TEM images of titania nano-crystals formed from TIP/toluene ratio of (a) 5:100, (b)
10:100, (c) 20:100, (d) 30:100, and (e) 40:100 respectively
Table 5.1 shows the particle diameter as a function of the alumina wall thickness, the
ratio of reactants and the dipping time. The details of the synthesis are given in Appendix 5.2.3.
The TEM images in Figs. 5.7, 5.8, and 5.9 show the wall thickness, diameter, and size of the
nano tubes synthesized from various molar concentrations [25].
TABLE 5.1: Relationship Between the Molar Ratios of the Precursor to Other Reactants and
the Wall Thickness and Diameter in the Synthesis of the Titania Nano Tubes/Rods.
MOLAR RATIO OF DIPPING TUBE

TI:ACAC: TIME WALL DIAMETER
H2 O:ETOH (MIN) THICKNESS (NM)
1. 1 : 2 : 3 : 20 10 50 nm 200
2. 1 : 1 : 3 : 20 10 15–20 10
3. 1 : 1 : 3 : 40 10 – 200–250
In summary, the wall thickness decreases in direct proportions to the concentration of

ACAC used. However, the nano tube’s dimensions could also be controlled by varying the
dipping time [22–24].
5.2.4 Overview of Other Synthesis Methods

A) Sol-gel Synthesis by Ultrasound-irradiation of TiO2
This technique involves the synthesis of nanosized TiO2 particles via ultrasonic irradiation
[15]. This process is a combination of sol gel synthesis + hydrolysis of titanium isopropoxide
and ultrasonication, done by adding to pure water, titanium isopropoxide (TIP). The synthesis
details are given in Appendix 5.2.4 A. Using this method, particles’ size varying from 5.1 to
21.6 nm with increasing size with increased temperature of calcinations is obtained. TiO2 of
size 14 nm is obtained for the ultrasound irradiated process, while the nonirradiated process
yielded particle size of 22 nm [15].
FIGURE 5.7: TEM nano-tubes of 200 nm diameter and 50 nm wall thickness

FIGURE 5.8: TEM nano-tubes of 15–20 nm wall thickness
B) Microemulsion-based Synthesis of TiO2

This method involves the hydrolysis of titanium tetraisopropoxide (TTIP) in W/O microemul-
sions comprising of water, tween series surfactants of various hydrophobic groups, and cyclohex-
ane. Involving centrifugation at higher rpms, this method yields microemulsion which is dried
and later calcined at higher temperatures. This process produces titania nanoparticles varying
from 9 through 17 nm [14]. The synthesis details could be referred in Appendix 5.2.4B.
C) Metal/Semiconductor Doped Synthesis of TiO2

Titania when synthesized by doping with a metal (one or more metals) or a semiconductor
resulted in better catalytic activity [8, 19]. The source of excitations is usually visible light or
UV rays. Various combinations resulting in different sizes collectively indicated the enhanced
catalytic activity to doping of titania. Notable among the doped families are, Ru–Co–Ti, Ti–
Au–Co, TiO2 –SiO2 ,TiO2 –Ag, and Ti-tungsten doping [8, 11, 18, 19]. Particle size as small
as 1.38 nm could be produced by doped synthesis methods [18].
FIGURE 5.9: TEM nano-rods of 200–250 nm diameter

Other notable methods include low temperature synthesis [17], dendrimer protected
method [26], etc. Further, the knowledge of optimum conditions designed for the synthesis of
titania nanoparticles throw light upon the much needed synthesis expertise [27].
5.3 SYNTHESIS OF ZINC OXIDE

5.3.1 Background
Zinc oxide (ZnO), commonly known as zinc white or calamine, is naturally found as zincite
mineral. It is white in color and cubical in structure. Zinc oxide is also associated with its
wurtzite structure as shown in Appendix 5.3.2. Ever since the early times of the modern age
of science, around early 1960s, ZnO has been a material of industrial significance [28]. For
instance, its white color is used in paint industries as a base and it is more transparent than
titania—its prevalent counterpart. ZnO processes excellent physical and structural properties;
the most notable of them is its pyroelectric and piezoelectric property [28]. Pyroelectric refers
to the property of a material to generate electric potential when heated or cooled, while
piezoelectricity refers to the property of a material (crystal) to generate voltage when subjected
to mechanical stress. The piezoelectric property of ZnO is attributed to its noncentral crystal
symmetry. More details of the crystallography of ZnO and its typical growth structures could
be referred elsewhere [28].
Yet another interesting fact about ZnO is its semiconductor properties, it has a band gap
of 3.37 eV finding applications in optoelectronics. Further, ZnO is known to have contributed
to field of sensors, transducers, and catalysts [28]. The increasing know-how of synthesizing
ZnO nano-structures and its overwhelming properties show a promising a pathway to achieve
breakthrough in optoelectronics, photonics, sensors, transducers, biomedical sciences, etc. The
fact that ZnO nano belts have evolved into nano-sensors, nano-cantilevers and field effect
transistors (FETs), and nano-resonators adds eminence to its prospective [28].
This section of the Chapter deals with the synthesis aspects of ZnO and the associated
parameters of chief interest in the synthesis, emphasizing on one particular method, namely the
sublimation (solid-vapor) technique. It involves a high-temperature heating of zinc precursor
which facilitates a solid to vapor transfer [28]. Later the vapor is cooled down to be grown
into desired pattern and sizes. Using the solid-vapor method a variety of nanostructures such
as nano tubes, nano rods, nano combs, nano rings, nano belts, nano helixes, nano springs, nano
wires, nano saw, and even nano cages are possible [28]. Undoubtedly, ZnO classifies one of the
richest family of nano structures having immense applications [28, 29].
5.3.2 The Solid-Vapor Synthesis of ZnO

As mentioned earlier the synthesis techniques of various nanostructures of ZnO described
in this section would deal with the solid-vapor method. The solid-vapor process involves the
evaporation of a condensed or powdered material (of interest—ZnO) into its vapor phase which
is later allowed to condense under the desired experimental conditions of pressure, temperature,
atmosphere, etc. to form the various nanostructures [28].
The solid-vapor method solicits the use of a horizontal tube furnace, the details of
which are discussed briefly in Appendix 5.3.1. The key point to be noted in this synthesis
technique is that the parameters that dictate the morphology, size, etc. of the product are the
temperature, pressure, the atmosphere, the substrate, time of evaporation, and the flux of gas
[28, 30–32].
a) Nanorods
The nanorods of ZnO are synthesized by following a vapor-liquid-solid (VLS) approach. This
approach involves the use of a nanorod/wire component and a catalyst component, both subjected
to the ideal reaction conditions. All the reactants after undergoing evaporation condense to
form the product during which the nanorods grow. Fig. 5.10 shows an SEM image of ZnO
nanorods synthesized on an alumina substrate with Au as the catalyst [28]. Compared to gold
(Au), tin (Sn) is nevertheless an eligible choice as a catalyst [30]. The use of Sn as a catalyst
produces more uniform nanorods [32]. Fig. 5.11 shows the image of aligned nanorods of ZnO
grown on a ZnO crystal carried out in the presence of Sn [32]. In these techniques, the choice
of the substrate plays a crucial role in the synthesis by governing the consequent morphology
of the nanostructures. The synthesis details of the ZnO nanorods could be found elsewhere
[28, 30–32].
FIGURE 5.10: SEM images of ZnO nano rods synthesized using Au as a catalyst. (a) Small magnifi-
cation and (b) higher magnification
FIGURE 5.11: SEM image of aligned ZnO nanorods/nanowires epitaxially grown on ZnO substrate
using Sn as a catalyst
b) Nanobelts
Nanobelts of ZnO are synthesized by mere sublimation of ZnO powders in the absence of
a catalyst. The typical structures of the nanobelts range from 50 to 300 nm in width and
10–30 nm in thickness as shown in Fig. 5.12 [33].
FIGURE 5.12: TEM images of the as-synthesized ZnO nanobelts, showing uniform morphology. (a)
Smaller magnification and (b) higher magnification
FIGURE 5.13: TEM image of ultrathin nanobelts of ZnO
Ultrathin nanobelts could be produced by the use of Sn catalyst which is in the form
of a thin film coating of 10 nm on the substrate used. The use of Sn catalyst yields very thin
nanobelts of average diameter 5.5 nm, [34] as shown in Fig. 5.13 [34]. More synthesis details
on nano belts and ultrathin nanobelts could be referred elsewhere [28, 33–35].
c) Hierarchical Nanostructures
The hierarchical nanostructures comprise of a central axial nanowire surrounded by
nanobranches. The hierarchical nanostructures are yet other possible exotic morphologies of the
ZnO clan as shown in Fig. 5.14 [36]. The synthesis technique of the hierarchical nanostructures
employs the use of Sn catalyst which initiates and leads the growth of the ZnO wires [28, 36].
The entire growth process could broadly be viewed in two stages: the growth of the central
axis and that of the surrounding branches. The surrounding nanobranches on the central axis
are symmetrical in six directions with a mutual angular displacement of 60˚ thus giving a more
uniform and aesthetic look. The details of the synthesis involved in producing the hierarchical
nanostructures could be referred elsewhere [9, 37, 38].
d) Nanocombs and Nanosaws

The growth of nanocombs/sawlike structure as depicted in Fig. 5.15 [36] involves the synthesis
procedure as described elsewhere [36, 39]. The synthesis could however be self-catalyzed growth
in the absence of catalyst [36]. These immaculate structures are not only limited to ZnO but
FIGURE 5.14: SEM images of the hierarchical ZnO nanowire junction arrays, (a) smaller magnification
and (b) higher magnification
also have been revealed for ZnS [40] and CdSe. Further details on nanocomb synthesis could
be referred elsewhere [36, 39–41].
e) Nanorings, Nanospirals, and Nanosprings

It has been demonstrated that In/Li doped ZnO yield polar surfaces in the resulting product
[42]. A polar surface [43] dominated nanobelt could be picturized as a capacitor with two
parallely charged plates as shown in Fig. 5.16(a) [44]. By the laws of nature, the nanobelt would
FIGURE 5.15: SEM image of ZnO nanocombs
try to attain a low energy state and hence it could take shape into a ring or a spiral or a spring
as shown in Figs. 5.16(b), 5.16(c), and 5.16(d) [44]. Further synthesis details could be referred
elsewhere [42, 44, 45]. The thickness of the nanobelts obtained by the doping technique ranges
from 5 to 20 nm with an aspect ratio of 1:4; they are extremely tough and flexible [28].
FIGURE 5.16: (a) The model of a polar nanobelt. (b), (c), and (d) are various shapes induced by the
polar surface of the ZnO
FIGURE 5.16(b): TEM image of a Zno nanoring
f) Nanocantilevers
Cantilevers of small sizes play a crucial role in modern day imaging, especially in scanning
probe microscopy (SPM). A classical example would be the AFM. Traditionally the SPMs
use Si, Si3N4, or SiC cantilevers of typical size of 100 nm in thickness, 5 um in width, and
50 um in length [28]. A smaller cantilever would allow more precision and details in probing.
The potential applications of using carbon nanotubes grown on cantilever tips have already
been proven and have been accepted to provide more details in surface morphology of the
scanned samples [46]. The possibility of using ZnO nanobelts as AFM cantilevers has also
been demonstrated [47]. Given the above situation, it is time of the nano realm to take over
SPM and revolutionarize it. The marriage of MEMS/NEMS (micro/nanoelectromechanical
systems) and the nano cantilevers would undoubtedly open newer avenues in the development
of devices for force, pressure, mass, thermal, biological, and chemical sensors. The smaller the
FIGURE 5.16(c): TEM image of a ZnO nanospiral

FIGURE 5.16(d): TEM image of a ZnO nanohelix
size the better is the sensitivity of cantilevers. The synthesis details of nanocantilevers could be
referred elsewhere [47].
The ZnO cantilevers shown in Fig. 5.17 correspond to various lengths; these cantilevers
have been aligned onto a silicon chip [47]. These cantilevers would eventually find applications
FIGURE 5.17: (a) Nanobelts as ultrasmall nanocantilever arrays aligned on a silicon chip. (b) An
enlarged SEM image recorded from the nanobelt cantilever
in SPM, which could be, but not limited to the contact, noncontact, and tapping modes of
AFM.
g) Piezoelectric-Nanoactuators and Nanosensors

The AFM measurement of piezoelectric coefficient of ZnO nanobelts reveals that the coeffi-
cient d33 of ZnO varies from 14.3 to 27.7 pm/V [48]. This high value suggests the possibility
of applications of ZnO nanobelts as nanoactuators and nanosensors. Another interesting ap-
plication is the development of a ZnO nanorods/wires based hydrogen and ethanol sensor
[49].
APPENDIX 5: SYNTHETIC ROUTES FOR NANOPARTICLES

5.1
5.1.1 Brust Method of Synthesis of Thiol Derivatized Gold NPs by Biphasic
Reduction
The method of synthesizing thiol derivatized gold NP of 1–3 nm size involving bi-phasic
reduction (involving an aqueous to organic phase transfer of gold particles). The following is
the list of materials and method of synthesis –
Materials.
1. HAuCl4 —hydrogen tetrachloroaurate trihydrate

2. DDT—dodecanethiol
3. TOAB—tetraoctylammonium bromide
4. NaBH4 —sodium borohydride
5. Toluene
6. Ethanol
Method. This technique involves the fabrication of thiol-coated gold NPs. An aqueous solution
of 25 ml, 30 mmol/L of HAuCl4 is mixed with a solution of 80 ml, 50 mmol/L TOAB in
toluene. The mixing is followed by vigorous stirring until there is a phase transfer of AuCl4 d
from the aqueous phase to the organic phase. Then 170 mg of DDT is added to the organic
phase (containing the AuCl4 −). Now, freshly prepared aqueous solution of 25 ml, 0.4 mol/L
of NaBH4 is added in minute quantities amidst vigorous stirring (usually delivered through a
syringe pump-needle set up). The stirring is continued for over 3 h and then the organic phase
containing gold is separated from the aqueous phase [2].
Then, in a rotary evaporator the organic-gold solution is evaporated to 10 ml and mixed
with 400 ml of ethanol in order to remove the excess thiol on the surfaces. The resulting solution
is subjected to –18◦ C for 4 h, in dark, yielding a brown precipitate. This precipitate is filtered
and later washed with ethanol. The resulting product is dissolved in 10 ml of toluene and
precipitated with 400 ml of ethanol. This method provides a simple route of synthesis of gold
NPs with thiol functionalization. The TEM images, as shown in Fig. 5.2, reveal the particle
size and other interesting features of the thiol functionalized gold NPs. The particle size had
maximum distribution between 2 and 2.5 nm and were found between 1 and 3 nm. Also, the
synthesized particles were mostly individually and very few were found twinned, unlike other
synthesis methods. As a result, this method is much in favor for an ideal choice of gold NP
fabrication [2].
5.2
5.2.1 Solvo-Thermal Synthesis of Titania Nano Crystals
This process involves the synthesis of titania nanoparticles in toluene with an average particle
size of 20 nm using titanium isopropoxide (TIP) as the precursor [20]. The wt% ratio of the
precursor (TIP) to the solvent (toluene) determines the ultimate particle size. The reaction
must be carried out in an inert atmosphere (argon).
Reactants:
1. Titanium isopropoxide (Ti(OCH(CH3 )2 )4 97%- TIP (Aldrich)

2. Anhydrous toluene 99.8% (Aldrich)
Method. TIP and toluene are mixed in the proportions of 5:100, 10:100, 20:100, 30:100, and
40:100, respectively in the presence of argon atmosphere in a glove box. The corresponding
wt% of TIP in the organic solution, in the above-mentioned concentrations, are 5%, 9%, 17%,
23%, and 29% respectively. Each of the solutions is mixed vigorously for 3 h by a magnetic
stirrer. After stirring, the solutions are transferred into an autoclave (stainless steel autoclave
with Teflon lining—capacity of 130 mL and 80% filling) and heated at 250◦ C at the rate of
4◦ C/min for 3 h (without stirring). Later the system is cooled down to room temperature.
Earlier, the thermal treatment causes the decomposition of TIP into the organic solution and
later upon cooling crystallization occurs, producing nano crystals of titania. After cooling the
precipitates are separated using a centrifugal separator and dried.
5.2.2 Sol-Gel Template Synthesis of Titania Nano Tubes and Rods

A template synthesis method usually comprises of a template into which the desired nanoparti-
cles are formed and grown. Gold nanoparticles produced by the sol-gel method are formed into
an alumina template. Several synthesis techniques existed already for the template synthesis
of titania [21–24]. However, most of these earlier methods were inappropriate for industrial
production and lacked reliability owing to very short dipping times and also there were issues
related to hydration of TIP rendering it milky white and undesired [22–24]. Moreover, these
techniques did not study the details and the role of molar concentration in determining the
particles size and shape [22–24]. The method described here is more reliable and controllable
while having studied the role of molar concentration on particle synthesis in detail [25].
The sol-gel template synthesis technique involves the use of commercially available
“Whatman Anopore filters from Fisher” as templates to synthesize the nano fibril/tubes in
[25]. These anodisks usually have uniform pore size (pore diameters). TIP FULL NAME is
used as the precursor to make titania nano tubes/rods. First, TIP is dissolved in ethanol to
produce a TI solution. Then, in a separate beaker, a solution of ethanol (EtOH), water, and
acetylacetone (ACAC) is prepared by mixing them using a magnetic stirrer. After thorough
mixing, the EtOH/ACAC/water solution is added in small quantities (usually by syringe pump
set-up) to the TI solution to form titania sol. The molar ratios of various reactants are chosen as
given in Table 5.1. The molar ratio of TI: ACAC: H2 O: EtOH determines the wall thickness,
the diameter, and the length of the nano tubes/fibrils and hence it is crucial. The anodic
alumina disks are dipped in the sol for about 10 min and then dried in room temperature
for 24 h.
This experiment deploys the use of 200–250 nm diameter anodisks (Whatman anodiscs—
Fisher). After drying, the anodisks are heated to 400◦ C for 24 h. After cooling the disks, the
surface films are removed by gentle polishing with sand paper. The disks are now immersed
in the NaOH solution of 20 wt%; this dissolves the alumina disk and exposes the titania nano
tubes/rods. The nano tubes and fibrils could then be filtered out and secured for characterization
[25]. Table 5.1 shows the particle diameter as a function of the alumina wall thickness, the
ratio of reactants, and the corresponding dipping time.
5.2.3 Overview of Other Synthesis Methods

5.2.3 A) Sol-gel synthesis by ultrasound-irradiation of TiO2
This technique involves the synthesis of nanosized TiO2 particles via ultrasonic irradiation
[15]. This process is a combination of sol gel synthesis + hydrolysis of titanium isopropoxide
and ultrasonication, done by adding to pure water, titanium isopropoxide (TIP) in drops and
stirring vigorously. Later, the solution is centrifuged for 6 h at 3500 rpm. Then ultrasonic
irradiation, in an ultrasonic clean bath (Branson, USA, 115 V, 2 kW, 38 kHz) is carried for 1
h. The sample is washed in distilled water and centrifuged for 10 min at 10 000 rpm
and dried at 100◦ C for 24 h. After drying, the sample is calcined at 300–700◦ C for 3 h. Particle
size varying from 5.1 to 21.6 nm with increasing size with increased temperature of calcinations
is obtained. TiO2 of 14 nm size is obtained for the ultrasound irradiated process, while the
nonirradiated process yielded a particle size of 22 nm [15].
5.2.3 B) Microemulsion-based synthesis of TiO2
A method of synthesis of titania NP via the micro-emulsion technique, the following has the
materials required and the method in detail.
Reactants. A polyoxyethylene (20) sorbitan monolaurate, monopalmitate, monostearate, and

trioleate (Tween 20, 60, and 85, respectively) with a different hydrophobic group and Brij 52
(polyoxyethylene glycol hexadecyl ether polyoxyethylene- 2-cetyl ether), Brij 56 (polyoxyethy-
lene glycol hexadecyl ether polyoxyethylene-10-cetyl ether), Brij 58 (polyoxyethylene glycol
hexadecyl ether polyoxyethylene-20-cetyl ether) with different hydrophilic groups are used in
the synthesis [14].
The purpose (hyrophile-lipohphile balance) of choosing these hydrophilic/
hydrophobic groups could be found elsewhere [14].
Method. This method involves the hydrolysis of titanium tetraisopropoxide (TTIP) in W/O
microemulsions comprising of water, tween series surfactants of various hydrophobic groups,
and cyclohexane. A reverse microemulsion solution is prepared by mixing 0.045 mol of surfac-
tants in cyclohexane. To this solution the required amount of distilled water is added. After
mixing, a water-clear appearance of the solution indicates the formation of microemulsion [14].
The hydrolysis of TTIP was carried out at 30˚C in a sealed four-way flask (500 ml). The reac-
tion is initiated by adding the TTIP solution into the reverse microemulsion amidst constant
stirring for about 1 h. The titania particles precipitated. The resulting sample is then subjected
to centrifugation at 10,000 rpm for 2 min. The precipitate is then washed with ethanol in a
Soxhelt extractor for about 24 h to remove any organic/surfactants on the particles. The secured
particles are then dried at 105◦ C for 12 h and later calcined for 3 h at 200–800◦ C. This process
yields titania nanoparticles varying from 9 through 17 nm [14].
5.3
5.3.1 The Solid-Vapor Synthesis of ZnO: Horizontal Tube Furnace
The solid-vapor evaporation process involves the evaporation of a condensed or powdered
material (of interest—ZnO) into its vapor phase which is later allowed to condense under
desired conditions of pressure, temperature, atmosphere, etc. to form the predefined structures
of the product. Generally this synthesis technique involves the use of a furnace as shown in
Fig. A5.3.1, in which the aforementioned process is carried out [28]. The horizontal tube
furnace comprises of a horizontal furnace, an alumina tube, a rotary pump, and a gas supply
system. A view window is provisioned at the left end of the alumina tube to facilitate the
monitoring of the synthesis process from the outside. The right-side end of the alumina tube is
FIGURE A5.3.1: Construction of a horizontal tube furnace used for the synthesis of ZnO nanostruc-
tures by the solid-vapor method
connected to the rotary pump. Further details of the synthesis technique and the operational of
the furnace could be referred elsewhere. The key point to be noted is that the parameters that
dictate the fate (morphology, size, etc.) of the product are the temperature, the pressure, the
atmosphere, the substrate, time of evaporation, and the flux of gas [28].
5.3.2 Wurtzite Structure of ZnO
FIGURE A5.3.2: The wurtzite structure model of ZnO. The tetrahedral coordination of Zn–O is
shown
REFERENCES
[1] M. Brust, et al., “Synthesis and reactions of functionalized gold nanoparticles,” J.
Chem. Soc., Chem. Commun., (16), pp. 1655–1656, 1995, DOI: 10.1039/C39950001655.
doi:10.1039/C39950001655
[2] M. Brust, et al., “Synthesis of thiol-derivatized gold nanoparticles in a two-phase liquid-
liquid system,” J. Chem. Soc., Chem. Commun., (7), pp. 801–2, 1994.
[3] I. Doron-Mor, et al., “Ultrathin gold island films on silanized glass,” Morphology and
optical properties. Chem. Mater., 16(18), pp. 3476–3483, 2004.
[4] K. C. Grabar, et al., “Nanoscale characterization of gold colloid monolayers: a comparison
of four techniques,” Anal. Chem., 69(3), pp. 471–477, 1997.
[5] N. R. Jana, L. Gearheart, and C. J. Murphy, “Wet chemical synthesis of high aspect
ratio cylindrical gold nanorods,” J. Phys. Chem. B, 105(19), pp. 4065–4067, 2001.
[6] B. R. Martin, et al., “Orthogonal self-assembly on colloidal gold-platinum nanorods,”
Adv. Mater., 11(12), pp. 1021–1025, 1999.
[7] D. M. Stefanescu, et al., “Synthesis and characterization of phosphido-monolayer-
protected gold nanoclusters,” Langmuir, 20(24), pp. 10379–10381, 2004.
[8] V. Subramanian, E. E. Wolf, and P. V. Kamat, “Catalysis with TiO2/gold nanocom-
posites,” Effect of metal particle size on the Fermi level equilibration. J. Am. Chem. Soc.,
126(15), pp. 4943–4950, 2004.
[9] Y. Tan, et al., “Preparation of gold, platinum, palladium and silver nanoparticles by the
reduction of their salts with a weak reductant-potassium bitartrate,” J. Mater. Chem.,
13(5), pp. 1069–1075, 2003.
[10] C. B. Almquist, and P. Biswas, “Role of synthesis method and particle size of nanostruc-
tured TiO2 on its photoactivity,” J. Catal., 212(2), pp. 145–156, 2002.
[11] Z. Ding, G. Q. Lu, and P. F. Greenfield, “A kinetic study on photocatalytic oxidation
of phenol in water by silica-dispersed titania nanoparticles,” J. Coll. Interface Sci., 232(1),
pp. 1–9, 2000.
[12] S.-S. Hong, et al., “Synthesis of nanosized TiO2/SiO2 particles in the microemulsion
and their photocatalytic activity on the decomposition of p-nitrophenol,” Catal. Today,
87(1–4), pp. 99–105, 2003.
[13] A. A. Ismail, “Synthesis and characterization of Y2O3/Fe2O3/TiO2 nanoparticles by
sol-gel method,” Appl. Catal., B, Environ., 58(1–2), pp. 115–121, 2005.
[14] M. S. Lee, et al., “Synthesis of TiO2 particles by reverse microemulsion method us-
ing nonionic surfactants with different hydrophilic and hydrophobic group and their
photocatalytic activity,” Catal. Today, 101(3–4), pp. 283–290, 2005.
[15] C. W. Oh, et al., “Synthesis of nanosized TiO2 particles via ultrasonic irradiation
and their photocatalytic activity,” Reaction Kinetics Catal. Lett., 85(2), pp. 261–268,
2005.
[16] J. Shim, et al., “Transdermal delivery of mixnoxidil with block copolymer nanoparticles,”
J. Control. Rel., 97(3), pp. 477–84, 2004.
[17] N. Uekawa, et al., “Low temperature synthesis and characterization of porous anatase
TiO2 nanoparticles,” J. Coll. Interface Sci., 250(2), pp. 285–290, 2002.
[18] S. H. Bossmann, et al., “Ru(bpy)32+/TiO2-codoped zeolites: synthesis, characterization,
and the role of TiO2 in electron transfer photocatalysis,” J. Phys. Chem. B, 105(23),
pp. 5374–5382, 2001.
[19] T. Tatsuma, et al., “Energy storage of TiO2-WO3 photocatalysis systems in the gas
phase,” Langmuir, 18(21), pp. 7777–7779, 2002.
[20] C.-S. Kim, et al., “Synthesis of nanocrystalline TiO2 in toluene by a solvothermal route,”
J. Cryst. Growth, 254(3–4), pp. 405–410, 2003.
[21] J. C. Hulteen and C. R. Martin, “A general template-based method for the preparation
of nanomaterials,” J. Mater. Chem., 7(7), pp. 1075–1087, 1997.
[22] B. B. Lakshmi, P. K. Dorhout, and C. R. Martin, “Sol-gel template synthesis of semi-
conductor nanostructures,” Chem. Mater., 9(3), pp. 857–862, 1997.
[23] B. B. Lakshmi and C. R. Martin, “Sol-gel template synthesis of semiconductor
nanostructures,” Proceedings—Electrochemical Society, vol. 97–11(Quantum Confinement:
Nanoscale Materials, Devices, and Systems), pp. 47–55, 1997.
[24] B. B. Lakshmi, C. J. Patrissi, and C.R. Martin, “Sol-gel template synthesis of semicon-
ductor oxide micro- and nanostructures,” Chem. Mater., 9(11), pp. 2544–2550, 1997.
[25] M. Zhang, Y. Bando, and K. Wada, “Sol-gel template preparation of TiO2 nanotubes
and nanorods,” J. Mater. Sci. Lett., 20(2), pp. 167–170, 2001.
[26] Y. Nakanishi and T. Imae, “Synthesis of dendrimer-protected TiO2 nanoparticles and
photodegradation of organic molecules in an aqueous nanoparticle suspension,” J. Coll.
Interface Sci., 285(1), pp. 158–162, 2005. doi:10.1016/j.jcis.2004.11.055
[27] Y. Bessekhouad, D. Robert, and J. V. Weber, “Synthesis of photocatalytic TiO2 nanopar-
ticles: optimization of the preparation conditions,” J. Photochem. Photobiol., A: Chem.,
157(1), pp. 47–53, 2003. doi:10.1016/S1010-6030(03)00077-7
[28] Z. L. Wang, “Zinc oxide nanostructures: growth, properties and applications,” J. Phys.:
Condens. Matter, 16(25), p. R829, 2004.
[29] C. Ye, et al., “Zinc oxide nanostructures: morphology derivation and evolution,” J. Phys.
Chem. B, 109(42), pp. 19758–19765, 2005.
[30] P. X. Gao, Y. Ding, and Z. L. Wang, “Crystallographic orientation-aligned
ZnO nanorods grown by a tin catalyst,” Nano Lett., 3(9), pp. 1315–1320, 2003.
doi:10.1021/nl034548q
[31] J. L. H. Chik, S. G. Cloutier, N. Kouklin, and J. M. Xu, “Periodic array of uniform ZnO
nanorods by second-order self-assembly,” Appl. Phys. Lett., 84(17), pp. 3376–78, 2004.
[32] Z. L. Wang, “Functional oxide nanobelts: materials, properties and potential applica-
tions in nanosystems and biotechnology,” Ann. Rev. Phys. Chem., 55(1), pp. 159–196,
2004. doi:10.1146/annurev.physchem.55.091602.094416
[33] Z. W. Pan, Z. R. Dai, and Z. L. Wang, “Nanobelts of semiconducting oxides,” Science,
291(5510), pp. 1947–1949, 2001. doi:10.1126/science.1058120
[34] X. D. Wang, Y. D., C. J. Summers and Z. L. Wang, “Large-scale synthesis of
six-nanometer-wide ZnO nanobelts,” J. Phys. Chem. B, 108, pp. 8773–8777, 2004.
doi:10.1021/jp048482e
[35] A. S. Barnard, Y. Xiao, and Z. Cai, “Modelling the shape and orientation of ZnO
nanobelts,” Chem. Phys. Lett., 419(4–6), p. 313, 2006. doi:10.1016/j.cplett.2005.12.003
[36] Z. L. Wang, X. Y. Kong, and J. M. Zuo, “Induced growth of asymmetric nanocantilever
arrays on polar surfaces,” Phys. Rev. Lett., 91(18), p. 185502, 2003.
[37] S. Yu, et al., “Precursor induced synthesis of hierarchical nanostructured ZnO,” Nan-
otechnology, 17(14), p. 3607, 2006. doi:10.1088/0957-4484/17/14/041
[38] X. S. Yaohua Zhang1, J. Z. Haihua Liu2, and a. L. Y. Xingguo Li1, 4, “Symmetric and
asymmetric growth of ZnO hierarchical nanostructures: nanocombs and their optical
properties,” Nanotechnology, 17, pp. 1916–21, 2006.
[39] S. Hashimoto and A. Yamaguchi, “Growth morphology and mechanism of
a hollow ZnO polycrystal,” J. Am. Ceram. Soc., 79(4), pp. 1121–1123, 1996.
doi:10.1111/j.1151-2916.1996.tb08559.x
[40] D. Moore, et al., “Wurtzite ZnS nanosaws produced by polar surfaces,” Chem. Phys. Lett.,
385(1–2), p. 8, 2004. doi:10.1016/j.cplett.2003.12.063
[41] P. X. G. Chang Shi Lao, Ru Sen Yang, Yue Zhang, and Y. D. a. Z. L. Wang, “Formation
of double-side teethed nanocombs of ZnO and self-catalysis of Zn-terminated polar
surface,” Chem. Phys. Lett., 417, pp. 359–363, 2005.
[42] X. Y. Kong and Z. L. Wang, “Spontaneous polarization-induced nanohelixes,
nanosprings, and nanorings of piezoelectric nanobelts,” Nano Lett., 3(12), pp. 1625–
1631, 2003. doi:10.1021/nl034463p
[43] H. Soon-Ku, et al. “Control of ZnO film polarity,” Journal of Vacuum Science &
Technology B: Microelectronics and Nanometer Structures. Vol. 20(4), pp. 1656–1663,
2002. doi:10.1116/1.1491544
[44] K. Xiang Yang and W. Zhong Lin, “Polar-surface dominated ZnO nanobelts and the
electrostatic energy induced nanohelixes, nanosprings, and nanospirals,” Appl. Phys. Lett.,
84(6), pp. 975–977, 2004. doi:10.1063/1.1646453
[45] X. Y. Kong, et al., “Single-crystal nanorings formed by epitaxial self-coiling of polar
nanobelts,” Science, 303(5662), pp. 1348–1351, 2004. doi:10.1126/science.1092356
[46] H. Dai, et al., “Nanotubes as nanoprobes in scanning probe microscopy,” Nature,
384(6605), p. 147, 1996. doi:10.1038/384147a0
[47] L. H. William and L. W. Zhong, “Nanobelts as nanocantilevers,” Appl. Phys. Lett.,
82(17), pp. 2886–2888, 2003. doi:10.1063/1.1570497
[48] M. H. Zhao, Z. L. Wang, and S. X. Mao, “Piezoelectric characterization of individual
zinc oxide nanobelt probed by piezoresponse force microscope,” Nano Lett., 4(4), pp. 587–
590, 2004. doi:10.1021/nl035198a
[49] C. S. Rout, et al., “Hydrogen and ethanol sensors based on ZnO nanorods, nanowires and
nanotubes,” Chem. Phys. Lett., 418(4–6), p. 586, 2006. doi:10.1016/j.cplett.2005.11.040
109
CHAPTER 6
Is Bionanotechnology a Panacea?
AN INSIGHT INTO NANO TOXICOLOGY

Introduction. The use of bionanotechnology in Medicine and Health Care depends on design,
synthesis, modification, and detection of “smart” nano-entities that actively or passively con-
tribute to diagnosis and therapy [1, 2]. It is necessary to establish the long-term safety of the use
of nanoparticles in humans, not only during therapy but also during manufacturing or any other
means of unintended exposure [3]. This chapter addresses toxicological aspects of bionanotech-
nology related to the presence of nanosize entities in the human body and the consequences of
their transport and interaction with human tissues and organs. Issues of economic, social, and
ethical concern in bionanotechnology applications are also briefly discussed. This is an area of
intense current activity and focus by the international community [4–8].
6.1 BACKGROUND
The medical and heath care industry harvests the unique properties of nanomaterials by employ-
ing nano-manufacturing techniques and processes to yield nano entities for specific applications.
Bionanotechnology is a new technology that is in the phase of drastic growth and development
[1, 2]. During this early growth phase, issues concerning the possible toxic long-term impact
of nanoparticles (NPs) during use, manufacture, disposal, and environmental exposure have
not yet been fully explored [9, 10]. The following section discusses health, environmental, and
safety aspects of nanotechnology applications in biology and medicine and charts the necessary
steps to address and answer some of these questions.
6.2 PRIMARY CONCERNS

The key features of nanoparticles are their small size, their higher surface area, the special optical
properties based on semiconducting materials, and possibly the specialty-coating surface coating
[1, 11, 12]. These same features, however, enhance their activity when they enter the human
body, and raise questions regarding systemic effects and long-term toxicity [11, 13]. A recurring
theme is the ability of nanoparticles to cross cell membranes [14] and due to their high surface
reactivity cause human and environmental toxicity [15]? If this tissue and cell permeability is
indeed happening, are there limits of safe exposure? Do the particles clear the body after a
certain time without adverse effects, or is there a long-term exposure issue? How can we define
the limits of safe use of nanoparticles? The same issues faced by bionanotechnology today have
already been faced by today’s mature materials such as plastics [16]. Plastics, once known to be
the materials of the future, have undergone increased scrutiny and their use and manufacture
evolved in ways to minimize environmental impact. No one can underestimate the impact of
NPs as they can easily be transported and remain undetected propagating through the food
chain and infiltrating into organisms at any level or hierarchy.
The very size of nanoparticles, lying in the nm range, is less than or equal to cellular
system components and associated sub-units like proteins [17]. It seems therefore plausible
that NPs could intrude and defeat host defenses [14, 17, 18]. The fact that NPs could even
cross the blood brain barrier [19–22], as mentioned in Chapter 2 of drug delivery, introduces
the need for long-term studies of possible long-term health effects.
6.3 ASSESSING POTENTIAL RISKS

Government and research agencies have implemented laws and regulations on the use of
airborn particles or other known harmful materials that could cause potential threat to human
health, upon exposure in manufacturing, synthesis, and disposal, when the toxic effects are
demonstrated and quantified with specific exposure levels. Similar studies will have to be
conducted with nanoparticles to assess their risk and limits of safe usage [9].
In order to assess the impact of nanoparticles on human health and the environment we
would need to:
r Identify potential threats and hazard.
r Determine the probability of exposure to the hazard.
r Perform life cycle analysis of the NPs.
r Control the nano-materials released in air water or through the food chain.
r Establish limits of safe usage.
r Devise methods and implement practices to control possible hazards.
Possible adverse effects of nanoparticle exposure can occur if there is systemic exposure
and nanoparticles can enter the human body via inhalation, ingestion, transdermal penetration,
or intended delivery in the blood stream. The following conditions must be met therefore:
r The NP comes in contact with the body
r The minimum dose to evoke body reactions is delivered into the body
r The particles reach its target
IS BIONANOTECHNOLOGY A PANACEA? 111
FIGURE 6.1: Sources, pathway, and routes of invasion of NPs into the human body
The above conditions could be facilitated through the following pathways –
r By direct inhalation
r By ingestion of the NP by the human being
r Contact—via skin
r Via medication—drugs, medicines, injections, and other routes
r Infected members of food chain—bacteria (lower level members)
It is quite evident from the disputes and discussions that nanotechnology needs a lot of
further research on areas of toxicology studies, exposure studies, health hazard impacts, risk
evaluation, and management to find an optimal solution that will serve human health taking
advantage of the breakthrough potential of bionanotechnology [10, 23, 24].
Fig. 6.1 shows the various sources, pathways, and modes (routes) through which NPs of
a particular material may reach the human body [4, 25]. There are several sources of delivering
nanoparticles to the environment and then NPs may intrude into the integral units of the
ecosystem.
6.3.1 Inhalation
Inhalation of NPs of various materials leads to pulmonary diseases [17, 26–35]. NPs have a
high probability to reach the lungs due to their small size [23, 36]. They easily escape the body’s
immune response (macrophages) as they may be too small to evoke a foreign body response.
At the same time the risk associated with entering and interfering with the cellular machinery
is high. Currently, commercial scale production of NPs includes zinc oxide, titania, iron oxide,
gold nanoparticles, quantum dots, and carbon nano tubes, and the list is expanding at a fast rate.
Manufacturing causes direct exposure of NPs to the workers in the environment and there is a
high probability of such particles entering the lungs in larger numbers [37], the case is same with
exposures occurring during research activities [4]. Opportunities to improve synthesis processes
of nanoparticles to a closed loop system minimizing exposure and waste must be given priority.
It is safer to think of handling nano-materials as hazardous/toxic entity and provide
professionals who handle them with adequate protection hygiene, respiratory protection, pro-
tection against skin/contact etc [4]. It is also important to educate the professionals on the
hazardous nature of the NPs and train them to handle accidents, emissions, spills.
Synthetic NP may contain residual catalysts used in their synthesis or in the preparation
of surface coatings surrounding them. For instance, CNT synthesis uses iron or other metals
as catalysts and as a result minute traces of iron are maintained within these tubes [38]. The
presence of iron/other metals could be associated with the CNT ability to produce free radicals
and provoke pro-inflammatory responses [38]. A dosage of 60–240 µg of single wall CNTs is
considered to be a high dose for epithelial exposure. Manufacturing plants of CNTs must be
strictly viewed as hazardous environment and implement safety measures. CNT, especially the
single wall carbon nano tubes (SWCNT) are known to be quite harmful to humans [39].
6.3.2 Contact/Dermal Delivery

The dermal route is another pathway though which NPs may enter the human body, either
from accidental exposure during manufacturing or from unintended use of a skin formulation
(cosmetic or pharmaceutical) that contains “inert” nanoparticles. Popular NPs used in dermal
formulations include titania and zinc oxide sun locks, iron oxide based lipsticks, face creams [4].
While titania is a scientifically proven safer material [40, 41], it does not cross the epidermis
too and is quite safe to be used in any size with/without surface coatings [4, 40]. However, the
case is not the same with zinc oxide nanoparticles. The recent concerns raised on the European
counterpart of FDA, the Scientific Committee on Cosmetic and Non-Food Products (SCC-
NFP), on inadequate disclosure of toxic studies of nanoparticle contained dermal formulations
[42] must serve as an example of pro-active studies that need to be undertaken [43]. FDA had
earlier approved zinc oxide to be used as a sun screen without size restrictions [44]; however
it is notable that ZnO NPs of size lesser than 200 nm (micro-fine) exhibit photo-toxic effects
on mammalian cells in vitro [43] and is a matter of raising concern [4]. Further studies are
required to ascertain the in vivo characteristics of nano-size zinc oxide.
6.3.3 Other Routes of Contact

Nanoparticles may simultaneously enter the body through multiple routes of entry and one
wonders if this creates increased risks of exposure of NPs to the body. The shape, size, surface
charge, and deformability of the particle will play a key role on its interaction with the body and
determine exposure risks [12]. To answer the above questions, significant research needs to be
done in these areas with close involvement of scientists, nanotech experts, and toxicologists to
examine every possible situation of threat.
6.3.4 Environmental Impacts of NPs and the Food Chain

Let us consider a food-chain as shown in Fig. 6.2, which shows man at the top of the food-chain
hierarchy. The food chain represented here has many integral members such as the aquatic life,
air, soil, etc. (not shown) in which the living beings of various levels thrive. There is great
possibility of NPs polluting the food-chain and the ecosystem as well.
A pilot study suggests the possible harmful impacts of C60 on the brains of the fish to
which they were exposed [45]. The study-results indicate higher oxidation of fats in the brain
FIGURE 6.2: Schematic of a food-chain with man at the topmost hierarchy

of the fish, though the results were at lower concentration, while it happens that the study
indicates a possible long-term harmful effects of NPs on aquatic life [45, 46]. Further, there are
several thousand microbial organisms, sea weeds, plants, and other aquatic members which are
a part of the food-chain; thus pollution of the environment takes less time to affect humans.
Nanoparticles may pollute the environment through their persistence, bioaccumulation,
and toxicity. This is why “inert” nanoparticles although non-toxic could cause environmental
damage due to their persistence or bioaccumulation potential.
Apart from the toxic studies carried out in humans and animals care must be taken to
other aspects of NPs pollution. For instance, the physical and chemical properties of NPs
subjected to various environmental conditions, their ability to react with the environment, their
stability, their active life-time, their abilities to agglomerate [6], etc.
Soil and water pollution by NPs is a significant potential threat to the environment and
human health, because it will affect vegetables, fruits, plants, etc. Fertilizers meant to nourish
the soil, which contain NPs, may also cause adverse effects. For instance, the ground water
pollution by iron nanoparticles is worth notable [47]. Thus, soil studies and materials employed
as fertilizers and in remediation need to be studied for interactions with the environment as
well as for long-term toxic effects. The longer we allow nanoparticles to accumulate unnoticed
in the environment, the faster their levels may reach toxic potential [4]. For instance, iron
nanoparticles could travel up to 20 m in the ground water-table, while being active for 4–8
weeks [47], thus posing a potential threat to invade the members of a food chain at any given
hierarchy.
6.3.5 Explosion Hazards

Dust explosions caused by adequate nano-powder discharges in air are a potential threat that
also needs to be addressed. Manufacturing plants of nano-powders, nano-tubes, nano-materials,
plastics, metallic powders, organic chemicals, sawdust, etc. are potential places where dust ex-
plosion may occur [48]. The data available for macro-scale particles and their dust explosion risk
cannot be simply extrapolated to nano-size particles. Further, the severity of an explosion and
its relation to particle size is speculative and needs to be ascertained with adequate research [48].
However, high heat treatment of nano/particles needs to be avoided or performed in constant
cooling or a liquid medium (colloidal preparations). For example, carbon-black processing is
safer if one avoids rotary driers where high heat is generated [4, 48].
6.4 LESSONS FROM THE PAST

A summary of the path followed to assess adverse effects of other new materials that resemble
nanoparticles could serve as a roadmap to the necessary steps for the safe use of nanoparticles.
Quartz, for example is a mineral of silicon di-oxide, found in abundance on the earth’s surface.
Often mining workers are exposed to high quantities of minute particles of quartz [49]. Lung
fibrosis leading to fatal conditions is a result of high concentration exposure to quartz. It has
become now known through rigorous research efforts that the surface of quartz particles is
highly reactive oxidizing cell membranes and causing inflammation, cell death, fibrosis, and
tumors [50–52]. Asbestos belongs to a family of fibrous metamorphic minerals of the hydrous
magnesium silicate variety. It is naturally available in various structures and is being used for
applications such as heat-resistant sheets, gaskets, brake shoes, etc. In 1918, a US insurance
company brought to light the labor deaths caused in asbestos industries [53, 54]. An article titled
“Mortality from respiratory diseases in dusty (inorganic) trades,” further described the role of
asbestos in premature death of workers [55]. Asbestos fibers less than 3 µm (aspect ratio 3) can
easily reach the lungs. After reaching the lungs, they cause foreign body response and initiate the
recruiting of macrophages, triggering a chain of foreign body processes ending up in scarring or
lung cancer [56, 57]. Other asbestos-related diseases include asbestosis, mesothelioma (cancer),
cancer of the larynx, etc [58]. Air pollution and its impact on human health and the environment
is a classical example that needs to be studied in depth to understand the critical aspects of
small-sized particles and their interactions with living matter. Particulate entities of the air
pollution are said to cause not only inflammations [4, 52], lung diseases [27, 50, 59], but also
cardiovascular diseases [60–63], it even extends to reach the brain as observed in the case of
urban dogs [64]. One of the best known sources contributing to air pollution is combustion,
where burning of a material in the presence of oxygen gives off a lot of heat and gaseous
combustion byproducts. These gases, upon condensation yield nanoparticles ranging from
10 nm to 100 nm [4]. Deaths due to air pollution have been associated with the nanoparticles
present in the pollution streams. The infamous London smog of 1952 killed almost 4000+
people, drawing the attention of the international community.
Extending the knowledge gained from studies of quartz, asbestos, and air pollution to
the nano-entities of value in biomedical applications we can summarize the key variables that
may affect nanoparticle toxicity:
1. The surface activity of a material [12, 16, 46, 57, 65] (native or surface coated [35])
2. The total surface area of the NP exposed to the organ/tissues [4, 23, 46].
3. The dose of the NP delivered [4, 23, 38, 66].
4. The solubility of the NPs [4, 35] (it would be inversely proportional to toxicity and
damage)
5. Length and diameter of the NPs, especially aspect ratio [26, 57].
6. Size (nano vs. micro) and deformability that allows entrance into the body [4, 36, 67]
7. Ability to produce free radicals [38, 45, 46].
6.5 CONCLUSION
Comprehensive data and studies on long-term effects of NPs on humans and the environment
need to be completed in order to create a rational basis for the open-minded acceptance of
bionanotechnology application. If adverse effects are discovered, toxic exposure levels must
be established and plans developed to address overexposure or release scenarios. To address
toxicological aspects as well as ethical issues, scientists from industry and academia on nan-
otechnology, biomedical applications and medicine, business leaders, environmental experts,
and law makers must work in highly inter-disciplinary research teams to study, quantify, and
estimate the NPs safety. The global aspects of nanoparticle burden on the environment must
also be addressed.
REFERENCES
[1] W. C. W. Chan, “Bionanotechnology Progress and Advances,” Biol. Blood Marrow
Transplant., vol. 12, pp. 87–91, 2006. doi:10.1016/j.bbmt.2005.10.004
[2] O. V. Salata, “Application of nanoparticles in biology and medicine,” J. Nanobiotechnol.,
vol. 2, p. 3, 2004. doi:10.1186/1477-3155-2-3
[3] 3i, Nanotechnology—size matters building a successful nanotechnology company,
E.I.U.a.t.I.o. Nanotechnology., 2002.
[4] T. R. S.-B. Govt., The Royal Society Report—‘Nanoscience and nanotechnologies:
opportunities and uncertainties’. Nanosci. Nanotechnol., pp. 1–111, 2004.
[5] R. J. a. A. G. Stephen Wood, Economic and Social Research Council (ESRC): Social
and Economic Challenges of Nanotechnology. 2005 [cited; Available from: http://www.
esrcsocietytoday.ac.uk/ESRCInfoCentre/about/CI/CP/research%5Fpublications/.
[6] J. S. M. Tsuji, D. Howard Andrew, C. James Paul, T. Lam John, Warheit Chiu-
wing, B. Santamaria David, B. Annette, “Research strategies for safety evaluation of
nanomaterials, part IV: risk assessment of nanoparticles,” Toxicol. Sci., vol. 89(1), pp. 42–
50, 2006. doi:10.1093/toxsci/kfi339
[7] C. Phoenix, and E. Drexler, “Safe exponential manufacturing,” Nanotechnology, vol. 15(8),
p. 869, 2004. doi:10.1088/0957-4484/15/8/00
[8] M. C Roco, “The US National Nanotechnology Initiative after 3 years (2001–2003),”
J. Nanopart. Res., vol. 6(1), pp. 1–10, 2004.
doi:10.1023/B:NANO.0000023243.25838.73
[9] A. A. Shvedova, et al., “Unusual inflammatory and fibrogenic pulmonary responses to
single-walled carbon nanotubes in mice,” Am. J. Physiol. Lung Cell Mol. Physiol., vol.
289(5), pp. L698–708, 2005.
[10] M. D. Mehta, From biotechnology to nanotechnology: what can we learn
from earlier technologies? Bull. Sci. Technol. Soc., vol. 24(1), pp. 34–39, 2004.
doi:10.1177/0270467604263119
[11] V. E. Kagan, H. Bayir, and A. A. Shvedova, Nanomedicine and nanotoxicology: two
sides of the same coin. Nanomed.: Nanotechnol., Biol. Med., vol. 1(4), p. 313, 2005.
doi:10.1016/j.nano.2005.10.003
[12] M. Geiser, S. Schurch, and P. Gehr, “Influence of surface chemistry and topography of
particles on their immersion into the lung’s surface-lining layer,” J. Appl. Physiol., vol. 94,
pp. 1793–1801, 2003.
[13] H. M. Kipen, and D. L. Laskin, Smaller is not always better: nanotechnology yields
nanotoxicology. Am. J. Physiol. Lung Cell. Mol. Physiol., vol. 289(5), pp. L696–697, 2005.
[14] L. C. Renwick, K. Donaldson, and A. Clouter, “Impairment of alveolar macrophage
phagocytosis by ultrafine particles,” Toxicol. Appl. Pharmacol., vol. 172(2), p. 119, 2001.
doi:10.1006/taap.2001.9128
[15] R. F. Service, “Nanomaterials show signs of toxicity,” Science, vol. 300, p. 243, 2003.
doi:10.1126/science.300.5617.243a
[16] S. R. BMRB, Nanotechnology: Views of the General Public [Quantitative and qualitative
research carried out as part of the Nanotechnology study], pp. 1–68, 2004.
[17] E. Bermudez, et al., “Pulmonary responses of mice, rats, and hamsters to subchronic
inhalation of ultrafine titanium dioxide particles,” Toxicol. Sci., vol. 77(2), pp. 347–357,
2004. doi:10.1093/toxsci/kfh019
[18] M. C. Lomer, R. P. Thompson, and J. J. Powell, Fine and ultrafine particles of the diet:
influence on the mucosal immune response and association with Crohn’s disease. Proc.
Nutr. Soc., vol. 61, pp. 123–130, 2002.
[19] R. N. Alyaudtin, et al., “Interaction of poly(butylcyanoacrylate) nanoparticles with the
blood-brain barrier in vivo and in vitro,” J Drug Target, vol. 9, pp. 209–221, 2001.
[20] U. Schroeder, et al., “Nanoparticle technology for delivery of drugs across the blood-brain
barrier,” J. Pharm. Sci., vol. 87, pp. 1305–1307, 1998. doi:10.1021/js980084y
[21] J. Kreuter, “Nanoparticulate systems for brain delivery of drugs,” Adv. Drug Deliv. Rev.,
vol. 47, pp. 65–81, 2001. doi:10.1016/S0169-409X(00)00122-8
[22] G. Oberdörster, et al., “Translocation of inhaled ultrafine particles to the brain,” Inhal.
Toxicol., vol. 16, pp. 437–445, 2004. doi:10.1080/08958370490439597
[23] P. Hoet, I. Bruske-Hohlfeld, and O. Salata, “Nanoparticles—known and unknown
health risks,” J. Nanobiotechnol., vol. 2(1), p. 12, 2004. doi:10.1186/1477-3155-2-12
[24] P. S. Anto’n, R. Silberglitt, and S. James, “The Globaltechnology Revolution:
Bio/Nano/Materials Trends and Their Synergies with Information Technology by 2015,”
RAND: National Defense Research Institute, Sanata Monica, CA. pp. 1–87, 2001.
[25] NIRE. Evaluation Technologies for Environmental Effects and Ecotechnology: Im-
pacts on our surroundings. [cited 2006 10/08/2006]; Image]. Available from:
http://www.nire.go.jp/eco tec e/hyouka e.htm.
[26] S. H. Moolgavkar, R. C. Brown, and J. Turim, “Biopersistence, fiber length, and
cancer risk assessment for inhaled fibers,” Inhal Toxicol, vol. 13, pp. 755–772, 2001.
doi:10.1080/089583701316941294
[27] M. Lippmann, Effects of fiber characteristics on lung deposition, retention, and disease.
Environ. Health Perspect., vol. 88, pp. 311–317, 1990. doi:10.2307/3431093
[28] G. Oberdorster, “Pulmonary effects of inhaled ultrafine particles,” Int. Arch. Occup. En-
viron. Health, vol. 74, pp. 1–8, 2001. doi:10.1007/s004200000185
[29] G. Oberdorster, “Toxicokinetics and effects of fibrous and nonfibrous particles,” Inhal.
Toxicol., vol. 14, pp. 29–56, 2002. doi:10.1080/089583701753338622
[30] D. B. Warheit, et al., “Potential pulmonary effects of man-made organic fiber (MMOF)
dusts,” Crit. Rev. Toxicol., vol. 31, pp. 697–736, 2001. doi:10.1080/20014091111965
[31] D. B. Warheit, et al., “Comparative pulmonary toxicity assessment of single wall carbon
nanotubes in rats,” Toxicol. Sci., vol. 77, pp. 117–125, 2003. doi:10.1093/toxsci/kfg228
[32] U. Heinrich, et al., “Pulmonary function changes in rats after chronic and subchronic
inhalation exposure to various particulate matter,” Exp. Pathol., vol. 37, pp. 248–252,
1989.
[33] K. P. Lee, et al., “Inhalation toxicity study on rats exposed to titanium tetrachloride
atmospheric hydrolysis products for two years,” Toxicol. Appl. Pharmacol., vol. 83, pp. 30–
45, 1986. doi:10.1016/0041-008X(86)90320-0
[34] G. Oberdorster, et al., “Extrapulmonary translocation of ultrafine carbon particle fol-
lowing whole-body inhalation exposure of rats,” J. Toxicol. Environ. Health A, vol. 65,
pp. 1531–1543, 2002. doi:10.1080/00984100290071658
[35] P. J. A. Borm, and W. Kreyling, Toxicological hazards of inhaled nanoparticles – po-
tential implications for drug delivery. J. Nanosci. Nanotechnol., vol. 4, pp. 1–11, 2004.
doi:10.1166/jnn.2004.081
[36] G. Oberdorster, J. Ferin, and B. E. Lehnert, “Correlation between particle size, in vivo
particle persistence, and lung injury,” Environ. Health Perspect., vol. 102, pp. 173–179,
1994. doi:10.2307/3432080
[37] G. Oberdorster, Lung particle overload: implications for occupational exposures to par-
ticles. Regul. Toxicol. Pharmacol., 21, pp. 123–135, 1995. doi:10.1006/rtph.1995.1017
[38] A. A. Shvedova, et al., Exposure to carbon nanotube material: assessment of nanotube
cytotoxicity usung human keratinocyte cells. J. Toxicol. Environ. Health Part A, vol.
66(20), pp. 1909–1926, 2003.
[39] D. B. Warheit, et al., “Comparative pulmonary toxicity assessment of single-wall carbon
nanotubes in rats,” Toxicol. Sci., vol. 77(1), pp. 117–125, 2004. doi:10.1093/toxsci/kfg228
[40] SCCNFP, Opinion of the scientific committee on cosmetic products and non-food
products intended for consumers on titanium dioxide (Colipa no S75), pp. 1–38,
2000.
[41] Bennat and G. Muller, “Skin penetration and stabilization of formulations containing
microfine titanium dioxide as physical UV filter,” Int. J. Cosmetic Sci., vol. 22(4), pp. 271–
283, 2000. doi:10.1046/j.1467-2494.2000.00009.x
[42] SCCNFP, The SCCNFPs notes of guidance for the testing of cosmetic ingredients and
their safety evaluation, pp. 1–114, 2000.
[43] SCCNFP, The scientific committee on cosmetic products and non-food products
(sccnfp) intended for consumers opinion concerning zinc oxide (COLIPA no S 76).
pp. 1–31, 2003.
[44] H. Food and Drug Administration, “Rules and regulations: sunscreen drug products for
over-the-counter human use,” Final Monograph, D.O.H.A.H. SERVICES, pp. 27666–
27693, 1999.
[45] E. Oberdörster, “Manufactured nanomaterials (fullerenes, C60) induce oxidative stress
in the brain of juvenile largemouth bass,” Environ. Health Perspect., vol. 12(10), pp. 1058–
1062, 2004.
[46] M. N. Moore, Do nanoparticles present ecotoxicological risks for the health of the aquatic
environment? Environ. Int.; 32(8), pp. 967–76, 2006.
[47] W. -x. Zhang, “Nanoscale iron particles for environmental remediation: an overview,” J.
Nanopart. Res., vol. 5(3–4), pp. 323–332, 2003. doi:10.1023/A:1025520116015
[48] D. K. Pritchard, “Literature review—explosion hazards associated with nanopowders,”
Health and Safety Laboratory, pp. 1–22, 2004.
[49] International Labour, O., Safety in the use of mineral and synthetic fibres; working
document and report of the meeting of experts on safety in the use of mineral and
synthetic fibres, Geneva, 17–25 April 1989. Occup. Safety Health Ser., vol. 64, pp. 1–94,
1990.
[50] A. Seaton, et al., “Pneumoconiosis of shale miners,” Thorax, vol. 36(6), pp. 412–418,
1981.
[51] R. F. Service, “Nanotoxicology: nanotechnology grows up,” Science, vol. 304(5678),
pp. 1732–1734, 2004. doi:10.1126/science.304.5678.1732
[52] V. Vallyathan, “Generation of oxygen radicals by minerals and its correlation to
cytotoxicity,” Environ. Health Perspect., vol. 102(Suppl. 10), pp. 111–115, 1994.
doi:10.2307/3432226
[53] Unknown, Midwest Asbestos Company—Arizona 1915, in Scripophily.
[54] P. Wong, Parliamentry Address—New South Wales (NSW) Legislative Council Hansard:
Asbestos. Parliament of New South Wales. p. 10492 2004.
[55] Hale, Julius, and Kershaw. Discovering Asbestos in Rockbridge County: What is
Asbestos? 2006 [cited; Available from: http://journalism.wlu.edu/indepth/Asbestos/
background.htm.
[56] D. W. Berman, et al., “The sizes, shapes, and mineralogy of asbestos structures that
induce lung tumors or mesothelioma in AF/HAN rats following inhalation,” Risk Anal,
vol. 15, pp. 181–195, 1995. doi:10.1111/j.1539-6924.1995.tb00348.x
[57] J. C. Wagner, et al., “A pathological and mineralogical study of asbestos-related deaths
in the United Kingdom in 1977,” Ann. Occup. Hyg., vol. 26(3), pp. 423–431, 1982.
doi:10.1093/annhyg/26.3.423
[58] Hale, Julius, and Kershaw. Discovering Asbestos in Rockbridge County: Health Haz-
ards. [News Article] 2006 [cited 2006 10/09/2006]; Available from: http://journalism.
wlu.edu/indepth/Asbestos/Health.htm.
[59] A. Seaton, Silicosis. In Occupational Lung Diseases, Eds. e.M.W.K.C.S. A. 3rd edition,
(Philadelphia, USA: WB Saunders), 1995.
[60] R. D. Brook, et al., Air pollution and cardiovascular disease: a statement for
healthcare professionals from the Expert Panel on Population and Prevention Sci-
ence of the American Heart Association. Circulation, vol. 109(21), pp. 2655–2671,
2004.doi:10.1161/01.CIR.0000128587.30041.C8
[61] D. Liao, et al., Daily variation of particulate air pollution and poor cardiac autonomic
control in the elderly. Environ. Health Perspect., vol. 107, pp. 521–525, 1999.
[62] A. Peters, et al., “Increased particulate air pollution and the triggering of myocardial
infarction,” Circulation, vol. 103, pp. 2810–2815, 2001.
[63] A. Peters, et al., “Air pollution and incidence of cardiac arrhythmia,” Epidemiology, vol.
11, pp. 11–17, 2000. doi:10.1097/00001648-200001000-00005
[64] L. Calderón-Garcidueñas, et al., “DNA damage and in nasal and brain tissue of
canines exposed to air pollutants is associated with evidence of chronic brain in-
flammation and neurodegeneration,” Toxicol. Pathol., vol. 31, pp. 524–538, 2003.
doi:10.1080/01926230309789
[65] V. Labhasetwar, et al., “Arterial uptake of biodegradable nanoparticles: effect of surface
modifications,” J. Pharm. Sci., vol. 87, pp. 1229–1234, 1998.
[66] G. Oberdörster, “Significance of particle parameters in the evaluation of exposure – dose
response relationships of inhaled particles,” Inhal. Toxicol., vol. 8, pp. 73–89, 1996.
[67] M. F. Stanton, et al., “Carcinogenicity of fibrous glass: pleural response in the rat in
relation to fiber dimension,” J. Natl. Cancer. Inst., vol. 58, pp. 587–603, 1977.
121
CHAPTER 7
Roadmap to Realization
of Bionanotechnology
7.1 INTRODUCTION
Having so far looked into intricate details of several aspects of bionanotechnology, we now
come to the concluding notes. In this chapter, we present to you a brief summary of the
previous chapters and also the futuristic aspects of bionanotech. However, the core of this
chapter deals with the global race and the roadmap to the realization of translation research
in bionanotechnology. The unprecedented growth and development in bionanotech forecasts
annual expenditure to the tune of $1 Trillion by the year 2015 in the United States-alone, the
same scenario is observed globally too. Thus, it is of supreme importance to capture the global
trend proceeding with bionano research.
7.2 NANO VISION: THE FUTURISTIC GOALS

OF BIONANOTECH
The typical expectation of people from a developing technology is often more than realistic
limits; bionanotechnology is no exception to this. The global expectation from bionanotech
to cater to various needs is increasing day by day. There are several industries, of interest to
us, which find direct application in bionanotechnology and there are others that are associated
with bionanotech that are striving for increased contribution from nanotechnology. A list of
such industries includes:
1. Precision Engineering. This might include a top-down approach or a bottom-up approach.

But the top-down approach uses various nano-lithographic techniques in creating nanodevices
for MEMS [1–3] and NEMS [1, 4, 5]. While the bottom-up approach would use synthetic
means of producing nano-products by building them from their molecules. Example for bottom-
up approach includes synthesis of various nano-particles such as nano-tubes [6–8], nano-rods
[9, 10], nano-clusters [11], other drug-capsules, etc.
2. Optics and Imaging. The depth of application of nanotechnology has greatly influenced
optics. Imaging various cells, tissues, organs, and other biological systems has come through a
great journey to attain high-magnification, more resolution, and information [12–20]. Modern
imaging devices such as electron microscopy, AFM [4, 21], TEM [22–24], NSOM, confocal
microscopy, etc. deal with nano-details of the specimen probed.
3. Medical. The medical field in general works toward improved implant and prosthetics
with better quality, life-extension, performance, and enhanced biocompatibility. The degree of
roughness and smoothness in nano-biomaterials [25–27], nano-scaffolds [28–30] are defined
in nm range to yield better performance.
4. Pharmaceuticals. This is one of the most booming outcome of bionanotechnology. While

it is easily evident that bionanotech has immensely contributed to the development of the
pharmaceutical industries and other biotech firms, it is increasingly expected of bionanotech
to play an even more significant role in these fields to fulfill the present day demands. The
pharmaceutical industry is driven toward nano-vector drug delivery, targeted delivery, avoiding
toxicity, controlled delivery through smart-vehicles, escaping the RES, etc. [31–44].
There is no doubt that the above-mentioned fields have benefitted from ground-breaking
research in bionanotech. However, the present goals set forth by various firms in drug delivery,
imaging, biosensors, precision engineering, optics, nano-electronics, medicine, etc. sometimes
seem too far-fetched from realization. It is widely believed and an accepted fact that many
scientists and industries are mislead by the so-called nano-hype to imagine un-realistic goals
to be feasible [45]. However, it is left to the present trends and the progress to decide on the
realizable goals and set the pathway for the future.
7.3 WORKING TOWARD REALIZATION: CURRENT PROGRESS

We have seen the development in bionanotech in several industries, and this is quite evident
from the material presented in Chapters 1–5. Although there are few setbacks and concerns in
bionano research like the toxic effects [46–49], the current progress made in every industry is
immense. The present development has encouraged more funding opportunities and further
room for development. We now focus onto three industries of utmost importance to the bionano
research:
r Biotechnology
r Drug Delivery
r Bio-Imaging
Biotechnology. Biotech has been revolutionized through bionano research and development.
The industry now talks of nano dimensions in every aspect. For instance, the surface function-
alization [14] at nano-scales is a top-priority bionano aspect, increasingly being exploited by
ROADMAP TO REALIZATION OF BIONANOTECHNOLOGY 123
the biotech companies. The use of anti-body, nucleic acids, other proteins, viruses, polymers,
etc. to functionalize bionano entities deployed in human diagnostic/therapeutic application is
a seemingly developing work in the biotech industries. The use of surface functionalization
techniques enables the design of nano-vectors, unique for chosen applications [14]. Such nano-
vectors are highly site-specific and multi-target capable [50]. The diagnostic and therapeutic
applications which deploy the nano-vectors can be used to treat deadly conditions and diseases
such as tumors [50], cancers [50], inflammations, and even chronic medical conditions such as
diabetes. Drug delivery and bio-imaging form a larger part of the bionano industry; they are
two important branches of the very biotech Industry, at large. The aforementioned applications
hold well for both bio-imaging as well as drug-delivery/pharmaceuticals. Targeted approach to
imaging and drug-delivery is of high interest today. Also, the surface functionalization tech-
niques enable several features in the nano-vectors for drug delivery, like escaping the RES [51],
avoiding overdose and toxicity [44, 52, 53], controlled [54] and site-specific delivery [16, 55],
automatic-identification of tumor sites, crossing the BBB [39], etc. While bio-imaging has
nevertheless seen adequate advancement on par to its pharmaceutical counterpart, bio-imaging
has been elevated to perform imaging enhancement, in techniques such as MRI [55–57], ultra-
sound [58–61], in-vitro cell imaging [15, 17, 20], and also develop the technologies of imaging
as seen in advancement of AFM [4, 21], TEM [22–24], NSOM, and ESEM.
7.4 SCREENSHOT OF REALITY:

BIONANO-UNBIASED/UNCENSORED
As seen in detail earlier in Chapter 6, we realize that nanotechnology or rather bionanotech
has its own limitations in applications and harms the human body, the environment, and the
society as a whole. For instance, the toxicity of several nano-particles such as CNT, titania,
etc. could cause harm to the body, while nano-metallic particles could pollute the water table
and the environment [45]. Having seen the ability of nano-entities of bionanotech to cause
harm, it is the need of the hour to set limitations, policies, and regulations to check any possible
nano-threat in the near and far future. The need to explore and articulate the toxicology aspects
of risk known/unknown nano-entities is reiterated time and again.
Bionanotech needs to be discussed in a public forum, within an industry in small and on
a global platform at large [45]. Such a public-discussion would bring into close quarters the
opinions of various sections of the society. It is important to know the interests of individu-
als/industries of varied background and then promote a public opinion based on later decisions.
This would help promote a steady and trustable progress in bionano research. A forum that
encourages the involvement of participants and non-participants of bionano research will lead
to taking into account all ideas, also this will promote to set apt future targets while receiving
criticism for the current progress and later goals. The need for the larger role of Federal
agencies, public and private industries, environmentalists, law makers, Congress men, Scien-
tists, Physicians, Engineers, and media has been identified. The future of bionano research will
depend upon the perspectives of the above-entioned personnel, which could be quite different
from one another.
Creating public awareness about the present and future of bionano research and invest-
ments will promote healthy participation of the informed-masses. However, to realize such
participation adequate research needs to be done in social, economic, ethical, and toxic aspects
of bionano industries. This would translate into setting up of newer boundaries, framed-policies,
regulations, safety-handling, waste treatment, and safe-disposal of bionano products, for the
future [45]. With the present progress and short—comings in mind, there have been predic-
tions about how nanotechnology, including bionanotechnology will impact the near and far
future, which can be referred elsewhere [62]. In the following section, we present a roadmap
to the realization of translational research in bionanotechnology. Much of the roadmap is
about the developments in the global nano-leaders, their initiatives, and the associated funding
scenario.
7.5 THE NANO MISSION: ROADMAP TO REALIZATION

OF TRANSLATION RESEARCH
Having taken into consideration every aspect of success and failure, advantages and disad-
vantages, gain and harm, the government, private industries, academia, scientists, and other
participants have carefully planned their investments in the form of funds, time, material,
and other resources to be allocated for future bionano research. An overall surveillance of the
scenario indicates an overwhelming support and trust from various levels of participation in
research. In this section, we present the current and future budgets of world leaders in bionan-
otech. An assessment of the global interest in bionano indicates the keen inclination of various
countries to participate and compete in the “nano-race.” Currently, there is a steady progress in
bionano research. Also there is enough planning and preparatory ground-work to participate
in the global competition. The nanomission is to realize the nano-visions and is substantially
backed up with adequate interest, directions, resources, funding, planning knowledge, facts,
and initiative.
THE BIONANO OUTLOOK: A GLOBAL UPDATE

7.5.1 Bionano in the US
The National Nanotechnology Initiative (NNI) formulated and devised in 2001 by the then
American President Bill Clinton [63]. Having attained Federal status and importance the NNI
has grown into newer heights in the Bush’s administration [63]. Year 2003 is to be marked
in history for having made the NNI’s mission into a Public Law: 108–153, referred to as
FIGURE 7.1: NNI budget for NIH–HHS granted for bionanotechnology research
“21st Century Nanotechnology Research and Development Act” [63]. The efforts and mission
of NNI have been well augmented by Federal funding and National efforts in grooming-up
the R&D work. NNI has received global recognition and plays a larger role in determining
the future of bionanotechnology. Bionano could be classified under various sections of the 13
Federal Agencies involved in NNI. The most important of all the agencies is the National
Institute of Health (NIH), head-quartered at Bethesda, Maryland [28]. The NIH funding
received from NNI is shown in Fig. 7.1; it shows a brief history of how the funding has
increased in the past few years [48, 64].
The NNI funding “emphasizes on nanotechnology-based biomedical advances occurring
at the intersection of biology and the physical sciences” [48]. Moreover, the funding for the
department of Health and Human Services (HHS) is mainly utilized for NIH and National
Institute of Occupational Safety and Health (NIOSH). A brief look into the tune of monetary
support allocated to HHS highlights the promising future of bionanotechnology. The following
graph indicates the Federal funding for HHS, of which NIH shares a larger portion. State level
supported academic institutions’ pioneering research in bionanotechnology includes Stanford
University, UPenn, the University of Wisconsin-Madison, Purdue, GATech, Caltech, Drexel
University, and many more.
Other global competitors in bionanotechnology include, but not limited to UK, Japan,
and the EU. In the following section, we present the initiatives of UK, Japan, and the EU in
developing bionanotechnology.
7.5.2 Bio-Nano in Japan
Japan, the second largest economy in the world, is one of the world leaders in nanotechnology
not far behind the United States. Since early years, Japan has been an able global competi-
tor in nanotechnology. The National funding and research in the nano realm is carried out
directly under the guidance of relevant Japanese ministries [65, 66]. The Japanese interest in
bionanotechnology is seen in the form of nanotechnology initiatives in medicine, biotechnology
and nano-materials, to the tune of 23 billion Yen, as early as 2001 [65]. The initiative by the
Japanese government to keep-up the pace in the international bio-nano race is quite evident
from the orchestrated ideology of Japan to partner with Western counterparts [4, 66].
7.5.3 Bio-Nano in UK
The UK has shown immense interest in research in bionanotechnology; it has formed strategic
partnerships with US, Japan, the European Union, etc. to significantly contribute to technolog-
ical advancement. UK enjoys a close tie-up with the United States in developing bionanotech.
The Interdisciplinary Research Collaboration (IRC), set up in 2002, is solely dedicated for
bionano applications [12]. UK has also partnered with Korea and Japan in several bionano
projects [12, 67], some notable ones include—dynamic imaging by high-speed AFM, signal
transduction by solid state NMR, energy conversion by new-generational nano-measurement
systems, bionanotechnology systems (bio-motors and chemo-sensory systems), DNA nano
structures, advanced fluorescence imaging, single-molecule detection, single-molecule AFM,
fighting viruses, novel drug development, etc [12].
The basic idea behind the IRC initiative is “to learn from nature—to understand the
structure and function of biological devices and to utilize Nature’s solutions in advancing science and
engineering in areas as diverse as biosensors, genomics, the discovery of new medicines, diagnostics,
and drug delivery.”
7.5.4 UK–Japan Joint Initiative for Bionanotechnology

The British “Biotechnology and Biological Sciences Research Council” (BBSRC) and the
“Japan Science and Technology Agency” (JST) have jointly begun an initiative in promoting
bionanotechnology [67]. Lucid plans have been laid forth 2003–2008 in promoting bionan-
otechnology as one of its foremost interests [4, 67]. The gigantic development in biotechnology
and sciences has led forth to further development which can be achieved through nano-means
and hence the bionano joint venture blossomed.
7.5.5 The EU Initiative in Bionanotech

In the gearing race for Bionano, the European Union is no exception. The European Union
formed the sixth Framework Program (FP6) alliance for ground-breaking research in Science
FIGURE 7.2: EU budget for bionanotechnology and associated research
& Technological Advancement [68]. Of the seven thematic priorities identified by EU under
the scope of FP6, two are exclusively for biotechnology and nanotechnology which concentrate
on [68]:
r Nano-technologies and nano-sciences

r Life sciences, Genomics and Biotechnology for Health
Bionanotechnology claims a substantial portion of the funds allocated for the FP6 re-
search. Fig. 7.2 shows the funds allocated by EU under the Scope of FP6 (2006) and FP7
(2007–13) respectively, for bionanotech associated research. Presently efforts are on the move
in creating a roadmap for a smooth transition from FP6 to FP7 (way of the future) which would
determine the advancement of science and technology in various applications [69]. The FP7
initiative of the EU corresponds to research during 2007–2013. Of the C = 50+ billions allocated
to FP7, about 20% is directly routed to bionanotechnology and its associated research fields
such as nano-devices and nano-materials [69].
It is quite evident from the information presented in this chapter that bionano un-
doubtedly has a promising future as of the preparatory work, funding and access to resource
are concerned. However, efforts need to be taken to ensure the same trust, harmony and
involvement of various sections/industries/countries of the society/global community is pre-
served and taken-forth into the future. This requires a larger participation from FDA, NIH,
and other federal agencies. It is the duty of the Federal Agencies to guide the research in the
right direction. Smaller goals must be set while in transition from the present to future along the
roads of development in bionanotechnology. In the words of Richard Feynman “What would
happen if we could arrange atoms one by one the way we want them?” Hinting at the bottom-up
approach on self-assembling techniques, Feynman’s world of bionano systems would soon be
realized in the near future. As envisioned by Eric Drexler, self-assembling bionano systems—
building a nano assembler or a nano surveillance system to perform in vivo functions has been
a long-standing dream waiting to become true [70]. The day is not far off to realize the nano-
visions. In the later section of this Chapter, we present you an interesting discussion on the
feasibility and future of “molecular assemblers” by Eric Drexler and Richard Smalley.
7.5.6 Bionano in Asia

Asia accounts to 60% of the world population, in which India and China together claim more
than one-third (33%) of the total human population. The rapidly growing economy in Asia
and its participation in various global competitions cannot be neglected easily. The investment
of China and India in bionanotechnology is a result of the booming biotech industries and
nanotechnology in both countries. Recently India has signed tie-ups with the United States in
nanotechnology research, including bionanotechnology [71]. Here, we present an insight into
India’s development in bionano research initiatives and progress.
India: The country has plunged itself into deep-waters of bionanotechnology. There has been
appreciable development in the past five years in bionano research throughout the nation. India
and its research interests are unique in many aspects. Often the diseases and ailments faced
by the third-world countries (developing nations) are quite different from that of developed
nations, and hence it is of top priority to promote bionano research to address specific issues,
common to developing nations. Some worth-while development in Indian bionano research
includes [71,72]:
Water purification: Using nano-tubes to filter out viruses as small as 25 nm, e.g., polio virus, E.
coli, other pathogens, and bacteria can be filtered out.
Typhoid detection kit: New method to identify S. typhi (typhoid causing) antigen, 30 times more
sensitive than present techniques and requires only 2–3 µl serum sample.
Drug delivery: US patented, reverse micelle based “smart” hydrogels for encapsulating water
soluble drugs, diameter less than 100 nm.
Medical implants: Developing drug delivery systems for stem cell implants for applications in
cardiology, ophthalmology, oncology, endocrinology, etc.
Bionano has greatly impacted India and is being actively pursued not only in Research but
also in Industries and Education [73]. Most of the above-mentioned researches are coordinated
by the Indian “Nano Science and Technology Consortium” (NASTCON). The major bionano
initiatives focus on biotech, biochips, medical, and sensor applications. India is working toward
capturing a $50 billion market in the next 10 years, of which bionano (Health Care) is one of
the top-priority [72].
The bionano fever has had a great impact on several countries in the East Asian region.
Countries such as Singapore, South Korea, Taiwan, Malaysia, etc. are eagerly participating
in developing bionano applications. Singapore, for instance, is committed to pursue bionano
research in a novel way by bringing in international community to participate in its Bionano ini-
tiatives [69,74]. The BioNano International Singapore Pte. Ltd [74] is one such notable initia-
tive from Singapore to promote bionano research. It is a bionanotechnology company dedicated
in developing newer bionano-techniques, focusing on developing bionano sensors, bionano-
probes, bionano-electrodes, bionano-electro-chemical workstations and bionano-instruments
[74].
THE SMALLEY–DREXLER DEBATE: CAN NANOTECHNOLOGY

CHANGE THE FUNDAMENTALS OF CHEMISTRY?
Background
Nobel Laureate Richard Errett Smalley and best selling author Kim Eric Drexler are uncrowned
gurus of the shrinking world of nanotechnology. Their ground breaking research and phenom-
enal contributions earned them well-deserved respect in the scientific society. Dr. Smalley
(June 6, 1943–October 28, 2005) won the Nobel Prize for Chemistry in 1996 for his invention
of C60 or Fullerenes, often referred to as the “Buckyballs”. He was the Gene and Norman
Hackerman Professor of Chemistry at Rice University, and his pioneering research focused on
Carbon Nanotubes [75] and its translation to cancer drug delivery among others. Dr. Drexler
is a creative genius and presently the Chief Technical Advisor of Nanorex Inc., involved in
the development of computational modeling tools specifically for the design and analysis of
productive nanosystems. Dr. Drexler earned one of his PhDs in Molecular Nanotechnology
(MNT) from the MIT Media Labs in 1991, the first of its kind ever. Dr. Drexler is presently
instrumental in the development of nano ENGINEER 1, 3D nanomechanical CAD software
that could be used to design nanosystems [76].
In December 2003, Dr. Drexler and Dr. Smalley argued their points for and against
“molecular assemblers”, respectively. Dr. Smalley openly criticized the concept of molecular
assemblers, envisioned by Dr. Drexler. Their arguments were published by the American
Chemical Society’s (ACS) journal, Chemical and Engineering News (C&EN), under “POINT
and COUNTER-POINT,” as a widely cited cover story [77]. In the following section, we
present the gist of the for and against arguments on the question: “Are molecular assemblers—
devices capable of positioning atoms and molecules for precisely defined reactions in almost
any environment—physically possible” [77].
Drexler’s phenomenal book, Engines of Creation: The Coming Era of Nanotechnology, pub-
lished in 1986, envisions of a world with molecular assembler, performing precision engineering
with almost no pollution. In one of the chapters, “Engines of Destruction,” the author examines
the possibilities of the destructive effects of such molecular assemblers, where he quotes: “Repli-
cating assemblers and thinking machines poses basic threats to people and to life on Earth”
[77]. This pioneer in the field of molecular nanotechnology is convinced about the capabilities
of molecular assemblers and recognizes the potential risk associated with what he believes they
are capable of.
Three books encompass the main ideas of Drexler; Engines of Creation was his first book,
and later he modified his PhD thesis into a book titled Nanosystems: Molecular Machinery,
Manufacturing and Computation in 1992, winning him the Best Computer Science Book of the
year—1992 from the Association of American Publishers. The third book was Unbounding
the Future: the Nanotechnology Revolution. Through his books and journal publications, Drexler
presented his visions of a molecular assemblers (nano-factories) that would create nano-factories
and nano-machines at a very small scale [77]. He argues that his system of molecular assembler
would be like a “robotic arm” controlled by a computer which employs conveyor belts and other
nano-machineries to transport the required molecules to the site of interest, and then by the
process of “Mechanosynthesis,” suitably position the molecules in strategic positions such that
a desired reaction is favored [77].
The Feasibility of Molecular Assemblers

Smalley argues that using a computer-controlled arm or a robotic arm could eventually bring
together reactants and even bias occurrence of a reaction, but it is not necessarily the desired
reaction. Further, Smalley refutes Drexler’s argument of seeking an alternate condition for
a desired reaction to happen on the basis of the absence of a “medium or liquid.” Smalley
claims that if two reactants when brought together do not result in a favored (desired) reaction,
there is a whole array of reasons explained by Chemistry that allow this to occur [77]. As
mentioned before by Drexler, Smalley too maintains the critical need of enzymes or enzyme-
like entities participating in the molecular assembly in a self-replicating nanorobot (nanobot).
Having assumed the presence of enzymes or ribosomes to participate in molecular assembly
of the nanobots, Smalley questions if the nanobots have a cell that produces the required
enzymes. If so, how do the nanobot get the required enzyme to the right position? What
would be the mechanism of error detection and how is correction and replacement of such
enzymes performed? Even further, what is the medium that is going to substitute for water in
the reaction, because aqueous-unstable systems cannot be created via the present method of
molecular assembly? If there is going to be a replacement medium for water in the nanobot
systems, how would dry systems, such as lasers or “ultrafast memory,” behave? Finally, Smalley
questions the feasibility of controlling atoms with precision owing to the fat finger and sticky
finger problem [77].
Fat finger refers to the “imprecision, a molecular assembler would have in selecting and
placing an atom to achieve a designed purpose” [78]. Sticky Finger refers to the arm of the
molecular assembler (or) the nanobot which when engaged in atomic assembly encounters
a “sticky” problem such that “the atoms of the manipulator hands will adhere to the atom
that is being moved” [79]. In lay man’s words, the molecular assembler or the hypothetical
self-replicating nanobot is engaged in assembling atoms in a particular fashion to achieve a
desired task. The robotic arm or the “finger” engaged in such atomic assembly is too big
to be accommodated between individual atoms to control them; there isn’t enough room
to accommodate all the “fingers” of the nanobot. Similarly the fingers of the nanobots will
be engaged with more than one (or) the required atom at a given time, while assembling
them, thus proving quite sticky to the surrounding atomic and lacks specificity, precision and
selectivity.
Drexler defends his stand on the basis that his concept of “molecular assembler” would
employ enzymes at the end of the robotic arm performing the assembling labor, a totally
mechanical task. He draws analogy of his system with Feynman’s idea of using factories to
create smaller factories and produce nanomachines with utmost precision [80, 81]. He talks
of the existence of a molecular assembler governed by Systems Engineering principles that
transcend traditional chemistry borders. Drexler attributes the working of the molecular assem-
bler to machine-phase chemistry rather than to solution-phase chemistry [77]. As mentioned
earlier, the participation of conveyors, positioners, etc. play a crucial role in performing the
mechanosynthesis resulting in high precision positional control of the reactants, thereby bring-
ing them together in the right co-ordinates to favor the desired reactions. In case of failure of
the desired reaction, Drexler suggests the use of a different condition or environment to perform
the task to achieve the desired result. Further he says that the very “positional control naturally
avoids most side reactions by preventing unwanted encounters between potential reactants.”
Drexler claims that “when molecules come together and react, their atoms (being “sticky”) stay
bonded to neighbors” and hence does not see the need for the Smalley fingers. Smalley on the
other hand rejects Drexler’s visions and arguments on the basis of the fundamental principles
of Chemistry. However, Drexler points at the feasibility of developing a “Bottom-up strategy:
using self-assembly to build solution-phase molecular machines,” then he envisions using this,
to acquire positional control of synthesis, and then “leveraging this ability to build systems
enabling greater control” [77].
Smalley concludes the arguments saying that one cannot “make precise chemistry occur
as desired between two molecular objects with simple mechanical motion along a few degrees of
freedom in the assembler-fixed frame of reference” [77]. Such works require guiding reactants
through a specific reaction coordinate, lying in a “many-dimensional hyperspace.” Creating a
“let alone self-replicating assembler—cannot be done simply by pushing two molecular objects
together,” it demands precision-control, and one needs “some sort of molecular chaperone that
can also serve as a catalyst” [77]. All atoms do not freely move when a molecule is moved, there
is a plethora of subtle factors cooperating to bring a reaction to completion, unseen and many
times misunderstood. The issues of “fat finger” and “sticky finger” need to be resolved, and
then the presence or absence of enzyme-like tools and water-like media need to be clarified.
According to Smalley, the concept of molecular assembly sounds utopian while it merely scares
away people by painting a future with “self-replicating monsters (nanobots) all around us.” His
message is that the essence of Chemistry has largely been forgotten in this envisioned futuristic
engineering marvel and needs to be brought back into focus. Smalley does not acknowledge
the threats of Nanotechnology, proposed by Drexler [77].
Epilogue
It is our hope that throughout this book, we have conveyed the ability of bionanotechnology to
transcend limits, once never known to have been crossed, and go beyond to improve quality of
life and health care. It is our desire to guide the reader to the references cited to understand the
concepts further and appreciate the details of the innovative approaches and significant results.
Fundamental knowledge gained in bionanotechnology is currently being translated to products
and devices that will affect patients immediately and in the near future. Further ahead new
discoveries will surprise us again and change the landscape. It is still, however, left to us to wisely
use this technology and devise environmentally conscious solutions to benefit the most in the
long term. Bionanotechnology is soon evolving into an enabling discipline, powerful enough to
realize the dreams of the great nano-visionaries, surprising us and continuously expanding our
capabilities.
REFERENCES
[1] V. M. Aponte, D. S. Finch, and D. M. Klaus, Considerations for non-invasive in-flight
monitoring of astronaut immune status with potential use of MEMS and NEMS devices.
Life Sci., vol. 79(14), p. 1317, 2006. doi:10.1016/j.lfs.2006.04.007
[2] G. Kotzar, et al., Evaluation of MEMS materials of construction for implantable medical
devices. Biomaterials, vol. 23(13), p. 2737, 2002. doi:10.1016/S0142-9612(02)00007-8
[3] N.-C. Tsai, and C.-Y. Sue, Review of MEMS-based drug delivery and dosing systems.
Sensors Actuators A, in press, corrected proof.
[4] I. Choi, et al., In situ observation of biomolecules patterned on a PEG-modified
Si surface by scanning probe lithography. Biomaterials, vol. 27(26), p. 4655, 2006.
doi:10.1016/j.biomaterials.2006.04.023
[5] M. J. Dalby, et al., Changes in fibroblast morphology in response to nano-columns
produced by colloidal lithography. Biomaterials, vol. 25(23), p. 5415, 2004.
[6] R. Haggenmueller, et al., Aligned single-wall carbon nanotubes in composites by melt
processing methods. Chem. Phys. Lett., vol. 330(3–4), p. 219, 2000.
[7] P. Nikolaev, et al., Gas-phase catalytic growth of single-walled carbon nanotubes from
carbon monoxide. Chem. Phys. Lett., vol. 313(1–2), p. 91, 1999.
[8] D. Tomanek, Carbon Nano Tubes—A time line. 2001 Sept 7, 2001 [cited; Available from:
http://www.pa.msu.edu/cmp/csc/nanotube.html.
[9] M. Zhang, Y. Bando, and K. Wada, Sol-gel template preparation of TiO2 nanotubes
and nanorods. J. Mater. Sci. Lett., vol. 20(2), pp. 167–170, 2001.
[10] Y. Zhang, et al., Synthesis of nano/micro zinc oxide rods and arrays by thermal evap-
oration approach on cylindrical shape substrate. J. Phys. Chem. B, vol. 109(27), pp.
13091–13093, 2005.
[11] A. L. Stroyuk, V. V. Shvalagin, and S. Y. Kuchmii, Photochemical synthesis and
optical properties of binary and ternary metal-semiconductor composites based on
zinc oxide nanoparticles. J. Photochem. Photobiol., A: Chem., vol. 173(2), pp. 185–194,
2005.
[12] 3i, “Nanotechnology—size matters building a successful nanotechnology company,”
E.I.U.a.t.I.o. Nanotechnology, 2002.
[13] M. E. Akerman, et al., Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci., vol. 99(20),
pp. 12617–12621, 2002.
[14] A. P. Alivisatos, Perspectives on the physical chemistry of semiconductor nanocrystals.
J. Phys. Chem., vol. 100(31), pp. 13226–13239, 1996.
[15] R. Bakalova, et al., Quantum dots as photosensitizers? Nat. Biotech., vol. 22(11), p. 1360,
2004.
[16] M. Brauer, In vivo monitoring of apoptosis. Prog. Neuro-Psychopharmacol. Biol. Psy-
chiatr., vol. 27(2), p. 323, 2003.
[17] W. C. Chan, et al., Quantum dot bioconjugates for ultrasensitive nonisotopic detection.
Science, vol. 281(5385), pp. 2016–2018, 1998.
[18] L. Hirsch, et al., Metal nanoshells. Ann. Biomed. Eng., vol. 34(1), p. 15, 2006.
[19] O. M. Koo, I. Rubinstein, and H. Onyuksel, Role of nanotechnology in targeted drug
delivery and imaging: a concise review. Nanomed.: Nanotechnol., Biol. Med., vol. 1(3),
p. 193, 2005.
[20] A. Smith, et al., Engineering luminescent quantum dots for in vivo molecular and cellular
imaging. Ann. Biomed. Eng., vol. 34(1), p. 3, 2006.
[21] F. Barrere, et al., Nano-scale study of the nucleation and growth of calcium phosphate
coating on titanium implants. Biomaterials, vol. 25(14), p. 2901, 2004.
[22] Z. L. Dong, et al., TEM and STEM analysis on heat-treated and in vitro plasma-
sprayed hydroxyapatite/Ti-6Al-4V composite coatings. Biomaterials, vol. 24(1), p. 97,
2003.
[23] Q. Hu, et al., Preparation and characterization of biodegradable chitosan/hydroxyapatite
nanocomposite rods via in situ hybridization: a potential material as internal fixation of
bone fracture. Biomaterials, vol. 25(5), p. 779, 2004.
[24] V. M. Rusu, et al., Size-controlled hydroxyapatite nanoparticles as self-organized
organic-inorganic composite materials. Biomaterials, vol. 26(26), p. 5414, 2005.
[25] S. L. Goodman, P. A. Sims and R. M. Albrecht, Three-dimensional extracellular matrix
textured biomaterials. Biomaterials, vol. 17(21), p. 2087, 1996.
[26] N. Morimoto, et al., Nano-scale surface modification of a segmented polyurethane with
a phospholipid polymer. Biomaterials, vol. 25(23), p. 5353, 2004.
[27] A. Thapa, et al., Nano-structured polymers enhance bladder smooth muscle cell function.
Biomaterials, vol. 24(17), p. 2915, 2003.
[28] V. J. Chen, L. A. Smith and P. X. Ma, Bone regeneration on computer-designed nano-
fibrous scaffolds. Biomaterials, vol. 27(21), p. 3973, 2006.
[29] M. A. Pattison, et al., Three-dimensional, nano-structured PLGA scaffolds for bladder
tissue replacement applications. Biomaterials, vol. 26(15), p. 2491, 2005.
[30] K. M. Woo, et al., Nano-fibrous scaffolding promotes osteoblast differentiation and
biomineralization. Biomaterials. Vol. 28(2): pp. 335–43, 2007.
[31] Bethesda, NIH Roadmap: Nanomedicine., 2006.
[32] T. S. Binghe Wang, Richard Soltero., Drug Delivery: Principles and Applications. Wiley-
Interscience, (462), pp. 57–83, 2005.
[33] L. Brannon-Peppas, and J. O. Blanchette, Nanoparticle and targeted systems for cancer
therapy. Adv. Drug Deliv. Rev., vol. 56(11), pp. 1649–1659, 2004.
[34] D. Bremner, Drug Delivery: Principles and Applications B. Wang, T. Siahaan and R. Soltero,
Eds., (London, United Kingdom: Chemistry & Industry), p. 24, 2005.
[35] P. Couvreur, et al., Nanotechnologies for drug delivery: Application to cancer and au-
toimmune diseases. Prog. Solid State Chem., vol. 34(2–4), pp. 231–235, 2006.
[36] R. Duncan, Nanomedicine gets clinical. Mater. Today, vol. 8(8, Supplement 1), p. 16,
2005. doi:10.1016/S1369-7021(05)71032-4
[37] E. Diederichs, J. and R. H. Muller, Future Strategies for Drug Delivery with Particulate
Systems. (Stuttgart-Germany: Medpharm GmbH Scientific Publishers), pp. 29–45, 1998.
[38] T.M. Fahmy, et al., Targeted for drug delivery. Mater. Today, vol. 8(8, Supplement 1),
pp. 18–26, 2005. doi:10.1016/S1369-7021(05)71033-6
[39] P. H. M. Hoet, I. Brueske-Hohlfeld, and O. V. Salata, Nanoparticles-
known and unknown health risks. J. Nanobiotechnol., vol. 2, 2004, pp. given.
doi:10.1186/1477-3155-2-12
[40] M. A. Horton, and A. Khan, Medical nanotechnology in the UK: a perspective from the
London centre for nanotechnology. Nanomedicine, vol. 2(1), pp. 42–48, 2006.
[41] S. K. Sahoo, and V. Labhasetwar, Nanotech approaches to drug deliv-
ery and imaging. Drug Discovery Today, vol. 8(24), pp. 1112–1120, 2003.
doi:10.1016/S1359-6446(03)02903-9
[42] T. Vo-Dinh, P. Kasili, and M. Wabuyele, Nanoprobes and nanobiosensors for monitor-
ing and imaging individual living cells. Nanomedicine, vol. 2(1), pp. 22–30, 2006.
[43] P. D. Vogel, Nature’s design of nanomotors. Eur. J. Pharm. Biopharm., vol. 60(2), pp. 267–
277, 2005. doi:10.1016/j.ejpb.2004.10.007
[44] A. Wickline Samuel, and M. Lanza Gregory, Nanotechnology for molecular imaging
and targeted therapy. Circulation, vol. 107(8), pp. 1092–5, 2003.
[45] T. R. S.-B. Govt, The Royal Society Report—‘Nanoscience and nanotechnologies:
opportunities and uncertainties’. Nanosci. Nanotechnol., pp. 1–111, 2004.
[46] V. E. Kagan, H. Bayir, and A. A. Shvedova, Nanomedicine and nanotoxicology:
two sides of the same coin. Nanomed: Nanotechnol., Biol. Med., vol. 1(4), p. 313,
2005. doi:10.1016/j.nano.2005.10.003
[47] J. Muller, et al., Respiratory toxicity of multi-wall carbon nanotubes. Toxicol. Appl.
Pharmacol., vol. 207(3), p. 221, 2005.
[48] J. S. M. Tsuji, D. Andrew Howard, Paul C. James, John T. Lam, Chiu-wing Warheit,
David B. Santamaria, Annette B., Research strategies for safety evaluation of nanomate-
rials, part IV: risk assessment of nanoparticles. Toxicol. Sci., vol. 89(1), pp. 42–50, 2006.
doi:10.1093/toxsci/kfi339
[49] D.B. Warheit, et al., Comparative pulmonary toxicity assessment of single-wall carbon
nanotubes in rats. Toxicol. Sci., vol. 77(1), pp. 117–125, 2004. doi:10.1093/toxsci/kfg228
[50] M. Ferrari, Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer,
vol. 5(3), p. 161, 2005. doi:10.1038/nrc1566
[51] M. J. Roberts, M. D. Bentley, and J. M. Harris, Chemistry for peptide
and protein PEGylation. Adv. Drug Deliv. Rev., vol. 54(4), p. 459, 2002.
doi:10.1016/S0169-409X(02)00022-4
[52] F. Chellat, et al., Therapeutic potential of nanoparticulate systems for
macrophage targeting. Biomaterials, vol. 26(35), pp. 7260–7275, 2005.
doi:10.1016/j.biomaterials.2005.05.044
[53] A. Nagayasu, K. Uchiyama, and H. Kiwada, The size of liposomes: a factor which affects
their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs.
Adv. Drug Deliv. Rev., vol. 40(1–2), p. 75, 1999. doi:10.1016/S0169-409X(99)00041-1
[54] L. S. A. B. C. Yu, Dekker Pharmaceutical technology: Biopharmaceutics. 2002.
[55] D. Thorek, et al., Superparamagnetic Iron Oxide Nanoparticle Probes for Molecular
Imaging. Ann. Biomed. Eng., vol. 34(1), p. 23, 2006. doi:10.1007/s10439-005-9002-7
[56] J. M. Perez, et al., Magnetic relaxation switches capable of sensing molecular interactions.
Nat. Biotech., vol. 20(8), p. 816, 2002.
[57] A. Tanimoto, and S. Kuribayashi, Application of superparamagnetic iron oxide
to imaging of hepatocellular carcinoma. Eur. J. Radiol., vol. 58(2), p. 200, 2006.
doi:10.1016/j.ejrad.2005.11.040
[58] F. Calliada, et al., Ultrasound contrast agents: basic principles. Eur. J. Radiol., vol.
27(Supplement 2), p. S157, 1998. doi:10.1016/S0720-048X(98)00057-6
[59] R. Campani, et al., Contrast enhancing agents in ultrasonography: Clinical applications.
Eur. J. Radiol., vol. 27(Supplement 2), p. S161, 1998.
[60] G. Maresca, et al., New prospects for ultrasound contrast agents. Eur. J. Radiol., vol.
27(Supplement 2), p. S171, 1998. doi:10.1016/S0720-048X(98)00059-X
[61] B. E. Oeffinger, and M. A. Wheatley, Development and characterization of a nano-scale
contrast agent. Ultrasonics, vol. 42(1–9), p. 343, 2004. doi:10.1016/j.ultras.2003.11.011
[62] J. C. Glenn, Nanotechnology: future military environmental health considerations B. Tech-
nological Forecast. Social Change, vol. 73: p. 128–137, 2006.
[63] History of the National Nanotechnology Initiative (NNI). 2006 [cited; Available from:
http://www.nano.gov/html/about/history.html.
[64] NNI, National Nanotechnology Initiative (NNI), Research and Development Leading to a
Revolution in Technology and Industry, Supplement to President’s FY 2006 Budget, March
2005. 2005.
[65] T. K. A. Y. Bando, Status and trends of nanotechnology R&D in Japan. Nat. Mater.,
vol. 3(March), pp. 129–131, 2004. doi:10.1038/nmat1086
[66] Nanotechnology (including bionanotechnology) R&D initiatives in Japan. 2006
[cited; Available from: http://www.globalwatchservice.com/pages/ThreeColumns.
aspx?PageID=146.
[67] Biotechnology and Biological Sciences Research Council (BBSRC) Report: World
Class Bioscience—Strategic Plan 2003–2008. Updated, British BBSRC. p. 1–47,
2005.
[68] EU Budget for FP6—Bionanotechnology Research initiative 2006. 2006 [cited; Available
from: http://cordis.europa.eu/fp6/budget.htm.
[69] EU Funding for FP7, Road Map for FP6 to FP7 (Science and Technology Re-
search Initiatives)—2007 to 2013. 2006 [cited; Available from: http://cordis.europa.eu/
fp7/budget.htm.
[70] S. Goodsell, D., Bionanotechnology: Lessons from Nature. John Wiley and Sons Inc. (311),
pp. 295–311, 2004.
[71] NASTCON. Nano Science and Technology Consortium (NASTCON). 2005 [cited; Avail-
able from: http://www.nstc.in/NSTCHead/Research Area.aspx.
[72] D. A. P. J. A. Kalam, President’s Address at the Inauguration of the Indo-Us Nanotech-
nology Conclave, P.I.B.P.G.o. India, Editor. Wednesday, February 22, 2006, President’s
Secretariat Govt of India.
[73] D. Richard, E. B. Booker, Nanotechnology For Dummies. pp. 1–384, 2005.
[74] BioNano. BioNano International Singapore Pte. Ltd. 2005 [cited; Available from:
http://www.bionano.com.sg/products.htm.
[75] R. Smalley, Research Areas of Dr.Smalley. 2005 [cited 2006; Available from:
http://smalley.rice.edu/smalley.cfm?doc id=4858.
[76] M. Sims, Eric Drexler Joins Nanorex. 2005 [cited 2006; Available
from: http://www.nanoengineer-1.com/mambo/index.php?option=com content&task=
view&id=69&Itemid=73.
[77] R. Baum, Nanotechnology: Drexler and Smalley make the case for and against “molecular
assemblers”. Chem. Eng. News, vol. 81(48), pp. 37–42, 2003.
[78] Fat Fingers. 2006 [cited; Available from: http://www.nanotitan.com/nCyclopedia/
fatFingers.htm.
[79] R. E. Smalley, Of chemistry, love and nanobots. Sci. Am., vol. 285(3), pp. 76–77, 2001.
[80] R. P. Feynman, There’s plenty of room at the bottom. 1959 [cited; Available from:
http://www.zyvex.com/nanotech/feynman.html.
[81] R. P. Feynman, Plenty of Room at the Bottom [Courtesy of The Archives, California Institute
of Technology]. 1959.
139
Author Biography
Aravind Parthasarathy earned his Masters Degree from Drexel University in Biomedical En-
gineering, in 2006. He is presently working as a Product Engineer at EPMedsystems, NJ where
he is involved in the design and development of diagnostic equipments for Cardiac Electro-
physiology. His research at Drexel concentrated on the applications of Bionanotechnology in
health care, and in improvising cardiac pacemakers. He earned his Bachelors degree in Electri-
cal & Electronics Engineering from Bharathidasan University, India. Apart from his writing
interests, he does quite a bit of circuit building for applications including medical devices,
robotics and controls & instrumentation. He is passionate about realizing his dream of making
a nanotechnology based “wireless cardiac pacemaker” and believes in seeing more of nanotech
based commercial medical devices in the near future.
Dr. Elisabeth S. Papazoglou is the author of more than 40 original articles and 12 patents in
materials and nanotechnology. During her 14 years experience in the chemical industry (Arco
Chemical, FMC, Great Lakes) she led basic and applied R&D and developed novel commercial
products based on nanotechnology. Dr. Papazoglou holds a Diploma in Chemical Engineering
from the Aristotelian University of Thessaloniki, Greece, a Masters in Chemical Engineering
from the University of Delaware and a Ph.D. in Macromolecular Science & Polymer Engi-
neering from Case Western Reserve University. She is currently an Assistant Professor in the
School of Biomedical Engineering at Drexel University where her research focuses on Bionan-
otechnology especially on the unique properties of nanoparticles for simultaneous delivery and
imaging applications. Her expertise includes, but is not limited to nano approach in wound
healing, nano imaging of skin chemistry and QDs based study of skin inflammation.

Bionanotechnology - E. Papazoglou, A. Parthasarathy (2007) WW

Uploaded by

Copyright:

Available Formats

Bionanotechnology - E. Papazoglou, A. Parthasarathy (2007) WW

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Bionanotechnology - E. Papazoglou, A. Parthasarathy (2007) WW

Uploaded by

Copyright:

Available Formats

Copyright © 2007 by Morgan & Claypool

ISBN: 1598291386 paperback

ISBN: 1598291394 ebook

A Publication in the Morgan & Claypool Publishers’ series

Library of Congress Cataloging-in-Publication Data

Series ISSN: 1930-0328 print

SYNTHESIS LECTURES ON BIOMEDICAL ENGINEERING #7

1. The Significance of Nano Domain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

2. Nano Drug Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

4. Successful Applications of Bionanotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

6. Is Bionanotechnology a Panacea?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .109

7. Roadmap to Realization of Bionanotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121

Author Biography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139

Dr. Richard E. Smalley—Nobel Laureate

FIGURE 0.1: Fullerene (Bucky ball)—discovery by Dr. Richard Smalley

Dr. Eric Drexler (April 25, 1955- )

Dr. Chad Mirkin (November 23, 1963- )

0.2 NANOTECHNOLOGY AND BIONANOTECHNOLOGY

TABLE 0.1: Comparison of Nanoparticles with Matter of Macro World

1. Glucose Thickness of human Thickness of A man of 8.3 feet

0.3 NOTABLE NANOIMAGES IN BIONANOTECHNOLOGY

FIGURE 0.2: AFM image of quantum dots

0.3.2 Nano-drug Delivery Chip

FIGURE 0.3: Drug delivery microchip

FIGURE 0.4: SWNT ropes with SWNT probe

0.3.3 Atomic Force Microscopy Image (AFM) of SWNT

0.3.4 Scanning Electron Microscopy Image (SEM) of SWNT

FIGURE 0.5: SEM images of CNT

0.4 OPPORTUNITIES AND CHALLENGES

0.5 GROWTH POTENTIAL OF NANOTECHNOLOGY

TABLE 0.2: Yearly US Nanotechnology Expendi-

ANNUAL BUDGET USD

It can confidently, be stated that:

FIGURE 0.7: Annual Research Expenditure in Nanotechnology in the US

The Significance of Nano Domain

1.1 LIMITATIONS OF MICRON SIZE

1.2 NEED FOR NANO-SIZE—SURFACE VOLUME RATIO

1.3 SIGNIFICANCE AND KEY FEATURES OF NANO-SIZE

1.4 DERIVATION OF BOHR’S ATOMIC RADIUS

But θ = 90◦ for a circular orbit, so Sin 90 = 1.

Kinetic energy expressed as angular momentum

λ = wavelength in meters (m)

The Bohr radius a 0 can be derived by equating.

m is the mass of the electron in kg,

According to DeBroglie’s equation of wavelength,

h = Planck’s constant = 6.626 × 10−34 JouleSec. = 4.136 × 10−15 eV.Sec

For first orbit 2πr = λ.

On simplifying for the Bohr’s radius r , we get

this radius is represented by a 0 . The numeric value is

FIGURE 1.1: Bohr’s atomic model

FIGURE 1.2: Quantized energy levels in hydrogen

FIGURE 1.3: Excitation by absorption of light and de-excitation by emission of light

E is the energy required for excitation or de-excitation,

1.5 COMPARISON OF PARTICLE BEHAVIOR AT NANO-SIZE

1.6 ADVANTAGES OF SCALING DOWN—NANO-SIZE

1. Accumulate in the tissue of mononuclear phagocyte system (MPS) (formerly

FIGURE 1.4: Multifunctional nanoparticle—nanovector

Fig. 1.4 is a schematic of a multifunctional nano-device (nanovector) comprising of two

FIGURE 1.5: Multifunctional targeting strategy in a tumor site